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ABSTRACT 
Vitamin D deficiency has been associated with human abdominal aortic aneurysm (AAA) in 
epidemiologic studies; however, its role in AAA pathogenesis and progression is unclear. 
Recently, it was reported that within Apolipoprotein E (ApoE-/-) mice in which sclerostin 
(SOST) was over expressed were protected from AAA induction by angiotensin II (AngII) 
infusion. Vitamin D has been reported to upregulate the expression of SOST in osteoclasts; 
however, its effect on the aorta and vascular smooth muscle cells (VSMCs) is unknown. The 
main hypothesis of this thesis was that vitamin D limited AAA development, growth and 
rupture through upregulation of SOST, particularly within the suprarenal aortic (SRA) wall. 
Effects of vitamin D on AAA development, growth and rupture were investigated in vivo 
using the AngII infusion ApoE-/- mouse model. The effect of vitamin D on VSMCs in vitro 
was also investigated. This thesis had four aims(1) to examine whether the active metabolite 
of vitamin D, 1,25(OH)2D3, induced SOST expression in VSMCs in vitro; (2) to investigate 
whether dietary-induced vitamin D deficiency reduced circulating levels of SOST and SRA 
SOST expression in ApoE-/- mice; (3) to investigate if dietary-induced deficiency of vitamin 
D promoted AAA development and rupture; and (4) to examine if raising circulating 
25(OH)D levels through cholecalciferol (CCF) supplementation limited progression of 
established AAA. 
Incubation of VSMCs with increasing concentrations of 1,25α-dihydroxyvitamin D3 
(1α,25(OH)2D3; 0, 0.1, 1, 10, 100 nmol/L) over 48 hours dose-dependently increased gene 
expression for SOST (P<0.001), vitamin D receptor (VDR; P<0.001), and  25-hydroxyvitamin 
D-24-hydroxylase (CYP24A1; P<0.001). In contrast, expression of 25-hydroxyvitamin D3 1-
alpha-hydroxylase (CYP27B1; P<0.001), osteopontin (OPN; P<0.001), matrix 
metalloproteinases-2 (Mmp-2; P=0.004), and β-catenin (CTNNB1; P<0.001) were dose-
dependently downregulated.  Vitamin D deficiency in mice (no measurable circulating 25-
hydroxyvitamin D) was associated with  decreased circulating and aortic levels of SOST. In a 
separate study, AngII infusion in vitamin D deficient ApoE-/- mice resulted in the 
development of larger AAAs as assessed by ultrasound (P=0.034) and ex vivo morphometry 
[median (inter-quartile range) maximum suprarenal aortic diameter 2.34(2.08-3.1) mm vs 
1.83(1.27-2.52) mm; P=0.041] that ruptured more commonly (48% vs 19%; P=0.028) than 
controls. Vitamin D deficiency was also associated with increased aortic expression of 
osteopontin (Opn), and Mmp-2 and Mmp-9 than controls. In the final study, CCF 
xvi | P a g e  
 
administration to mice with pre-established AAA limited growth of AAA as assessed by 
ultrasound (P<0.001); and ex vivo morphometry [median (inter-quartile range) maximum 
suprarenal aortic diameter 3.03 (2.56-5.27) mm vs 2.54 (1.82-2.69) mm; P=0.035] and 
reduced rupture rate (8% vs 46%; P=0.031) which was associated with upregulation of 
circulating and aortic SOST. Additionally, CCF supplementation was shown to reduce SRA 
mRNA expression for a number of markers for that are involved in AAA progression, 
including Mmp-2 (P=0.035), Mmp-9 (P=0.020) and Opn (P=0.035). 
In conclusion, the investigation suggested that vitamin D deficiency promotes development 
of large AAA with more propensity to rupture in an experimental mouse model. Furthermore, 
it was shown that CCF administration could limit both growth and rupture of AAA in mice 
with pre-established AAA. These effects of vitamin D appear to be mediated via changes in 
genes involved in extracellular matrix remodelling, particularly SOST. Findings from this 
thesis are supportive of future clinical trials aiming at evaluating therapeutic benefits of 
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BMI body mass index 
BSA Bovine Serum Albumin 
CALD1:  Caldesmon 1 
CCF:  Cholecalciferol 
CCL-1: Chemokine (C-C motif) ligand 
CNN1:  Calponin-1 
CVD: Cardiovascular disease 
CYP24A1: Cytochrome P450 family 24 subfamily A member 1 
DAPI 4′,6-diamidino-2-phenylindole 
Dkk-1 Dickkopf Wnt signalling pathway inhibitor 1 
DMEM Dulbecco’s modified eagle medium 
DMSO dimethyl sulfoxide 
ECM:  Extracellular matrix 
EGFR:  Epidermal growth factor receptor 
Epi-C3-25(OH)D: Epi-C3-25-hydroxyvitamin D 
FGF23:  Fibroblast growth factor 23 
GAPDH:  Glyceraldehyde 3-phosphate dehydrogenase 
GSK-3 Glycogen synthase kinase 3 
hrSOST human recombinant SOST 
HBSS Hank's Balanced Salt Solution 
HDL:  High-density lipoprotein 
HIF1α:  Hypoxia-inducible factor 1-alpha 
IHC:  Immunohistochemistry  
IL-1: Interleukin-1 
IU International Unit 
IQR: Interquartile range 
JCU/AEC James Cook University/Animal Ethics Committee  
LV:  Left ventricle 
MAPK mitogen-activated protein kinase 
MMP:  Matrix metalloproteinase 
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MYH11:  Myosin, Heavy Chain 11, Smooth Muscle 
NFκB: Nuclear factor-κB 
NHF:  National Heart Foundation 
NOTCH:  Notch homolog, translocation-associated 
OCN Osteocalcin 
OCT:  Optimum cutting temperature 
OPG Osteoprotegerin 
OPN Osteopontin 
PAD:  Peripheral artery disease 
p-GSK-3: Phosphorylated-glycogen synthase kinase 3 
PPARα/γ:  Peroxisome proliferator–activated receptor α/γ 
PTH: Parathyroid hormone 
RXR: Retinoid X receptor 
SBP Systolic blood pressure 
SMD:  Standard mean difference 
SMTN: Smoothelin 
SNPs single nucleotide polymorphisms 
SOST Sclerostin 
SRA Suprarenal aorta 
TAA:  Thoracic aortic aneurysm 
TAD:  Thoracic aortic dissection 
TAGLN:  Transgelin 
TGF-β:  Transforming growth factor-β 
TNF-α: Tumour necrosis factor-α 
UK:  UK small aneurysm trial 
UKSAT:  United Kingdom 
USA:  United States of America 
UVB:  ultraviolet B 
VDBP:  Vitamin D binding protein 
VDD Vitamin D deficient 
VDR Vitamin D receptor 
VDS Vitamin D sufficient 
VSMCs Vascular smooth muscle cells 
μL Microliter 
% Percentage 
< Less than 
≥ Greater than or equal to 
≤ Less than or equal to 
> Greater than 
o Degree 
µg Microgram 
µM Micro molar 
  
 
xxi | P a g e  
 
 
















2 | P a g e  
 
1.1. ABDOMINAL AORTIC ANEURYSM 
1.1.1. The aorta in health and disease 
Physiologically, the aorta channels oxygenated blood to the rest of the systemic arterial tree 
from the heart. Anatomically, the aorta extends from the valve adjoining the left ventricle (LV) 
where it facilitates post contraction outflow of blood and supply of the coronary circulation. 
The aorta then ascends slightly (≈ 5.0 cm long), before arching and extending through the 
thorax (thoracic aorta) and the abdomen (abdominal aorta). The thoracic aorta is posteriorly 
located in the mediastinal cavity, running longitudinally to the spinal cord, and to the 
diaphragm hiatus. The abdominal aorta extends from diaphragm hiatus, superior to renal 
arteries, (suprarenal), then infra-renally, before reaching the point where it bifurcates into the 
common iliac arteries (Figure 1.1). In the human adults, the normal aortic diameter is about 
3.5 cm at the aortic root, and diminishes gradually to approximately 2.0 cm in the abdominal 
region. From early embryogenesis, the abdominal aorta is physiologically conditioned to 
effectively deliver blood directly to vital organs via its branching arteries, including the celiac, 
mesenteric (superior and inferior), renal (right and left) gonadal (right and left), common iliac 
(right and left) and spinal cord arteries. 
Although it has been previously described as a conduit, the aorta is not merely a tube. It exhibits 
a highly organised physiology that facilitates an ever-continuous and dynamic function (Belz, 
1995). The aorta plays a central role as an elastic buffer following every ventricular stroke 
(systole-diastole) through its recoil and distention (the Windkessel function) (Belz, 1995). 
Characteristically, the aortic wall consists of three concentrically arranged layers. The intima 
(innermost), media (middle) and adventitia (external) (Table 1.1). Each of three layers presents 
with unique histological features that are known to contribute to the homeostasis of the aorta 
(Stenmark et al., 2013). The aortic intimal lining is a selectively permeable and plays a critical 
role in the regulation of vascular tone, haemostasis and cellular leukocyte extravasation. The 
intima consists of endothelial cells, sub-endothelial basement and the fenestrated membrane. 
Endothelial function is important in the regulation of the blood flow due to their ability to 
provide an antithrombotic lining surface that is conducive to the smooth flow of blood and 
blood constituents (Table 1.1). This uniform blood flow is regulated via secretion and uptake 
of vasoactive factors that dilate and constrict neighbouring vascular smooth muscle cells 
(VSMCs) in a paracrine manner.  
3 | P a g e  
 
While earlier research had directed more interests to the function of the endothelium, recent 
progresses in vascular biology now recognizes an important role of all three layers in the 
regulation arterial function (Baltgaile, 2012). In addition, originally only thought to be a 
supportive tissue and extension of perivascular fats, adventitia is presently known to play 
distinct roles response to vascular hypoxia, injury and pulmonary hypertension (Stenmark et 
al., 2013; F. Xu, J. Ji, L. Li, R. Chen, & W. Hu, 2007; F. Xu, J. Ji, L. Li, R. Chen, & W. C. Hu, 
2007). The adventitia has been shown to respond to both physiological and pathophysiological 
conditions including vascular remodelling, tissue repair and extracellular matrix (ECM) 
deposition. The aortic wall consists of elastic fibres (≈40%); however, elastin content 
diminishes progressively from towards distal aorta (Bader, 1967). Elasticity in the human aorta 
predicts the aortic stiffness; and this has been shown to correlate with age and physiological 
pressure (Lindesay, Ragonnet, Chimenti, Villeneuve, & Vayssettes-Courchay, 2016).  
 
Table 1.1: The aortic wall structure 
Aortic layer  Major component Main physiological function 
Intima Basal lamina  Structural support and permeability control  
Endothelial cells  Secretion vasoactive factors and vascular tone 
Sub-endothelial tissue  Endothelial support & connective tissue 
Media Concentric VSMCs  Distention and recoiling and synthesis of ECM 
Elastic lamellae  Structural support of the aorta 
Elastin  Viscoelasticity; recoil and distention properties 
Collagen Tensile strength, resilience to over-distention 
Adventitia ECM Integral support, aortic wall structural resilience 
Abbreviation: VSMCs: vascular smooth muscle cells; ECM: extracellular matrix 
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Figure 1.1: Schematic diagram of aortic anatomy 
(A) The descending thoracic aorta spans from distal to the origin of the left subclavian artery to the diaphragm. Abdominal aortic aneurysms 
commonly develop in the infrarenal region. The normal aortic wall structure. (B) Normal aortic wall comprises of intima (innermost layer), media 
(the middle layer) and adventitia (the outer layer). Aortic diameter can be measured based on inner wall-to-inner wall which is the inside space of 
the aorta, or can be measured from outer layer-to-outer layer which indicates the maximal aortic diameter when measured at systole. Adapted from 
Sakalihasan et al (2018) 
intima Media Adventitia
A B
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1.1.2. Abdominal aortic aneurysm, prevalence and risk factors  
Abdominal aortic aneurysms (AAA) is a multifactorial cardiovascular pathology characterised 
by gradual weakening in the aortic wall (Johnston et al., 1991; Joseph V Moxon et al., 2010; 
Natzi Sakalihasan, Limet, & Defawe, 2005). In human, AAA is commonly defined as localised 
expansion of the infrarenal aorta ≥3.0 cm. Contemporary reports suggest that AAA affects 
between 1-2% of men and about 1% of women in the general population (Golledge et al., 2019). 
Described as an age-related disease, AAA is currently recognised as one of the causes of 
premature deaths in people aged >65 years old (Sampson et al., 2014). AAA rupture is a life-
threatening emergency with up 90% risk of death (Budd, Finch, & Carter, 1989; Johansson & 
Swedenborg, 1986; Moll et al., 2011; Natzi Sakalihasan et al., 2005). The natural course of 
AAA is progressive expansion, which increases aortic rupture risk (Baxter et al., 2016; Longo 
et al., 2002; Wassef et al., 2001). Ruptured AAA is a life-threatening medical emergency that 
has been associated with almost 95% mortality (Budd et al., 1989; Johansson & Swedenborg, 
1986; Moll et al., 2011; Natzi Sakalihasan et al., 2005), although recent advances in AAA 
patient care now suggest >50% mortality (Chaikof et al., 2018). The prevalence of AAA varies 
among epidemiological studies depending on the target population (Moukarzel, Mao, & Eraso, 
2013; Tang et al., 2016). Actual mortality data resulting from AAA is sometimes hampered by 
possible undocumented causes of deaths (Golledge, Muller, Daugherty, & Norman, 2006; 
Moukarzel et al., 2013). 
Despite the significant public and healthcare burden posed by the disease, there still exists no 
effective pharmacological treatment for AAA (Golledge & Norman, 2011; Golledge & Powell, 
2007; Kokje, Hamming, & Lindeman, 2015; Lindeman & Matsumura, 2019). Repair surgery 
remains the only medical option presently afforded to AAA patients (Golledge & Norman, 
2011; Golledge & Powell, 2007; Kokje et al., 2015; Lindeman & Matsumura, 2019). 
Guidelines recommend that small AAA (3.0-5.0 cm) be conservatively managed with serial 
ultrasound surveillance until they reach the elective diameter for surgery (i.e. 5.5 cm for men 
and 5.0 for women) (Golledge & Norman, 2011; Golledge & Powell, 2007; Kokje et al., 2015; 
Lindeman & Matsumura, 2019). Although rupture risk in small aneurysms is minimal, the 
majority of AAAs continue to expand thus increasing the risk of rupture (Golledge, Norman, 
Murphy, & Dalman, 2017). AAA repair surgery is also associated with a significant mortality 
rate, and cost-effectiveness of the procedure remains debatable (Dua, Kuy, Lee, Upchurch Jr, 
& Desai, 2014). For instance, with approximately 25000 AAA repair procedures (endovascular 
and open surgery) performed in the USA yearly, the median in-hospital cost has been estimated 
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to be $58,305 USD (Suckow et al., 2018). The figure markedly goes up  for procedures 
performed on ruptured AAA (84,744 USD) (Dua et al., 2014). The figures from Centre for 
Disease Control and prevention (USA) indicated that, in 2009, AAA was the primary killer in 
10,597 deaths and an accomplice in another 17,215 deaths (Go et al., 2013; Kochanek, Xu, 
Murphy, Minino, & Kung, 2011; Suckow et al., 2018). Although women are underrepresented 
in epidemiological studies compared to men, it has been suggested that the prognosis of small 
AAA is worse in women; and that women have a higher post-operative mortality compared 
with men (Hultgren, Vishnevskaya, & Wahlgren, 2013; Ulug, Sweeting, von Allmen, 
Thompson, & Powell, 2017).  
The majority of AAAs are diagnosed when they are small to medium in size (i.e. 3.0-5.0 cm) 
(J. Golledge, Norman, Murphy, & Dalman, 2016). Most AAAs continue to expand to >5.5 cm; 
a diameter at which surgical repair may be required to prevent aortic rupture because the risk 
of rupture increases significantly from this diameter (Powell et al., 2017). Although the 
commonly reported average expansion rate has varied between 0.25 to 0.50 cm per year, larger 
AAAs tend expand much faster than smaller aneurysms (J. Golledge, Norman, et al., 2016). 
Recent reports have shown that about 25000 AAA repair procedures (endovascular and open 
surgery) are performed in the USA, annually (Dua et al., 2014). 
Ultrasound is a useful tool in both AAA research and clinical diagnosis. Ultrasound assessment 
is a non-invasive accurate and specific modality for AAA diagnosis. It however remains an 
unmet need to find biomarkers that can be specifically used for AAA diagnosis. Until now, no 
single biomarker that has been found to be highly sensitive and specific enough for prediction 
of AAA rupture (Filis et al., 2014; Golledge, Tsao, Dalman, & Norman, 2008; Hellenthal, 
Buurman, Wodzig, & Schurink, 2009; Moxon et al., 2014; Moxon et al., 2010; Stather et al., 
2014). Moreover, AAA is understood to be a multifactorial and a multistage disease, suggesting 
that factors in early stages of the disease could be different from those involved in the disease 
progression (Nordon, Hinchliffe, Holt, Loftus, & Thompson, 2009). Well-documented risk 
factors for AAA include advanced age (≥ 60), cigarette smoking, male gender and genetic 
predisposition (Björck & Wanhainen, 2013; Nordon et al., 2009). Other AAA risk factors, also 
including uncontrolled hypertension, dyslipidaemia and presence of cardiovascular events 
comorbidity (Björck & Wanhainen, 2013; Brewster et al., 2003; Nordon et al., 2009). AAA 
risk factors can also be classified as modifiable and non-modifiable. Lifestyle modification 
such smoking cessation, dietary and exercise regimen are among modifiable risk factors while 
genetic predisposition, age and race are non-modifiable risk factors (Björck & Wanhainen, 
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2013; Brewster et al., 2003; Nordon et al., 2009). Given that individuals who are smokers are 
seven times more likely to develop AAA compared with than non-smokers, cigarette smoking 
remains biggest modifiable risk factor (Aggarwal, Qamar, Sharma, & Sharma, 2011; Aune, 
Schlesinger, Norat, & Riboli, 2018). In addition, AAA has been reported to expand faster in 
smoking patients compared with non-smokers (Aggarwal et al., 2011; Aune et al., 2018). 
Therefore, smoking cessation is the most important lifestyle modification that patients are 
advised to make as this has been shown to regress the risks (Aune et al., 2018). Dietary regimen 
such as increase intake of fruits and vegetables has also been reported to lower the risk of AAA 
development (Nordkvist, Sonestedt, & Acosta, 2018; Stackelberg, Bjorck, Larsson, Orsini, & 
Wolk, 2013).   
1.1.3. AAA pathophysiology 
Current understanding of the mechanisms implicated in  AAA pathogenesis remains somewhat 
incomplete. However, it is likely that aortic wall inflammation and degradation of the 
adventitial layer influence both development and progression of AAA (Golledge et al., 2019; 
Nordon et al., 2009; Wassef et al., 2001). Depletion of vascular smooth muscle cells (VSMCs) 
and destruction of the supportive extracellular matrix (ECM) are the primary characteristics of 
AAA diseased tissue (Nordon et al., 2009). Infiltration of inflammatory and immune cells has 
also been consistently reported in the pathogenesis of AAA (Krishna et al., 2017; Krishna et 
al., 2015; Nordon et al., 2009). Chronic transmural inflammation contributes to AAA 
development through infiltration of mononuclear phagocytes and lymphocytes in the media 
and adventitial layer (Krishna et al., 2017). The infusion of AngII in ApoE-/- mice, one of the 
most commonly used rodent models, induces inflammation, atherosclerosis and ECM 
proteolysis (Daugherty & Cassis, 2004; Davis, Rateri, & Daugherty, 2014; Krishna et al., 2017; 
Seto, Krishna, Moran, Liu, & Golledge, 2014). Within this mouse model, collagen and elastin 
are degraded due chronic production of inflammatory mediators, including leukocyte adhesion 
molecules and chemokines is understood to drive the progression of AAA growth (Krishna et 
al., 2017; Krishna et al., 2015). The infiltration of lymphocytes expressing IL-4, IL-5, IL-8 and 
IL-10 and tumour necrosis factor (TNF-alpha), which regulate the local immune response, have 
also been reported as important contributors in AAA formation (Daugherty & Cassis, 2004; 
Davis et al., 2014; Juvonen et al., 1997; Krishna et al., 2017; Seto et al., 2014). Involvement of 
mast cells has also been highlighted in AAA formation due to their release of several proteases, 
growth factors, cytokines, and chemokines through degranulation (Lindholt & Shi, 2006). 
Furthermore, mast cells are likely implicated in AAA development by inducing the activation 
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of T-lymphocytes and macrophages which in turn release various pro-inflammatory cytokines 
(Lindholt & Shi, 2006). It was suggested that the peptide fragments resulted from the 
degradation of the ECM might serve as chemotactic agents for the infiltrating macrophages 
(Lindholt & Shi, 2006). Secretion of chemokines such as interleukin 8 (IL-8), monocyte 
chemoattractant protein 1 (MCP-1) continually trigger leukocyte recruitment in the 
microenvironment of the aortic wall, resulting in chronic inflammation (Juvonen et al., 1997; 
Krishna et al., 2017; Lindholt & Shi, 2006). 
Experimental studies on AAA formation and progression have relied heavily on rodent models 
(in vivo) and cell experiments (in vivo) (Golledge & Norman, 2010; Nordon et al., 2009). 
Descriptive assessments of diseased AAA tissue and circulating biomarkers have also informed 
the current understanding of AAA pathogenesis. Among other hallmark features, presence of 
inflammatory cell infiltrates within the aortic wall, depletion of medial VSMCs and 
degradation of ECM in the adventitia have been consistently reported in AAA tissue (Boddy 
et al., 2008; Maegdefessel, Dalman, & Tsao, 2014). A number of circulating biomarkers have 
also been associated with AAA presence (Golledge, Walker, Norman, & Golledge, 2009; 
Golledge et al., 2008). Among these are matrix degrading proteins, thrombogenic markers and 
inflammatory markers (Golledge et al., 2008; Hellenthal et al., 2009; Urbonavicius et al., 
2008). Interestingly, there has been strong evidence on association between AAA and 
atherosclerosis, although a causal relationship between the two conditions has not yet been 
established (Golledge & Norman, 2010). Similarly, within a mouse model of AAA, a diseased 
supra-renal aortic (SRA) wall is characterised by presence of immune and inflammatory cells 
as well as proteolytic degradation of ECM (Krishna et al., 2017). Other features include 
presence of atherosclerotic plaques and intraluminal thrombus (ILT) (Nordon et al., 2009). 
1.1.4. Medical management of AAA 
The lack of pharmacological therapy for AAA patients unfortunately means that small AAAs 
are managed through serial surveillance with ultrasound. Theoretically, all AAAs continue to 
expand and may ultimately require prophylactic measures to slow or limit their progression to 
rupture (Chaikof et al., 2018; Tang et al., 2016). In male AAA patients, surgery is indicated in 
patients with AAA ≥ 5.5 cm while in female surgery is recommended when the diameter is 
equal or exceeds 5.0 cm (Chaikof et al., 2018; Golledge, Norman, et al., 2016). Additionally, 
prophylactic AAA repair may be recommended when there is rapid diameter expansion >1.0 
cm/year or when the patient complains of symptoms such as abdominal and/or back pain and 
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distal embolization (Chaikof et al., 2018; Robinson, Mees, Verhagen, & Chuen, 2013; Natzi 
Sakalihasan et al., 2005). In Western countries, vascular surgery centres are reported to 
electively perform about 75-85% of AAA repairs for intact aneurysms (Beck et al., 2016; 
Karthikesalingam et al., 2016). AAA surgery is categorised into two main options: open AAA 
repair surgery or endovascular AAA repair (EVAR) surgery (Chaikof et al., 2018). Irrespective 
of whether a less invasive EVAR or an invasive open surgery is carried out, AAA repair surgery 
always comes with a number of significant risks ranging from short-term and long-term risks. 
Short-term risks may include perioperative complications such as death and renal failure while 
long-term risks include graft failure requiring repeat surgical procedures or death resulting 
from AAA rupture (Chaikof et al., 2018; Golledge, Norman, et al., 2017; Natzi Sakalihasan et 
al., 2005). Open surgery is an invasive procedure usually performed with laparotomy and 
consists of the interposition of an arterial prosthesis to contain the aneurysmal sac (Chaikof et 
al., 2018). Open AAA repair procedure is important for patients in whom EVAR is 
contraindicated, patients with persistent endoleak, graft infection or mycotic AAA (Chaikof et 
al., 2018).  Reports suggest that young and healthy patients, with an AAA 5.0 - 5.4 cm, may 
benefit from early repair, especially young women (IMPROVE Trial Investigators: Ulug P et 
al, 2017). However, older patients with significant comorbidities or other frailty risk factors 
that are considered risky for surgery may be delayed even for AAA diameter greater than 5.4 
cm (IMPROVE Trial Investigators: Ulug P et al, 2017; Powell et al., 2017). In contrast to 
asymptomatic AAA, ruptured AAA are regarded as life-threatening emergencies. Ruptured 
AAA requires immediate and prompt surgical repair, and both EVAR and open surgery are 
currently offered to patients with ruptured AAA (Chaikof et al., 2018). Contemporary reports 
suggest that short and long-term benefits may be better in AAA patients undergoing EVAR 
surgery compared with open surgery (IMPROVE Trial Investigators: Ulug P et al, 2017; 
Powell et al., 2017). 
1.1.5. Pharmacological management for AAA 
A common theme in findings from clinical trials and pharmacological intervention for AAA 
remains that there is an unmet need in AAA research (Golledge et al., 2019; Golledge, Norman, 
et al., 2017; Lindeman & Matsumura, 2019; Sakalihasan et al., 2018; Yoshimura et al., 2018). 
In essence, continuous expansion of AAA and consequent aortic rupture may be inevitable in 
many cases unless AAA repair surgery is offered to patients at the right time. Pharmacological 
therapy to prevent AAA progression could have significant impacts on the management of 
patients. Indeed, AAA pathophysiology is thought be categorised into 3 stages which are 
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initiation, progression and rupture (Bi et al., 2014; Nordon et al., 2009). The initiation stage 
has been suggested to be characterised by immune response, inflammation, atherosclerosis and 
matrix dysfunction, suggesting that these pathways are attractive targets to inhibit AAA 
formation. The progression stage is understood to exhibit exacerbated chronic inflammation, 
matrix degradation and VSMCs depletion (Bi et al., 2014; Krishna et al., 2015; Nordon et al., 
2009). Biomechanical disturbance is also understood to play an adverse role during AAA 
progression, particularly at the point where the aortic wall integrity can longer withstand 
internal hemodynamic stress (Aronow et al., 2011; Bi et al., 2014). Indeed, the majority of 
previous and recent studies have focused on effects of pharmacological interventions that can 
specifically target to lower blood pressure, eliminate Chlamydia pneumoniae infection, correct 
dyslipidaemia and prevent plaque formation, or limit inflammation and matrix remodelling 
(Table 1.2 & Table 1.3) (Golledge et al., 2019; Lindeman & Matsumura, 2019). 
 
Examples of targeted inflammatory pathways are summarised herein; and have included 
inhibition of NFκB (Saito et al., 2013), inhibition of the Rho kinase signalling (Wang et al., 
2005) and modulation of immune and inflammatory cells (Eliason et al., 2005) (Table 1.2 & 
Table 1.3). Notably, inhibition of antigen-induced allergic reactions, a mast cell target, 
pemirolast, was investigated in a randomized clinical trial (Sillesen et al., 2015). Another 
interesting pharmacological target for AAA formation has been inhibition of proteases such as 
MMPs (Ennis et al., 2012), serine protease (Deng et al., 2003) and cysteine protease (Sun et 
al., 2012) (Table 1.2 & Table 1.3). In particular, inhibition of MMPs such as MMP-2 and 
MMP-9 are an interesting target since these proteases are consistently demonstrated within the 
aortic tissue of AAA patients and in blood markers (Golledge et al., 2009; Meijer et al., 2013; 
Mosorin et al., 2001). However, translation of pre-clinical findings into clinical trials has 
continued to yield disappointing outcomes. A comprehensive systematic review and meta-
analysis by Golledge et al (2019) that examined the effect of different antibiotic regimens on 
AAA progression in randomised placebo-controlled trials showed no significant effects on 
AAA growth rate (mm/year). Further analysis on effects of different antihypertensive drugs, 
including propanol, perindopril and amlodipine on reduction of AAA rupture or delaying AAA 
surgical repair (defined as clinical events) in randomised placebo-controlled trials showed 
marginal benefits (Golledge et al., 2019). 
 
Most pre-clinical investigations in AAA research have been investigated in mouse models 
(Davis et al., 2014; N. Sakalihasan et al., 2018). Given, the differences between humans and 
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animal models, it is also important that effectiveness of pharmacological interventions be 
studied using human cells and possibly in human AAA explant culture (Davis et al., 2014; 
Manning, Cassi, Huang, Szilvassy, & Daugherty, 2002). Regulation of pro-inflammatory 
mediators, the renin-angiotensin system (RAS) are thought to be critical targets in order to halt 
the development and progression of pre-existing AAA have also been investigated (Golledge 
et al., 2019; Sakalihasan et al., 2018; Natzi Sakalihasan et al., 2005). In addition, abrogation of 
ECM degradation through inhibition of MMPs is also believed to be an effective approach in 
preventing AAA development and progression (Golledge et al., 2019; Golledge, Norman, et 
al., 2017; Sakalihasan et al., 2018). Previously, treatment with HMG-CoA reductase inhibitors 
(statins) or angiotensin-converting enzyme inhibitors was also effective in reducing 
inflammatory responses in human AAA tissue culture (Yoshimura et al., 2018).  In addition, 
AAA cell therapy that has been performed using local infusion of bone marrow-derived 
mesenchymal stem cells (BM-MSCs), endothelial cells or VSMCs, as well as systemic 
injection of BM-MSCs, was shown to be effective in suppressing the progression of pre-
existing AAA in animal models (Allaire et al., 2004; Schneider et al., 2013; Yamawaki-Ogata 
et al., 2014). 
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Figure 1.2: Hypothetical model of AAA pathogenesis. 
Development and progression of AAA is believed to be driven by inflammation and matrix remodelling. These processes result in breakdown of 
extracellular matrices (ECM), apoptosis of vascular smooth muscle cells (VSMCs) and activation of immune response. AAA tissue samples exhibit 
increased local production of collagenases, elastase, and MMPs which degrade collagen and elastin ECM proteins. Serine proteases, neutrophil 
elastase, as well as cysteine proteases are also elevated in AAA tissue. These proteinases are produced by macrophages, ECs, VSMCs and 
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High blood pressure is thought to play an important role in the development and progression 
of AAA in a sense that hypertension affects the aortic wall ability to withstand the 
haemodynamic stress in AAA patients (Kobeissi, Hibino, Pan, & Aune, 2019). Current clinical 
guidelines suggest that CVD related events and risk factors should be promptly managed in 
patients with AAA (Golledge & Norman, 2011; Golledge & Powell, 2007; Lindeman & 
Matsumura, 2019). Propranolol, a β-blocker, was one of the first drugs to be proposed for 
inhibition of AAA development in animal models (Lindeman & Matsumura, 2019). Seemingly, 
the choice to test propranolol in subsequent clinical trials is because pre-clinical studies in 
animals had used this beta-blocker, suggesting that other beta-blocker agents would perhaps 
work in similar manner  (Brophy, Tilson, & Tilson, 1989; Ricci et al., 1996; Simpson, 1972; 
Simpson & Boucek, 1983; Simpson, Boucek, & Noble, 1976; Slaiby, Ricci, Gadowski, 
Hendley, & Pilcher, 1994). However, in a randomized trial, AAA patients did not tolerate 
propranolol well, and the drug did not significantly affect the growth rate of AAA 
(Investigators., 2002). Randomized clinical trials of antibiotics, including doxycycline and 
azithromycin, were conducted previously, but did not clearly demonstrate the effect of reducing 
AAA growth rate (Golledge et al., 2019; Lindeman & Matsumura, 2019; Meijer et al., 2013). 
Disappointingly, another randomised trial that investigated effects of  doxycycline, an MMP 
inhibitor, in a larger number of patients for a longer period (18 months) still reported that 
doxycycline treatment did not reduce AAA growth or delay the need for patients to require 
AAA surgical repair (Meijer et al., 2013). Recently, pemirolast, a mast cell inhibitor, and 
perindopril, an ACE inhibitor, have been investigated in patients but neither drug reduced AAA 
growth rate (Sillesen et al., 2015). Several small observational studies demonstrated an 
association between statin administration and decreased AAA growth, although the beneficial 
effect of statins has not been confirmed in larger clinical trials (Kokje et al., 2015; Lysgaard 
Poulsen, Stubbe, & Lindholt, 2016; Yoshimura et al., 2018). There is therefore no scientific 
evidence currently to support the efficacy of pharmacological treatment to reduce AAA growth 
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Table 1.2: Examples of targeted pathways and mechanisms in previous 
pharmacotherapy studies 
Targeted cluster Reported mechanisms References* 
Antibiotics Elimination of Chlamydia 
pneumoniae‡ 
Karlsson, et al (2009) 
Anti-inflammatory Inhibition of NFκB 
AP-1  
Saito, et al (2013) 
Yoshimura, et al (2005) 
Inhibition Rho kinase Wang, et al (2005) 
Inhibition of IL1  
TNFα 
CCL-1 
Johnston, et al (2013) 
Xiong, et al (2009) 
Wang, et al (2014) 
Depletion of B cell or γδT-cells Schaheen, et al (2016) 
Zhang, et al (2018) 
Neutrophil inhibition Eliason, et al (2005) 
Baxter & Pipinos (2006) 
Mast cell inhibition‡ Sillesen, et al (2015) 
Complement inhibition Zhou, et al (2013) 
Oxilipin inhibition Ahluwalia, et al (2007) 
Immune suppression Marinkovic, et al (2013) 
Protease inhibition MMP inhibition‡ Allaire, et al (1998) 
Ennis, et al (2012) 
Cysteine protease inhibition Sun, et al (2012) 
Serine protease inhibition Deng, et al (2003) 
Oxidative stress Antioxidant enzymes Maiellaro-Rafferty, et al (2011) 
Secondary antioxidants Gavrila, et al (2005) 
Blood pressure 
lowering 
β-Blockers‡ Lindholt, et al (1999) 
Propranolol Aneurysm Trial 
(2002)  
Ca antagonists Miao, et al (2015) 
ACE inhibitors‡ Xiong, et al (2014) 
Liao, et al (2001) 
ATR1 antagonists Iida, et al (2012) 
iNOS inhibition Lizarbe, et al (2009) 
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Lipid metabolism Statins Shiraya, et al (2009) 
Kalyanasundaram, et al (2006) 
HDL Delbosc, et al (2016) 
PPARα/γ activation ‡ Golledge, et al (2010) 
 Krishna, et al (2012) 
 RXR Escudero, et al (2015) 
Martorell, et al (2016) 
Cell therapy Mesenchymal stem cells Blose, et al (2014) 
Fibroblasts Giraud, et al (2017) 
Matrix/morphogens Interference with TGF-β 
signalling 
Gaoand, et al (2014) 
Interference with NOTCH 
signalling  
Cheng, et al (2014) 
Interference with Wnt signalling  Krishna, et al (2017)  
Thrombospondin inhibition  Krishna, et al (2015) 
EGFR inhibition Obama, et al (2015) 
Metabolism Inhibition of HIF1α Yang, et al (2016) 
Activation of AMPK Yang, et al (2017) 
Nutraceuticals Polyphenols Wang, et al (2017) 
Phytoestrogens Lu, et al (2014) 
Omega-3 fatty acids Meital, et al (2019) 
Resveratrol Moran, et al (2017) 
Sex hormones Castration Zhangand, et al (2015) 
Oestrogens Martin-McNultyand, et al (2003) 
Abbreviations: ACE: angiotensin-converting enzyme; AMPK, 5' AMP-activated protein 
kinase; AP-1, activator protein-1; ATR1, angiotensin II receptor type 1; CCL-1, chemokine 
(C-C motif) ligand; EGFR, epidermal growth factor receptor; HDL, high-density 
lipoprotein; HIF1α, hypoxia-inducible factor 1-alpha; IL-1, interleukin-1; iNOS, inducible 
NO synthase; MMP, matrix metalloproteinase; NFκB, nuclear factor-κB; NOTCH, notch 
homolog, translocation-associated;  PPARα/γ, peroxisome proliferator–activated receptor 
α/γ; RXR, retinoid X receptor; TGF-β, transforming growth factor-β; and TNF-α, tumour 
necrosis factor-α. * Not an exhaustive list of references; ‡ Indicates targeted mechanisms 
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1.2. SOST AND WNT/Β-CATENIN SIGNALLING IN AAA 
AAA is a multifactorial and multistage disease; and given the complex pathophysiological 
mechanisms, potential therapies should plausibly possess pleiotropic effects. One interesting 
pathways that is emerging as important in cardiovascular and vascular wall function is Wnt/β-
catenin signalling (Foulquier et al., 2018). Wnt/β-catenin signalling negative regulators play 
an important role in bone diseases and other pathophysiological conditions (Marinou, 
Christodoulides, Antoniades, & Koutsilieris, 2012; Mason & Williams, 2010; Nusse & 
Clevers, 2017). Mechanistically, in the absence of competitive ligands, Wnt molecules interact 
with the frizzled receptors, mainly LRP5/6, which leads to downstream effects on cytosolic 
subunits such as phosphorylation of the GSK-3α/β and upregulation of axin (Jho et al., 2002). 
Phosphorylated GSK-3α/β results in dissociation and accumulation of the β-catenin complexes 
in the cytoplasm. The β-catenin complex then translocates to the nucleus and mediates gene 
transcription through TCF/LEF transcriptional factors. In the presence of competitive Wnt 
inhibitors, however, non-phosphorylation of the GSK-3α/β subunits results in proteasomal 
degradation of β-catenin thus limiting further translocation into the nucleus. Activation of 
Wnt/β-catenin signalling releases the β-catenin from the binding protein subunits such as axin 
and increases the cytoplasmic accumulation of β-catenin subunits, eventually promoting 
nuclear translocation of these subunits. Within the nucleus, β-catenin interacts with 
transcriptional factors, initiating the expression of several target genes (Nusse & Clevers, 
2017). Conversely, in the absence of Wnt binding, perhaps due to competitive inhibitors such 
as Sost or Dkk-1, β-catenin is in a steady state, and free β-catenin is eventually degraded by 
26S proteasome (Nusse & Clevers, 2017). Wnt/β-catenin signalling controls the expression of 
OPG, OPN and matrix metalloproteinase (MMP) -2, -7 and -9 which have all been implicated 
in AAA pathogenesis (Maruotti, Corrado, Neve, & Cantatore, 2013; Wu, Crampton, & Hughes, 
2007; Zhang, Gaspard, & Chung, 2001).
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Table 1.3: Examples of pharmacological agents tested in pre-clinical AAA studies and have progressed to randomised clinical trials 
Agent Reported findings from pre-clinical studies* Clinical trial Trials outcomes on AAA diameter 
Propranolol Findings: Propranolol preserved structural 
morphology aortic elastic fibres which was 
associated with reduction of aortic rupture in 
turkeys whereby AAA was induced by β-
aminopropionitrile (BAPN) (Charles F. Simpson 
et al., 1976).  
In normotensive and genetically hypertensive rats 
in which AAA was induced by perfusion of the 
isolated infrarenal aorta with elastase; 
propranolol slowed AAA size postoperatively 
Propranolol versus placebo trial  
(Lindholt et al., 1999) 
AAA annual growth rate was similar 
between the placebo and the 
propanol group.  
18 | P a g e  
 
which was assessed at days 7 and 14 (Ricci et al., 
1996; Slaiby et al., 1994). 
 
Mechanisms:  Increased aortic tensile strength, 
decrease in blood pressure, lower heart rate and 
reduced myocardial contractility (Simpson, 1972; 
Simpson & Boucek, 1983; Simpson et al., 1976). 
Reduced systolic tail blood pressure monitored 
with a plethysmograph (Ricci et al., 1996; Slaiby 
et al., 1994). 
 
Propranolol for Small 
Aneurysms (Investigators., 
2002). 
Patients in the propranolol group had 
significantly poorer quality of life 
scores in the physical functioning, 
which questioned the safety and 
tolerability of the drug 






Findings: Treatment of Chlamydia pneumoniae 
infected rabbits with azithromycin at early stage 
prevented atherosclerosis which was thought to 
be a cause for AAA development (Fong et al., 
1999; Kol, Bourcier, Lichtman, & Libby, 1999). 
 
Mechanism: Antibiotic (Macrolide) were 
associated with presence of Chlamydia 
Azithromycin Trial 
(Karlsson et al., 2009)  
No effect with Azithromycin on 
AAA expansion and no correlation 
was found between serological 
markers for Chlamydia pneumoniae 
and AAA expansion which 
suggested that no clinical relevance 
for Chlamydia pneumoniae testing in 
AAA surveillance. 
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pneumonia which results in atherosclerosis 
plaques formation within the aorta, which was 
thought to be a cause for AAA development. 
Both Azithromycin and Roxithromycin are 
antibiotics that limited growths of Chlamydia 
pneumoniae. 
Roxithromycin Trial 1 
(Vammen, Lindholt, Ostergaard, 
Fasting, & Henneberg, 2001) 
During the first year the mean annual 
expansion rate of AAAs was reduced 
by 44% in the Roxithromycin group. 
During the second year the 
difference was only 5%. Multiple 
linear regression analysis showed 
that Roxithromycin treatment and 
initial AAA size were significantly 
related to AAA expansion when 
adjusted for smoking; diastolic blood 
pressure and immunoglobulin A. 
Roxithromycin Trial 2 
(Hogh et al., 2009) 
Intermittent, long-term 
Roxithromycin-treatment reduced 
mean annual growth rate by 36% 
compared with placebo after 
adjustment for potential confounders. 
Long-term Roxithromycin-treated 
patients had a 29% lower risk of 
being referred for surgical 
evaluation, increasing to 57% after 
adjusting for potential confounders. 
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Doxycycline Findings: Doxycycline inhibited MMP activity 
and elastin degradation of the aortic wall and 
attenuated AAAs development in individual 
animals  (Pyo et al., 2000).  
 
AAA-suppressing effects of doxycycline were 
reported to be dose-dependent and were different 
from its antibiotic activities, and they coincide 
with the structural preservation of medial elastin 
fibres (Curci et al., 2000; Curci, Petrinec, Liao, 
Golub, & Thompson, 1998). 
 
Mechanism: Antibiotic was shown to limit 
Chlamydia pneumoniae and limit MMP 
degradation of the aortic wall. 
Doxycycline Trial I 
(Mosorin et al., 2001) 
AAA expansion rate in the AAA 
diameter was lower in doxycycline 
treated group compared with placebo 
group during the 6- to 12-month 
follow-up period. 
Doxycycline Trial II 
(Baxter et al., 2016) 
The outcome is yet to be reported.  
PHAST Trial 
(Meijer et al., 2013) 
Treatment with doxycycline 
surprisingly increased AAA growth 
rate compared with placebo group 
during the 18-month follow-up 
period 
Pemirolast Findings: reported that human AAA lesions had 
high numbers of chymase-immunoreactive mast 
cells and serum chymase level were found to be 
correlated with AAA growth rate AAA in in 
wild-type mice and mice deficient in mast cell 
protease-4 (Sun et al., 2009). 
AORTA trial 
(Sillesen et al., 2015) 
There was no difference in AAA 
growth between patients who were 
treated with pemirolast and placebo. 
Pemirolast intervention did not affect 
the need for AAA surgery repair. 
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Inhibition of chymase by a specific chymase 
inhibitor, NK3201, was shown to suppress 
MMP-9 in a dog AAA model (Furubayashi et al., 
2007), inhibited AAA development in a hamster 
experimental model (Tsunemi et al., 2004); and 
inhibited elastase-induced AAA in mice (Sun et 
al., 2007). 
 
Mechanism: Mast cells develop from bone 
marrow-derived progenitor cells and are present 
as two different types (one type, which expresses 
tryptase, and another type, which expresses 
chymase, carboxypeptidase and cathepsin G). 
Mast cells are known to limit inflammation and 
chronic MMP proteolysis in the aortic wall. 
Mast cells are already known to reduce antigen-
induced allergic reactions in patients. 
Fenofibrate Findings: Administration of Fenofibrate or 
pioglitazone in AngII-infused ApoE−/− mice 
resulted in reduced suprarenal aortic diameter 
and reduced OPN cytokines and macrophage 
FAME-2 Trial 
(Pinchbeck et al., 2018) 
Fenofibrate did not reduce AAA 
growth rate in comparison with 
placebo controls  
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infiltration compared to vehicle control mice (J. 
Golledge et al., 2010).  
Also, Fenofibrate administration in low-density 
lipoprotein receptor-deficient resulted in reduced 
suprarenal aortic diameter, reduced aortic arch 
atherosclerosis reduced infiltration of 
macrophages, T lymphocytes compared with 
controls receiving vehicle (Krishna et al., 2012). 
 
Mechanism: Fenofibrate is PPARα ligand that 
limits osteopontin and macrophages infiltration 




Findings: Perindopril was reported to inhibit 
aortic degeneration and AAA formation in a rat 
model of AAA (F. Xiong et al., 2014).  
 
Mechanism: ACE-Inhibitors that are effective 
for reducing blood pressure. However, effects of 
Perindopril appear to be independent of its 
influence on blood pressure but rather its ability 
to inhibit inflammatory cell influx and protection 
AARDVARK 
(Kiru, Bicknell, Falaschetti, 
Powell, & Poulter, 2016) 
Neither perindopril nor amlodipine 
significantly reduced the AAA 
growth rate over 24 months of 
follow-up. 
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against intimal thickening and the preservation of 
aortic medial elastin. 
Ticagrelor Findings: Treatment with AZD6140, a P2Y(12) 
receptor antagonist, inhibited platelet activation 
and attenuated of experimental AAA in rats in 
which AAA was induced by implanting a 
segment of sodium dodecyl sulphate-
decellularised guinea pig aorta in rat aortas (Dai, 
Louedec, Philippe, Michel, & Houard, 2009). 
  
Mechanism: As a platelet inhibitor, Ticagrelor 
inhibits platelet aggregation and prevents ILT 
formation. 
TicAAA Trial  
(Wanhainen et al., 2019) 
Ticagrelor did not reduce growth of 
small AAAs 
AAA: abdominal aortic aneurysm. NK3201: 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[3,4-dioxo-1-phenyl-
7-(2-pyridyloxy)]-2-heptyl]acetamide; AngII: Angiotensin II; ApoE−/−: Apolipoprotein E-null; PPARα: peroxisome proliferator–
activated receptor α/γ;  AT1: Angiotensin II receptor 1; MMP: matrix metalloproteinases; ILT: intraluminal thrombus * References to 
preclinical studies is not an exhaustive list. 
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The Wnt signalling pathway regulates cell-to-cell interactions, including cell polarity, 
differentiation, migration and apoptosis as well as overall tissue morphogenesis (MacDonald, 
Tamai, & He, 2009). SOST is a protein product of the SOST gene, a potent bone morphogenic 
protein antagonist previously known to be exclusively expressed by osteocytes. SOST has been 
shown to modulate osteoblast proliferation, differentiation, apoptosis and matrix formation and 
mineralization of mature osteoblasts (Keller & Kneissel, 2005; Sutherland, Geoghegan, Yu, 
Turcott, et al., 2004; van Bezooijen, ten Dijke, Papapoulos, & Löwik, 2005; Winkler et al., 
2003). As a competitive inhibitor for Wnt signalling, SOST binds to the low-density lipoprotein 
receptor-related proteins 5 and 6, thereby acting as a Wnt antagonist (Brandenburg et al., 2015; 
Krishnan, Bryant, & MacDougald, 2006; Xiaofeng Li et al., 2005; Vaclav Veverka et al., 
2009). In the presence of the Wnt ligand and its interaction with the Frizzled receptors and low-
density lipoprotein receptor-related protein 5/6 co-receptors, the β-catenin complex is 
stabilised and able to translocate to the cell nucleus where it modulates gene transcription. 
(MacDonald et al., 2009). In the absence of the Wnt ligand, proteasomal degradation of the β-
catenin complex occurs prior to reaching the nucleus and before modulating gene transcription 
(MacDonald et al., 2009).  
Data published from our laboratory previously showed that an experimental mouse model of 
AAA exhibited 3-fold downregulation in aortic expression of the SOST gene compared to mice 
that did not develop AAA (Rush et al., 2009). Subsequently, results from human AAA and 
experimental mouse models corroborated these findings showing that SOST was 
downregulated in human AAA tissue as well as in mice that developed larger AAA (Figure 
1.3A—B) (Krishna et al., 2017). Additionally, it was demonstrated that SOST injection and 
transgenic SOST-overexpression in mice inhibited AAA formation (Figure 1.3C) (Krishna et 
al., 2017). Nonetheless, although these data support the role of SOST deficiency in AAA 
development, the exact underlying mechanisms that lead to downregulation of SOST protein 
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Figure 1.3: Human and mice expression of SOST 
Western blot showing downregulation of SOST in human (A) and AngII-infused mice (B). 
SRA diameter was decreased in response to mrSOST injection and in SOST tg mice (C).  
Abbreviations: AAA: abdominal aortic aneurysm; SRA suprarenal aortic, tg: transgenic; 
AngII: angiotensin II; mrSOST: human recombinant sclerostin. Adapted from (Krishna et al., 
2017).
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Figure 1.4. : SOST downregulation is implicated in AAA development 
When active, SOST binds to Wnt co-receptor LRP5/6 to inhibit Wnt1 class signalling. Wnt 
interacts at the cell surface with frizzled receptor (Fzd) and low-density lipoprotein receptor-
related 5/6 (LRP5/6). In the cytoplasm, β-catenin binds to the multiprotein complex containing 
kinases such as Gsk3-α/β and Casein kinase-1, which phosphorylates specific amino acids on 
the β-catenin. In the absence of Wnt binding, β-catenin is in a steady state and free β-catenin 
is eventually degraded by 26S proteasome. In contrast, activation of Wnt binding releases the 
β-catenin from the binding proteins, inhibits its phosphorylation, resulting in accumulation of 
β-catenin cytoplasmic levels and eventually promotes its translocation into the nucleus. After 
translocation, β-catenin interacts with transcriptional factors initiating the expression of several 
27 | P a g e  
 
target genes. It is possible that the SOST promoter undergoes inactivation due to DNA 
methylation; resulting in the activation of Wnt signalling which then promotes atherosclerosis, 
inflammation and degradation of ECM, thus promoting development of AAA. (Red arrows 
show activated pathway and blue shows inhibition). Abbreviations: p-Gsk3-α/β: 
phosphorylated glycogen synthase kinase 3-α/β, SOST, sclerostin; TF, transcription factor. 
Adapted from Krishna, et al (2017).  
 
1.3. VITAMIN D 
The term “vitamin D” is a misnomer usually used to describe CCF (vitamin D3) and 
ergocalciferol (vitamin D2) as well as their derived metabolites. The active metabolite of 
vitamin D is 1α,25(OH)D which has to undergo a number of hydroxylation steps before 
activation. It was not until 1930s when a German team led by Windaus clarified the chemical 
structure of vitamin D (Hirsch, 2011). Vitamin D is a group of fat-soluble seco-steroids 
(steroids with broken ring) which take the responsibility of regulating calcium and phosphorus 
balance in the body (Holick, 2006). The structure of vitamin D is almost similar to that of 
cholesterol, except vitamin D has double bonds between C-7 and C-8, and C-10 and C-19, and 
an open B ring structure (Hollis, 2005). There are two main forms of vitamin D in the human 
body, CCF (vitamin D3) and ergocalciferol (vitamin D2) and both have four intact rings in 
their inactive form. When the strength of sunlight UVB reaches the wavelength ranging 
between 290-315 nm, the bond between C-9 and C-10 of the B ring breaks down (Hollis, 2005). 
Consequently, a double bond is formed between C-10 and C-19, making the pre-vitamin D3. 
Thermogenic isomerization plays the major role in turning pre-vitamin D3 to CCF. In a similar 
manner, ergosterol from plant sterols or yeast can be irradiated to form supplemental 
ergocalciferol. 
CCF is produced endogenously and is transported to the liver using D-binding protein (DBP), 
while supplemented D2 or D3 within the dietary fats are primarily absorbed in the duodenum. 
Both CCF and ergocalciferol are then transported to the liver through lymph channels. Within 
the liver, CP27A1, one of the monooxygenase enzymes of the cytochrome P450 family, adds 
a hydroxyl group to C-25 forming 25-hydroxyvitamin D3 or D2 [25(OH)D] (Christakos, 
Dhawan, Verstuyf, Verlinden, & Carmeliet, 2016). In turn, 25(OH)D is further metabolized to 
the “active” form of vitamin D by hydroxylation of C-1 in the kidney. This role is accomplished 
by another member of cytochrome P450 family, CYP27B1, to produce 1-alpha-25-
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dihydroxyvitamin D3 or D2 (1α,25(OH)2D), widely known as calcitriol (Christakos et al., 
2016). Although, the conversion of pre-vitamin D to 25(OH)D is not well regulated, the 
conversion to the active 1α,25(OH)2 form is tightly regulated by high parathyroid hormone 
(PTH) and low levels of calcium and phosphorus (Christakos et al., 2016). When circulating 
levels of calcium decrease and/ or the serum phosphate level increases, it triggers the release 
of calcium from the bones, enhances active reabsorption of calcium distal tubules and increases 
the absorption of calcium in the intestine (Bikle & Bouillon, 2018).  
Table 1.4: Vitamin D and derivatives—nomenclature  
Name Source Function Different names 
7-DHC cholesterol precursor 






created from irradiation 




vitamin D3 made in the skin when 
exposed to light; sourced 





25(OH)D A product of 
hydroxylation of vitamin 
D (mainly) in the liver 
Main circulating 
form of vitamin D 
(considered best 
indicator of 





A product of 25(OH)D 
hydroxylation in renal 
tubules and other target 



















present in infants 
3-epi-25-hydroxyvitamin 
D 
Notes: Both vitamin D2 and vitamin D 3 must undergo the same pathway for downstream 
metabolism with derivatives having comparable biological actions. The distinction between 
their derivatives is connoted 2 or 3 at the end (e.g. 25(OH)D3 or 25(OH)D2. 
Abbreviations: 1α, 25-dihydroxyvitamin D; 7-DHC: 7-dehydrocholesterol 
 
It is thought that almost a sixth of people worldwide do not have adequate levels of circulating 
25(OH)D in their blood (Gordon, DePeter, Feldman, Grace, & Emans, 2004; Holick, 2007). 
Contemporary reports suggest that there is a worldwide deficiency of vitamin D in most 
populations, especially infants, pregnant and lactating women, people living away from the 
equator, persons who are not exposed to the sun, and populations with dark skin pigmentation 
(Jamil et al., 2018; Kuhnlein, 2018; Macdonald et al., 2011). A cross-sectional study  including 
727 females living in Sweden found that serum levels of 25(OH)D3 are positively associated 
with age, oral contraceptive use, and seasonal variations in blood collection (summer / autumn) 
(Macdonald et al., 2011). Circulating levels of 25(OH)D3 were also positively associated with 
a high dietary intake of vitamin D and serum concentrations of creatinine, phosphate and 
calcium. The positive association between vitamin D and contraceptives can be explained by 
the fact that oestrogen increases the levels of 25(OH)D-binding proteins (Grzechocinska, 
Warzecha, Szymusik, Sierdzinski, & Wielgos, 2018; Mayor, 2016). However, there is currently 
strong evidence showing that vitamin D deficiency is predominantly prevalent among elderly 
people (Boucher, 2012; MacLaughlin & Holick, 1985). Possible explanations for this 
association have been related to poor cutaneous photosynthesis, decreased intestinal 
absorption, impaired renal function and restricted sun exposure (Boucher, 2012; MacLaughlin 
& Holick, 1985; Tsiaras & Weinstock, 2011).  
Activated vitamin D exerts its cellular functions by modulating the transcription of target genes 
after binding to the nuclear Vitamin D Receptor (VDR) (Rachez & Freedman, 2000). 
Interaction of VDR with its ligand 1α,25(OH)2D3 induces formation of two independent 
protein interaction sur-faces on the VDR, one that facilitates association with the retinoid X 
receptor (RXR) necessary for DNA binding, and one that is required for recruitment of co-
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regulators necessary for gene modulation (Christakos et al., 2016; Rachez & Freedman, 2000). 
Following interaction with 1α,25(OH)2D3-VDR dimerizes with RXR and translocates to the 
nucleus where it binds to vitamin D response elements (VDRE) in vitamin D responsive genes 
(Christakos et al., 2016). Depending on the target gene, either co-activators or co-repressors 
are attracted to the VDR/RXR complexes to induce or repress gene transcription (Christakos 
et al., 2016). VDR was found to be expressed in almost all body cells, including immune, 
myocardial or vascular cells, points to involvement of vitamin D-mediated effects in several 
other systems not only the musculoskeletal system (Bikle & Bouillon, 2018; Christakos et al., 
2016; Giustina et al., 2019). These actions involve the regulation of calcium homeostasis, cell 
growth and differentiation and modulation of adaptive and innate immunity (Christakos et al., 
2016; Di Rosa, Malaguarnera, Nicoletti, & Malaguarnera, 2011). VDR expression and activity 
are important for all stages of a T cells life, ranging from development to differentiation and 
elicitation of effector functions (Cantorna, Snyder, Lin, & Yang, 2015; Di Rosa et al., 2011). 
The genes encoding for 1α,25(OH)2D3-catabolizing cytochrome P450 enzyme (CYP24A1) 
and the human cathelicidin antimicrobial protein (CAMP) are examples of 1α,25(OH)2D3-
regulated target genes (Heulens et al., 2016). Previous evidence suggests that differential 
expression of CYP24A1 and CAMP may affect vitamin D status (Heulens et al., 2016) and 
susceptibility to infectious diseases (Cantorna et al., 2015; Di Rosa et al., 2011). 
1.3.1. Vitamin D and cardiovascular disease 
Physiologically, vitamin D is sourced from cutaneous radiation by ultraviolet B (UVB) and 
dietary intake, followed by hepatic hydroxylation to 25(OH)D (main circulating metabolite) 
and renal hydroxylation to 1α, 25-dihydroxyvitamin D [1α,25(OH)2D] (hormonally bioactive 
metabolite) (Dusso, Brown, & Slatopolsky, 2005; Holick & Chen, 2008). 25(OH)D circulates 
bound to DBP and accounts for endogenous and exogenous sources. Assay of 25(OH)D 
metabolite is recommended for assessment of vitamin D status (Holick et al., 2011). In addition 
to transportation of vitamin D metabolites in the circulation, DBP also regulates the uptake of 
25(OH)D and 1α,25(OH)2D by target cells (Dusso et al., 2005). The classic role of vitamin D 
is to regulate calcium and bone homeostasis. However, an increasing body of evidence shows 
that vitamin D exerts numerous biological benefits in extra-skeletal tissue and cells (Holick & 
Chen, 2008). Interestingly, pathological links between mineral and bone disorders, renal 
diseases and cardiovascular diseases (CVD) has been indicated by previous evidence 
(Brandenburg et al., 2015; Lampropoulos, Papaioannou, & D'Cruz, 2012). Recent studies have 
shown that deficiency of vitamin D is an important risk factor for CVD, including ischemic 
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heart disease, stroke, hypertension and atherosclerosis (Kim, Sabour, Sagar, Adams, & 
Whellan, 2008). Observational studies have shown that low 25(OH)D is associated with 
peripheral arterial diseases (PAD) (Fahrleitner-Pammer et al., 2005; Fahrleitner et al., 2002; 
McDermott et al., 2014; Michal L. Melamed et al., 2008; Zagura et al., 2011), a common 
comorbidity with AAA (Olin & Sealove, 2010). Finally, a meta-analysis performed on these 
cross-sectional studies demonstrated that lower levels of 25(OH)D were associated with PAD 
presence, particularly in patients with advanced PAD symptoms (Nsengiyumva et al., 2015). 
The rennin-angiotensin-system (RAS) plays an essential role in the pathogenesis of 
cardiovascular diseases and has been consistently implicated in AAA formation (Carrara et al., 
2014). Paricalcitol, a bioactive analog of 1α,25(OH)2D3 was shown to prevent cardiac 
hypertrophy in rats infused with a moderate dose of AngII (800 ng/kg/min) over a 14-day 
period (Chen & Gardner, 2013). In addition, administration of paricalcitol (intraperitoneal 
injection of 300 ng/kg every48 hours) resulted in partial reversal of AngII effects (Chen & 
Gardner, 2013). Moreover, Kong, et al (2010) previously showed that a combination of vitamin 
D analog with losartan generates a degree of therapeutic synergism in the attenuation of left 
ventricular hypertrophy. 
Previously, 1α,25(OH)2D has been shown to inhibit the RAS lowering the blood pressure and 
improve endothelial function through regulation of endothelial cell-dependent vasodilation (Al 
Mheid & Quyyumi, 2017; Carrara et al., 2014; Schroder-Heurich et al., 2019). The relationship 
between vitamin D and hypertension was also reported by the NHANES III study which 
demonstrated that the average systolic blood pressure (SBP) was nearly 3 mm Hg lower in 
subjects with the highest quartile of 25(OH)D compared with those in the lowest quartile 
(Scragg, Sowers, & Bell, 2007). A meta-analysis of 3 cohorts showed that lower circulating 
25(OH)D were associated with an 80% higher risk of  the incidence  of hypertension (Pittas et 
al., 2010). However, a separate analysis of 10 clinical trials suggested reported that vitamin D 
supplementation reduced SBP by only 2 mm Hg and had no effect on diastolic blood pressure 
(Pittas et al., 2010). Nonetheless, a meta-analysis of 10 randomized controlled trials that 
examined the effects of vitamin D supplementation (with or without calcium) on blood pressure 
and incident hypertension found a very modest and non-significant improvement in SBP and 
diastolic blood pressure with supplementation. A higher dose (1000 IU/day) of vitamin D, 
compared with lower doses, had no effect on SBP but a small effect on diastolic blood pressure 
(Pittas et al., 2010). Upregulated expression of CYP24A1 gene, which encodes an enzyme that 
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catalyses 25(OH)D and 1α,25(OH)2D3 into 24-hydroxylated products has been associated with 
higher SBP and DBP (Kunutsor, Burgess, Munroe, & Khan, 2014).  
It has been previously suggested that obesity is risk factors for AAA development, albeit 
inconsistently (Cronin, Walker, & Golledge, 2013; Stackelberg, Bjorck, Sadr-Azodi, et al., 
2013). Wortsman and colleagues (2000) reported that obesity is associated with decreased 
bioavailability of vitamin D characterised by lower 25(OH) in obese patients. Two main 
explanations were hypothesized for this relationship, the first one was that continuous vitamin 
D deposition in adipose tissue leads to lower circulating 25(OH)D levels in the blood while the 
other theory posited that vitamin D deficiency may be a contributing factor leading to obesity  
(Foss, 2009; Wortsman et al., 2000). However, a bi-directional Mendelian Randomization 
study lately showed a one directional causal relationship supporting that obesity leads to lower 
vitamin D levels (Vimaleswaran et al., 2013). In this study, 21 cohorts were included, 
comprising a total number of 42,024 adult patients and 12 well-known single nucleotide 
polymorphisms (SNPs) related to body mass index (BMI) and four typical vitamin D-related 
SNPs were analysed. It was demonstrated that each unit increase of BMI was associated with 
a 1.15% decrease of 25(OH)D after adjustments for other confounders. Conversely, genetically 
determined 25(OH)D levels were not significantly related to BMI, suggesting that obesity may 
be causal for lower 25(OH)D and not vice-versa (Vimaleswaran et al., 2013). 
Several recent studies have reported high rates of CV diseases in patients with lower circulating 
levels of 25(OH)D, suggesting that deficiency of vitamin D plays a role in cardiac pathology. 
In 1,739 Framingham Offspring Study participants who were free of CV disease at baseline, 
the rate of major CV disease events was 53% to 80% higher among those with low vitamin D 
levels, with the increased risk magnified among those with hypertension (Wang et al., 2008). 
It was however suggested that a slight increase in CV risks was also associated with higher 
25(OH)D levels (Wang et al., 2008). In an analysis of 13,331 adults from the NHANES III 
study followed up for a median of 8.7 years, mortality was inversely associated with vitamin 
D levels, with the lowest quartile of 25(OH)D (<17.8 ng/ml) having a 26% increased mortality 
compared with the highest quartile (Melamed, Michos, Post, & Astor, 2008). A prospective 
study of 3,258 consecutive patients scheduled for coronary angiography, low 25(OH)D and 
1α,25(OH)2D levels were independently associated with all-cause and CV mortality (Dobnig 
et al., 2008). Moreover, a 10-year follow-up of 18,225 men in the Health Professionals Follow-
up Study reported that low levels of 25(OH)D were associated with higher risk of myocardial 
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infarction, even after controlling for other coronary heart diseases risk factors (Giovannucci, 
Liu, Hollis, & Rimm, 2008). It should however be noted that not all studies reported on a 
significant association between low 25(OH)D levels and increased risk of CVD (Welsh et al., 
2012). Furthermore, the efficacy of vitamin D supplementation on CVD risks remains topically 
debatable. A meta-analysis that summarized randomized trials of vitamin D supplementation 
(until 2010) reported no significant effect of vitamin D on death, stroke, myocardial infarctions, 
lipid fractions, blood pressure, or blood glucose values. It is also important to mention that they 
analysed randomized trials with enrolled participants without severe vitamin D deficiency 
(Elamin et al., 2011). Comprehensively, an umbrella review of systematic reviews and meta-
analyses performed on observational studies and randomised trials on vitamin D and multiple 
health outcomes reported found that available evidence is less convincing on effects of vitamin 
D and multiple health outcomes (Theodoratou, Tzoulaki, Zgaga, & Ioannidis, 2014). 
1.3.2. Vitamin D and Inflammation 
Administration of 1α,25(OH)2D to subjects with vitamin D deficiency has been shown to 
down-regulate inflammatory biomarkers such as C-reactive protein (Christakos et al., 2016). 
VDR have a broad tissue distribution that includes VSMCs, macrophage, and lymphocytes 
(Christakos et al., 2016; Zhang et al., 2012). Moreover, there is evidence that VSMCs and 
endothelial cells possess the enzyme 25(OH)D-1 α-hydroxylase, which is responsible for the 
conversion of 25(OH)D to 1α,25(OH)2D (Norman & Powell, 2014). Vitamin D induces 
prostacyclin in VSMCs, which prevents thrombus formation, cell adhesion, and VSMC 
proliferation (Norman & Powell, 2014). Furthermore, vitamin D regulates the expression of a 
number of other proteins relevant to the arterial wall, including vascular endothelial growth 
factor (VEGF), MMP-9, myosin, elastin, type I collagen, and γ-carboxyglutamic acid, a protein 
that protects against arterial calcification (Norman & Powell, 2014). Vitamin D suppresses pro-
inflammatory cytokines, including interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α) 
in vitro and in vivo (Gardner, Chen, Glenn, & Ni, 2011). Low circulating vitamin D has been 
reported to be implicated in aortic inflammation localised within the adventitial layer in patients 
(Oma et al., 2017). 
1.3.3. A role of vitamin D in AAA formation 
The realisation that VDR are expressed within the heart and arterial cells has suggested that 
vitamin D plays an important role within the cardiovascular system (Christakos et al., 2016). 
While circulating levels of 25(OH)D are the best indicator of individual vitamin D status 
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(Dusso et al., 2005; Holick et al., 2011; Kleerekoper et al., 2011). Active vitamin D, 
1α,25(OH)D, is the active metabolite that mediates both genomic and non-genomic functions 
(Christakos et al., 2016). Vitamin D supplementation and consequent achievement of optimal 
circulating levels has been reported to confer extra-skeletal benefits that include cardio-
protective effects (Lee, O'Keefe, Bell, Hensrud, & Holick, 2008). Moreover, findings from 
cross-sectional studies have previously suggested that low levels of 25(OH)D are associated 
with vascular-related diseases, including aneurysmal subarachnoid haemorrhage (Alvarado 
Reyes, Perez, & Rodriguez-Vega, 2017; Guan et al., 2016), coronary arterial diseases (CAD) 
(Gondim, Caribe, Vasconcelos, Segundo, & Bandeira, 2016; Kunadian, Ford, Bawamia, Qiu, 
& Manson, 2014) and peripheral arterial diseases (PAD) (Nsengiyumva et al., 2015).  
Vitamin D can be implicated in AAA formation through several mechanisms. AAA is an age-
related disease and given that cutaneous synthesis of sunlight-derived vitamin D diminishes 
over time due to aging, it is possible that limited bio-availability of 25(OH)D in the elderly 
people may cause AAA formation (Fahrleitner et al., 2002; Mosekilde, 2005). This notion is 
well supported by previous reports showing that older people are at risk of severe vitamin D 
deficiency characterised low circulating 25(OH)D levels (Fahrleitner et al., 2002; Grober, 
Spitz, Reichrath, Kisters, & Holick, 2013; Melamed et al., 2008). Numerous clinical trials have 
showed that optimal levels of 25(OH)D may indeed prevent bone fracture in institutionalised 
patients. Indeed, beneficial effects of vitamin D in bone health remains the highest available 
level of evidence. Emerging findings however suggest that dysregulation of a number of bone 
proteins, including osteoprotegerin (OPG), osteopontin (OPN), osteocalcin (OCN) and 
sclerostin (SOST) is an independent risk factor for development of aortic aneurysms 
(Lerchbaum, Schwetz, Pilz, Boehm, & März, 2014; Li et al., 2016; Moran, Jose, Erik Biros, & 
Golledge, 2014; Vianello et al., 2017). Findings carried out in rodent models and human AAA 
tissue have already shown that bone proteins, including OPG, OPN and SOST are implicated 
in the pathogenesis of aortic aneurysms (Lerchbaum et al., 2014; Li et al., 2016; Moran et al., 
2014). However, mechanistic understanding of how vitamin D is implicated in AAA formation 
remain somewhat elusive. 
Previously, observational studies have reported an inverse relationship between circulating 
levels of 25(OH)D and AAA presence (Table 1.6 & Figure 1.6). Wong, et al (2013) reported 
that lower circulating levels of 25(OH)D were associated with AAA diameter in a dose-
dependent manner. An inverse association remained statistically significant even after 
adjustment for several traditional AAA risk factors and other potential confounders. Further 
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analyses demonstrated that AAA patients in the lowest quartile of 25(OH)D were at an 
increased risk of 5 times likely to develop larger AAAs (≥ 4.0 cm) compared healthy 
participants (Wong et al., 2013). Similarly, Demir et al (2012) showed that patient with thoracic 
aortic aneurysm (TAA) had lower levels of 25(OH)D compared with the control group. The 
study (2012) included 87 patients with thoracic aortic dissection (TAD) who were aged 40—
70 years old and found that vitamin D deficiency was as an independent factor associated TAD 
presence. Another study by Van De Luijtgaarden et al (2012) examined the association of 
vitamin D deficiency with aneurysmal diseases patient and PAD patients; and concluded that 
low 25(OH)D levels were strongly associated with both arterial conditions, independent of 
traditional cardiovascular risk factors. While these findings showed no significant difference 
in circulating levels of 25(OH)D between PAD and AAA patients, a moderate decrease in 
25(OH)D levels was noted within AAA patients.  
Preliminary evidence to suggest that vitamin D may be implicated in AAA development 
probably comes from proteomic analyses performed on human AAA patients’ tissue showing 
that VBP was altered in AAA patients (Gamberi et al., 2011; Spadaccio et al., 2016; 
Urbonavicius et al., 2010). Proteomic analyses in AAA tissue and intraluminal thrombus and 
plasma were performed and expression of VDBP was characterised (Gamberi et al., 2011; 
Spadaccio et al., 2016; Urbonavicius et al., 2010). Urbonavicius, et al. (2010) first showed that 
VBP expression was positively correlated with AAA presence in aortic tissue. However, 
Gamberi et al (2011) found a negative correlation between plasma VBP expression and AAA 
presence. In later study, Spadaccio et al (2016) reported that expression of plasma VBP 
increased by 1.92-folds in AAA patients compared with controls. It was proposed that the 
discrepancy between the two studies would be attributed to differences in the origin of tissue 
used. VBP mainly acts as a plasma carrier protein for 25(OH)D and other vitamin D 
metabolites, although its role in vascular remodelling has also been suggested (Gamberi et al., 
2011). 
Almost all cells that are implicated AAA development and progression, including VSMCs, 
endothelial cells and macrophages and immune cells have been shown to have the ability to 
synthesise 1α,25(OH)D2 from locally circulating 25(OH)D (Christakos et al., 2016; Dusso et 
al., 2005). Valcheva et al (2014) reported that lack of VDR signalling in VSMCs increased 
local production of AngII, which then contributed to vascular ageing, oxidative stress and 
premature senescence. A number of studies that investigated molecular link between vitamin 
D and AAA are presented in Table 1.5. In a recent study, Martorell et al (2016) showed that 
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incubation of active vitamin D3, calcitriol, with human umbilical vein endothelial cells 
inhibited AngII-induced leukocyte-endothelial cell interactions and decreased production of 
endothelial pro-inflammation. Furthermore, it was shown that abrogation of VDR-RXR 
interaction limited these effects, suggesting the importance of vitamin D metabolism pathway. 
Moreover a review by Vanherwegen et al (2017) reported on possible preferential 
immunomodulation mediated by 1α,25(OH)D2 on macrophages, dendritic cells, T cells and B 
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Table 1.5: Mechanistic assessments performed on tissues collected from aortic aneurysm 
patients and animal models 
References Main findings 
Nieuwland et al (2016) Daily injection of 1 µg of paricalcitol to patients who were 
scheduled for open AAA was associated with reduced 
inflammation compared with controls.  
Spadaccio et al (2016) Western blot analysis of 10 AAA patients’ tissue versus 10 
control (no-AAA) tissue showed that expression of vitamin 
D-binding protein (VDBP) increased 1.7-fold in AAA 
patients. 
Gamberi et al (2011) Western blot analysis AAA tissue showed a negative correlation 
between the vitamin D-binding proteins (VDBP) with AAA 
presence.  
Urbonavicius et al (2010) A proteomic approach on AAA tissue using 2D-PAGE and 
LC-MS/MS showed positive correlation of DBP (p=0.042) 
with AAA presence. 
Lutsey et al (2018) A total of 12,770 participants for AAA incidence and 449 
AAA cases occurred over a median follow-up duration of 
19.7 years. Markers for vitamin D metabolism, including 
25(OH)D, FGF23, phosphorus and PTH were not associated 
with risk of AAA incidence. 
Martorell et al (2016) The study showed that within the AngII infused ApoE-/- mice, 
oral administration of calcitriol resulted in reduced AAA 
dissection. 
Abbreviations: AA: aortic aneurysm; AAA: abdominal aortic aneurysm;  FGF23: 
Fibroblast growth factor 23; VDBP: vitamin D-binding protein; 2D-PAGE: Two-
dimensional poly-acrylamide gel electrophoresis; LC-MS/MS: liquid chromatography 
coupled with tandem mass spectrometry; AngII: angiotensin II; PTH: parathyroid 
hormone; 25(OH)D: 25-hydroxyviatmin D. 
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Table 1.6: Cross-sectional studies examining 25(OH)D levels in aortic aneurysm patients and controls 




Wong et al (2013) 311 65.0±22.8 3922 68.6±23.3 Comparing AAA patients with AAA-free healthy controls, 
circulating levels of 25(OH)D levels were significantly lower 
among AAA patients compared with controls. Furthermore, the 
data revealed a graded inverse relationship between circulating 
25(OH)D and AAA size. 
Demir et al (2012) * 87 29.7±18.8 93 39.9±12.4 Comparing the patients with TAD and healthy controls as 
diagnosed or excluded by transthoracic echocardiography, 
TAD patients had significantly lower 25(OH)D levels. 
van de Luijtgaarden 
(2012) † 
236 57±31.0 254 59.2±27.0 Comparing patients with AAA or TAD and controls who were 
PAD patients, it was demonstrated that low 25(OH)D levels 
were independently associated with both arterial diseases with 
the levels being slightly lower among AA patients compared 
with PAD patients. 
Results are presented as mean ± SD. *This study investigated groups of patients who hath thoracic aneurysm. †This studies included patients 
presenting with AA and patients who had PAD were chosen as controls. Abbreviations: 25(OH)D: 25-hydroxyvitamin D;  PAD: peripheral 
arterial diseases; Abbreviations: 25(OH)D: 25-hydroxyvitamin D; AA: Aortic aneurysm; TAD: thoracic aortic aneurysm, PAD: peripheral 
arterial diseases 





Figure 1.5: Forest plot showing the overall and subgroup concentrations of 25(OH)D (nmol/L) among aortic aneurysm patients and controls 
participants 
Forest plot of standard mean difference (SMD) and 95% confidence interval of 25(OH)D concentrations in patients with aortic aneurysm compared 
with control participants. Standard mean difference (SMDs) and 95% confidence interval were computed in a random effects model using Review 
Manager (Version 5.3). Abbreviations: 25(OH)D: 25-hydroxyvitamin D, AA: aortic aneurysm. 
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Nieuwland, et al (2016) recently reported that daily administration of 1 µg of paricalcitol to 
patients on daily basis attenuated inflammation; characterised by aortic tissue 
immunohistochemistry (IHC) and gene expression. A relatively long-term follow-up study 
recently assessed the link between AAA development and vitamin D metabolism (Lutsey et 
al., 2018). The study used a cohort of 12, 770 black and white individuals and examined the 
serum collected from ARIC to assess whether low serum 25(OH)D levels, elevated calcium, 
FGF23, phosphorus, and PTH were associated with AAA. Findings from this study concluded 
that current evidence is insufficient to establish whether vitamin D plays a role in AAA 
development. Genomic and non-genomic effects of VDR and subsequent downstream 
signalling owing to vitamin D supplementation is an important factor. The paucity of evidence 
on VDR activation in AAA formation and AAA tissue is in in fact a limiting factor in our 
understanding of mechanistic insights of vitamin D and AAA formation. Interestingly, so far, 
only one study has investigated the effects of vitamin D in aortic aneurysm development within 
a mouse model (Martorell et al., 2016). Findings from this study showed that within the AngII-
infused ApoE-/- mice, oral administration of 1α,25(OH)D resulted in reduced aortic dissection. 
These effects were reported to be unrelated to SBP or plasma cholesterol concentrations 
(Martorell et al., 2016). Furthermore, examination of mice SRA tissue showed significant 
decrease in macrophage infiltration and neovascularisation which was accompanied by 
downregulated expression of Mmp-2 and Mmp-9 (Martorell et al., 2016). Currently, the 
mechanism by which vitamin D deficiency promotes AAA remains unknown. Moreover, there 
is lack of clinical and pre-clinical evidence exploring therapeutic potentials of vitamin D 
supplementation that can be better translated to AAA management in human. 
Cellular experiments using 1α,25(OH)2D3 have shown that vitamin D can be metabolised by 
these cells resulting in VDR activation and other downstream pathways (Christakos et al., 
2016; Norman & Powell, 2014). Within VSMCs, deletion of the VDR was shown to induce 
premature senescence, possibly through upregulation of the cyclin-dependent kinase inhibitor 
(Valcheva et al., 2014). Although the cells primarily implicated in AAA formation are VSMCs, 
effects of vitamin D on other cell lines provide invaluable information on the mechanisms 
implicated.  In vitro effects of 1α,25(OH)2D3 have been investigated in a number of cell lines 
that are known to contribute to aortic wall homeostasis, notably, endothelial cells and 
inflammatory cells and immune cells (Querfeld, 2013; Schroder-Heurich et al., 2019; 
Vanherwegen et al., 2017; Yong Zhang et al., 2012). Norman et al (1995) previously suggested 
that excess vitamin D may have a detrimental role in arterial wall and a possible cause for AAA 
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development. Hypothetically, it was argued that exposure to excessive vitamin D during 
maternal development or in early infancy could potentially result in an individual being 
predisposed to AAA formation in later life. A recent study that prospectively followed up 
12,770 participants for incident of AAA and 449 AAA incidents occurred over a median 
follow-up of 19.7 years. Recently, Lutsey et al (2018) reported that a number of vitamin D 
metabolism markers, including 25(OH)D, FGF23, phosphorus, and PTH were not associated 
with risk of AAA incidence. Well-designed experiments using AAA animal models are a 
driving force for basic research and a foundation for further translational research. Given that 
vitamin D is a well-known nutraceutical with limited side effects profile, it is important that 
new biological effects are examined using animal models which are suited for AAA 
management. Of note, while a meta-analysis of epidemiologic studies clearly shows that lower 
circulating 25(OH)D levels are associated with AAA presence (Figure 1.5), the levels reported 
in these studies cannot necessarily be interpreted as deficient (Holick et al., 2011). Currently, 
the mechanism by which vitamin D deficiency may promote AAA remains unknown. There is 
therefore lack of clinical and pre-clinical evidence to demonstrate therapeutic potential of 
vitamin D supplementations in AAA management. Findings from cross-sectional studies are 
largely prone to limitation since they do not provide conclusions on cause-and-effect. 
In conclusion, a relatively low circulating concentration of 25(OH)D has been associated with 
human aortic aneurysms in a number of cross-sectional studies (Demir et al., 2012; Van De 
Luijtgaarden et al., 2012; Wong et al., 2013). Contrary to this evidence, however; it has been 
reported that the prevalence of AAA is highest in Australasia where levels of ultraviolet 
exposure (and thus likely vitamin D) are very high (Li, Zhao, Zhang, Duan, & Xin, 2013; 
Sampson et al., 2014). Excess vitamin D has also been reported to have potential pathological 
effects such as inhibiting production of elastin (an important aortic matrix protein) by VSMCs 
(Hinek, Botney, Mecham, & Parks, 1991; Norman et al., 1995; Norman, Moss, Sian, Gosling, 
& Powell, 2002). Therefore, further experimental research is currently needed to resolve the 
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1.4. HYPOTHESES AND AIMS 
The present thesis hypothesized that vitamin D protects against AAA pathogenesis through 
upregulation of SOST (Figure 1.6). Therefore, effects of vitamin D on AAA development, 
growth and rupture were investigated in vivo using the ApoE-/- mouse model in which AAA 
was induced by AngII infusion. The AngII infused ApoE-/- mouse model is well accepted for 
its pathological characteristics that it shares with human AAA (Daugherty & Cassis, 2004; 
Patelis et al., 2017; Senemaud et al., 2017; Trollope, Moxon, Moran, & Golledge, 2011). This 
thesis also investigated effects of vitamin D on human aortic VSMCs in vitro. 
 
 
Figure 1.6: Hypothetical Mechanism on the role of vitamin D in AAA development 
Vitamin D deficiency promotes downregulation of SOST, which results in activation of Wnt/β-
catenin activation. Cytoplasmic accumulation of β-catenin and translocation of β-catenin 
complex in the nuclear promotes genes that are implicated in pro-inflammation, extracellular 
matrix degradation and aortic wall remodelling, resulting in focal expansion of the aortic wall 
and aortic. Plausibly, replenishment or up-titration of vitamin D may protects against AAA 
development and rupture or reverse these effects through upregulation of SOST and 
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Specifically, the following hypotheses were proposed: 
1. 1α,25(OH)2D3 promotes SOST expression in human aortic VSMCs 
2. Dietary restriction of vitamin D reduces SOST in ApoE-/- mice. 
3. Dietary restriction of vitamin D promotes AAA development and rupture in the ApoE-/- 
AngII)-infused mouse model. 
4. CCF supplementation attenuates AAA growth and rupture in AngII-infused ApoE-/- mice. 
 
 
These aims were developed: 
 
1. To examine whether 1α,25(OH)2D3 induced SOST expression in human VSMCs. 
2. To examine if dietary deficiency of vitamin D reduced SOST in the ApoE-/- mice. 
3. To investigate if dietary deficiency of vitamin D promoted experimental AAA growth 
and rupture in a mouse model. 
4. To examine whether up-titration of 25(OH)D levels through CCF supplementation 
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2.1. Introduction 
Validity, feasibility and reproducibility of methodologies in basic science are of paramount 
importance (Baker, Lidster, Sottomayor, & Amor, 2014; Kilkenny, Browne, Cuthill, Emerson, 
& Altman, 2011). Findings from preclinical studies, particularly animal studies are increasingly 
becoming scrutinised due to poor translatability into subsequent clinical investigations (Baker 
et al., 2014; Kilkenny et al., 2011). Major critiques suggest that some of findings generated 
from preclinical studies remain irreproducible by peer researchers and therefore may not be 
translated to clinical trial (Baker et al., 2014). ARRIVE guidelines  underscore a number of 
checkpoints that are required to be considered by publishing journals (Baker et al., 2014). This 
chapter therefore aims to provide details on the general materials and methods used across all 
animal experiments (i.e. Chapters 3, 4 & 5).  
2.2. Animal studies 
The mice used in animal studies (Chapters 3, 4 & 5) were all male, ApoE-/- mice (C57BL/6J 
background). All mice were sourced from the Animal Resource Centre (Manning Vale, 
Western Australia) at 10-12 weeks old. Gene expression was confirmed in these mice through 
routine genotyping. All animal procedures described herein were conducted in personal 
containment levels 2 laboratory in the established animal house at the James Cook University. 
Mice husbandry and agistment were carried out in the PC2 laboratory in individually 
ventilated, temperature/humidity-controlled cages (Aero IVC Green Line; Tecniplast). Mice 
were housed in temperature controlled rooms under a 12-hour light-dark cycle (relative 
humidity: 55-60%; temperature: 22±1ºC) and given portable water ad libitum. The animal 
weight was monitored on a weekly basis. All animal studies described in this thesis were 
approved by the James Cook University/Animal Ethics Committee (JCU/AEC) and adhered to 
the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, USA.  
2.3. Angiotensin-II infusion in Apolipoprotein E-null mice 
AngII infusion results in the development of aneurysm in the suprarenal region of the aorta in 
the majority of ApoE-/- mice (Patelis et al., 2017; Senemaud et al., 2017; Trollope et al., 2011). 
Mice were surgically implanted with osmotic minipumps (Model 1004, Alzet, Durect 
Corporation) that have been programmed to deliver 1μg/kg/min of human AngII (Sigma-
Aldrich, NSW, Australia) over 28 days (Equation 5.1). The AngII vials contained 50 mg (in 
powder form) of synthetic peptide human AngII (C50H71N13O12) were first reconstituted with 
2 ml of ultrafiltered, autoclaved milli-Q H2O to make up a stock solution of 25mg/ml. The 
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solution was then diluted to get the actual concentration per mouse. Each osmotic mini-pump 
was filled up to ≥90% which was ensured by measuring the before and after filling pump 
weight. Each mouse was weighed on the day and the weight was used to determine the required 
amount of AngII required for that particular mouse (Equation 5.1). Prior to surgery, the mouse 
was sedated under 2.4% of isoflurane inhalation and the adequacy of anaesthesia was 
monitored by continuous monitoring of physiological parameters and by performing a reflex 
response test. The hair was removed around the mouse’s dorsal area using a hair clipper or 
depilatory cream and a small lateral incision was made between the scapulae. The osmotic 
mini-pump was subcutaneously inserted and positioned in the ventral region in a small pocket 
created by separating the skin from the connective tissue using a haemostat. The incision was 
then closed with polyamide monofilament non-absorbable sutures (Dafilon®; B. Braun 
Surgical, Spain). Topical antiseptic (Betadine, Purdue Products LP, USA) was applied to 
prevent infection to the wound. Mice were then allowed to recover under a heated lamp and 
monitored twice daily until terminal dissection. Mice were checked daily for general health, 
including eating habits (weight loss), docility (locomotion), behaviour (stress, depression 
aggressiveness), and appearance (wound infection and limping). In general, the mice remained 
lethargic and fairly docile on the day of surgery but were in a normal state within 2-3 days; 
with no wound infection or other complications.  
2.4. Tissue collection  
2.4.1. Aortic rupture post angiotensin-II infusion 
Aortic rupture and dissection are common in the first 14 days of AngII infusion in this animal 
model, accounting for nearly 26% of mortality (Cao, Amand, Ford, Piomelli, & Funk, 2010). 
Therefore, necroscopic analysis was performed within 12 hours on all mice that died post-
AngII infusion. Necroscopic dissection to expose the full aorta from the heart and to the point 
of bifurcation was carefully carried out under a dissection microscope. In particular, signs of 
aortic rupture and intramural thrombus presence were noted and photographed. In these mice, 
aortic rupture was commonly characterised by presence of blood clot around the juxtarenal 
region (retroperitoneal regions) or around the aortic arch. Mice which died from aortic rupture 
were not included in subsequent experiments (i.e. tissues were not stored for further analysis).  
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 2.4.2. Collection of blood  
Both the source and method of blood collection can have been shown to affect blood 
parameters, and consequently affect the quality of findings (Parasuraman, Raveendran, & 
Kesavan, 2010). In this study, serial blood collection was achieved via tail vein bleeding; and 
at terminal procedure, the blood was collected via cardiac puncture. Both methods typically 
yield a mixture of venous and arterial blood (Parasuraman et al., 2010). During the experiment, 
mice were comfortably secured in the restrainer and a heating lamp was placed above the tail 
region at the temperature of 24—270C. Topical anaesthesia (Emla® 5% cream, Australia) 
containing lignocaine (25mg/g) and prilocaine (25mg/g) was applied and left to absorb through 
the skin on the mouse tail. A sterile surgical scalpel was then used to nick the vein and the 
blood was collected into lithium heparin coated tubes (BD Bioscience, USA). In accordance 
with to the AEC recommendation, up to 200 μl of blood volume could be collected from each 
mouse. 
2.5. Assessment of AAA growth 
2.5.1. Ultrasound assessment of AAA 
ApoE-/- mice usually develop AAA in the suprarenal aortic region (P. E. Norman & Powell, 
2010). In order to assess in vivo growth of AAA, the SRA diameter was monitored first at 
baseline (day 0, before AngII) and then monitored serially every after 14 days throughout the 
study in all AngII-infused mice (cf. Chapter 4 and 5). The mice were briefly sedated with 3.5% 
isoflurane inhalation and the hair was removed in the abdominal area using depilatory cream. 
The ultrasound was perform in B-mode using a MyLab™ 70 VETXV platform (Esaote, Italy) 
which was connected to an LA435 linear transducer (Esaote, Italy). Warm transmission 
ultrasound gel was applied on the exposed skin surface. The ultrasound transducer was then 
positioned perpendicular to the animal ventral region and to acquire the SRA region in a trans-
axial plane. Anatomical landmarks, including spinal cord and renal arteries were used to 
facilitate proper orientation. The application on the machine was set-up to an automatic focal 
zone and frequency of ‘tendon equine’ ‘mouse’ in a sagittal mode. Maximum SRA diameter 
was measured at peak systole using an in-built calliper feature from outer wall to outer wall.  
Given the importance of SRA diameter in this study, inter-assessor repeatability of ultrasound 
assessment was carried out by two assessors, whereby the second observer was blinded to 
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experimental groups. The repeatability was ensured early on during the habituation of animals 
(i.e. prior to commencing the actual data collection). 
2.5.2. Morphometric assessment and classification of AAA 
AAA severity was also assessed in harvested aortas ex vivo (morphometry) by measuring the 
maximum diameter of the aortic arch, thoracic aorta (TA), SRA and infra-renal aorta (IRA). 
During dissection, phosphate buffered saline (PBS) was carefully perfused through the aortas 
for complete removal of blood clots. The aorta was then excised by ensuring complete removal 
of perivascular fats, and then the whole aorta was placed on a graduated template and digitally 
photographed (Coolpix 4500, Nikon). Analysis was performed on the images using a 
computer-aided software (Adobe® Photoshop® CS5 Extended version 12, Adobe Systems 
Incorporated). In order to establish an acceptable inter-observer reproducibility, a second 
observer who was blinded to samples labelling repeated measurements. Morphometric 
analyses were performed on aortas of mice that were alive until terminal dissection (i.e. 
ruptured aortas were excluded). It has been previously demonstrated that both ultrasound and 
morphometric measurements can be performed with excellent inter-observer reproducibility 
(Krishna et al., 2015). 
 
In addition, a scale-based assessment of gross appearance was performed on excised and 
digitally photographed aortas according to the protocol devised by Daugherty et al (2001) 
(Daugherty, Manning, & Cassis, 2001). Briefly, during the assessment, aneurysms were scored 
and classified as type I if they manifested a dilated lumen in the supra-renal region of the aorta 
with no thrombus. Aneurysms were scored as type II if they manifested a remodelled tissue in 
the SRA region, accompanied by presence of thrombus. Type III aneurysms were characterised 
by pronounced bulbous form of the type II and contained thrombus. Aneurysms were classified 
as type IV if multiple, overlapping aneurysms were present within the SRA whereas type 0 
meant absence of aneurysm or dissection within the aorta. This classification of aneurysms was 
complemented by histological staining of the aortic section by haematoxylin and eosin (H&E) 
as described below (Section 2.8.1). Assessments were performed by two assessors whereby the 
secondary assessor (Dr Smriti Krishna) was blinded to animal groups. The final score was 
achieved with a final 100% concordance. Ruptured aortas (confirmed by necroscopy) were 
excluded in the analysis. 
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2.6 Non-invasive tail-cuff plethysmography 
SBP, diastolic blood pressure (DBP) and heart rate were measured in mice at baseline, prior to 
starting AngII infusion and 14 and 28 after AngII infusion started. Measurements were 
performed using a computerized non-invasive tail-cuff system (CODA Monitor, Kent 
Scientific). Mice were habituated to the device by handling them on a daily basis for one week. 
Mice were allowed to settle for 2 hours at room temperature prior to assessment. An average 
of five consistent readings that were consecutively recorded were taken. Excellent 
reproducibility for this technique has been previously reported (Krishna et al., 2016; Krishna 
et al., 2015; Seto et al., 2014). 
 
2.7. Plasma analyses 
Collection of blood was performed into heparin coated tubes (BD Microtainer). The plasma 
was recovered by centrifugation at 3000 x g for 10 minutes at 40C and then stored at -800C 
until use. Cell-free plasma was obtained by centrifugation at 2000 x g at 40C for 10 minutes 
followed by a further 10 minutes centrifugation at 15000 x g at 40C if required. The plasma 
samples were snap-frozen in liquid nitrogen and stored -800C for later use.  
2.7.1. Measurement of plasma 25(OH)D3, 25(OH)D2 and epi-C3-25(OH)D 
There is ongoing debate surrounding vitamin D assays (Carter, 2011; Holick et al., 2011; 
Holick, 2009; Kleerekoper et al., 2011). According to a prominent panel of experts within the 
vitamin D research field (Kleerekoper et al., 2011), 25(OH)D is the metabolite that most 
accurately depicts an individual’s vitamin D status and assays of this metabolite by  mass 
spectrometry (MS) is a gold standard. Measurement of 25(OH)D was therefore performed as 
previously described (Clarke, Tuckey, Gorman, Holt, & Hart, 2013). Plasma 25(OH)D was 
thawed at room temperature and diluted (1:2) in RPMI Media 1640 (i.e. 75μl of serum + 75μl 
1640 RPMI Media)  to make up 150μl and shipped on dry ice for assaying in a vitamin D assay 
accredited laboratory (Centre for Metabolomics, WA, Australia). The assay for 25(OH)D was 
performed using a two-dimensional ultra-performance liquid chromatography separation 
coupled tandem mass spectrometry (2D UPLC-MS/MS) (Clarke et al., 2013). The lower 
detectable limit for 25(OH)D was 2.0 nM. The 2D UPLC-MS/MS technique has been 
previously demonstrated to accurately quantitate 25(OH)D3, 25(OH)D2 and epi-25(OH)D3 
metabolites (Albarhani et al., 2015; Clarke et al., 2013). 
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2.7.2. Measurement of plasma SOST 
Plasma SOST was assayed using a Quantikine® ELISA kit (R&D Systems; cat#:MSST00). 
Briefly, samples and standards were prepared according to the manufacturer’s instructions. 
Samples (50 μl) were tested in duplicates along with assay diluent and standards to their 
respective wells followed by incubation for three hours at room temperature. The plate was 
washed five times with 400μl of the wash buffer and 100μl of mouse SOST conjugate was 
added to each well and incubated for 1 hour at room temperature. The plate was washed five 
times, 100 μl of the substrate solution was added, followed by a 30 minutes incubation at room 
temperature. The reaction was stopped by addition of the stop solution (100 μl). The plate 
optical density was read at 540 λ with wavelength correction option (Omega, BMG Labtech). 
2.8. Assessment of atherosclerosis lesion  
The Sudan IV stain was prepared by weighing 5.0 g of Sudan IV and then mixed in 500.0 ml 
of acetone and 500.0 ml of 70% ethanol. The mixture was dissolved on a stir plate for 30 
minutes. 80% ethanol was used as a decolorizing solution. Aortic arches were individually 
collected and stored in optimum cutting temperature (OCT, ProSciTech) and stored at -800C 
until dissection. For staining, aortic arches were brought at room temperature, serially washed 
with PBS (3x) to remove the residual OCT and fixed in 70% ethanol overnight. Excess 
perivascular fatty tissue was carefully trimmed, including removal of brachiocephalic arteries. 
The arches were then cut open longitudinally and stained for 15 minutes with Sudan IV solution 
[0.1% Sudan IV dissolved in 1:1 acetone and 70% ethanol (v/v)]. This was followed by with 
differentiation with 80% ethanol for 5 minutes and a wash with water for 5 minutes, a 
decolorizing solution. Stained arteries were then rinsed with running H2O for several minutes 
until the background was cleared. All stained aortic arches were immediately digitally 
photographed and the atherosclerotic plaque areas were analysed using a computer-aided 
software (Adobe®Photoshop® CS5 Extended version 12, Adobe Systems Incorporated) as 
previously reported (Krishna et al., 2016; Krishna et al., 2012; Krishna et al., 2015). En face 
Sudan IV staining was quantitated as percentage of stained area over the whole tissue area. An 
acceptable reproducibility of this technique has been previously reported (Krishna et al., 2015; 
Krishna et al., 2012). 
 
Aortic arches were individually collected and stored in optimum cutting temperature (OCT, 
ProSciTech) and snap-frozen in liquid N2 and stored at -800C during dissection. En face Sudan 
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IV staining was performed on these aortic arch samples to identify intimal atherosclerotic 
plaque as previously reported (Krishna et al., 2012).Aortic arches were thawed at room 
temperature, washed PBS to remove residual OCT and fixed in 70% ethanol overnight. The 
arches were then cut opened longitudinally and stained for 15 minutes with Sudan IV solution 
[0.1% Sudan IV dissolved in 1:1 acetone and 70% ethanol (v/v)]. This was followed by tissue 
decolourisation with 80% ethanol for 5 minutes and wash by H2O for several minutes until 
artefact stain disappeared. All stained aortic arches were immediately digitally photographed 
and the atherosclerotic plaque areas were analysed using a computer-aided software (Adobe® 
Photoshop® CS5 Extended version 12, Adobe Systems Incorporated). 
 
2.9. Histological and histopathological assessments  
In these experiments, aortic segments were collected and processed for assessments. 
Histological assessments are commonly used to characterise the gross appearance of the SRA 
tissue within the AngII infused ApoE-/- mouse model (Cao et al., 2010; Krishna et al., 2017;  
Krishna et al., 2015). Additionally, histopathological assessments usually aim to characterise 
the pathological effects within the SRA tissue in this mouse model (Cao et al., 2010; Krishna 
et al., 2017; Krishna et al., 2015). During terminal dissection, the SRA segments were isolated 
and stored in OCT compound (ProSciTech) for later histological analysis. SRA segments from 
all mice from each group were processed for sectioning. SRA segments were first washed of 
OCT by serial rinsing in the PBS solution then fixed in 70% EtOH overnight. The sections 
were then orientated in cassettes with OCT as frozen sections at -200C. 
2.9.1. Morphology of suprarenal aortic by Haematoxylin and Eosin 
Serial cryostat sections (5μm) were cut from each SRA segment and air dried on silane coated 
slides for 30 min. For nuclei staining sections were covered with haematoxylin for 4 minutes 
and then rinsed with running milliQ-H2O. Slides were dipped into 0.25% hydrochloric acid in 
absolute EtOH (v/v), 10x, then rinsed in milliQ-H2O for 2 min. Slides were then differentially 
stained by dipping them 10x into a 0.09% ammonia chloride solution in milliQ-H2O (v/v) 
followed with rinsing under running milliQ-H2O and then immersed into 95% EtOH for 10 
sec. Sections were then counterstained with eosin for 15 sec and dehydrated by immersion into 
95% EtOH (5 minutes) and then into absolute EtOH (5 minutes). Final clearance was achieved 
by immersions of slides into xylene for 5 min (2x) followed by mounting with in Entellan 
52 | P a g e  
 
mounting medium (ProSciTECH, Australia). Stained sections were then left to be air dried in 
fume cupboard for 24 hr prior to visualisation under a microscope (Nikon, Japan). 
 
2.9.2. Assessment of suprarenal aortic wall elastin 
SRA sections were stained with Elastin Van Giessen (EVG) staining (Polysciences, Inc, 
Australia) to measure the elastin content. Differentiation of all connective tissue components 
cannot be readily distinguished by gross morphology staining using H&E. Elastin Verhoeff’s 
Van Gieson (EVG) stain is an iron-haematoxylin stain that specifically binds to elastic fibres. 
The stain was freshly made using 5% alcoholic haematoxylin, 10% aqueous ferric chloride and 
iodine solution. The tissue was first rehydrated and OCT removed using PBS for 3 minutes and 
then stained in the EVG solution for one hour. Sections were then rinsed 3 times with tap water 
and differentiated using 2% ferric chloride for 2-5 minutes. Since elastin has a strong affinity 
for the iron-haematoxylin complex in the stain, it is expected that elastin fibres holds the dye 
longer than other tissue components. Elastin therefore remains stained even after other tissue 
elements are decolourised. The differentiation was stopped by washing the section through 
several changes of tap water. Stained sections were photographed using a Nikon Eclipse 50i 
microscope fitted with a CCD Camera (DSFi1) and digital images captured to a PC supported 
with image analysis software (NIS Elements, version F2.30). Qualitative evaluation of elastin 
fibre integrity was performed on digital images by semi-quantitative grading by a blinded 
observer as follows; 1- no elastin degradation or mild degradation; 2- moderate; 3- moderate 
to severe; and 4- severe elastin degradation following previously published protocols and 
showed good reproducibility (Krishna et al., 2015; Wang, 2014). 
  
2.9.3. Assessment of suprarenal aortic collagen 
Collagen is an important structural protein that controls the distension in the aortic wall by 
maintaining its tensile strength. It is the key element of the ECM in the aortic wall and its 
depletion can significantly reduce the aortic wall structural integrity by up to 50 times. Type I 
and III collagen are the most abundant proteins within the aortic wall. The picrosirius red 
staining is an effective method commonly used to characterise collagen I (old) and III (newly 
forming) within the tissue. This technique also aids to semi-quantify the amount of collagen in 
a given area of aortic wall tissue. Collagen type I and III are distinguished from each other 
under polarized light microscopy. 
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For the animal studies, SRA segments were collected and placed in OCT, then stored at -80oC. 
In this experiment, SRA frozen sections were serially sectioned to 5-6 μm using a microtome. 
Slide sections were air dried and dehydrated using 75% EtOH, then stored at -200C until use. 
Slides were then retried and brought to room temperature for 30 minutes then immersed in PBS 
for 10 minutes. Sections were fixed on slides using 10% formalin for 5 minutes and rinsed in 
water. Sections were then stained with Weigert’s Haematoxylin for 5 minutes, then rinsed in 
Milli-Q H2O (3X), then placed in phosphomolybdic acid for 2 minutes. Slides were then 
immersed in picrosirius red F3BA solution for 90 minutes followed by 5 rinses in milli-Q H2O. 
Slides were then immersed into 0.1 N hydrochloride acid for 2 minutes, then rinsed in milli-Q 
H2O. Slides were then serially rehydrated in absolute, 90% and 70% EthOH for 2 minutes each, 
then covered using mounting media. Sections were then visualised under polarised light 
microscope and digitally photographed using. Stained tissue showed that collagen fibres 
stained red, type I collagen stained yellow while type III collagen stained green. It was 
previously reported that all these histological measurements could be repeated with good 
reproducibility (Krishna et al., 2015). 
 
2.10. Suprarenal aortic tissue protein assay by ELISA 
2.10.1. Preparation of suprarenal aortic tissue samples 
The SRA tissue was thawed on ice, cleared of OCT, rinsed in PBS, transferred to a clean 
microfuge tube and snap frozen in liquid nitrogen. The tissue was then minced manually with 
a pestle with addition of 500µl of ice-cold radioimmunoprecipitation assay (RIPA; i.e. 1 x 
RIPA buffer; 50 mM Tris-HCl pH 7.4, 150 mM NaCl; 2 mM EDTA, 1% TritonX-100, 0.1% 
SDS, and 0.1% sodium deoxycholate) buffer (Cell Signalling Technology) which also 
contained protease inhibitors (Roche) and phosphatase inhibitors (PhoSTOP). The tissue was 
then homogenised with the pestle attached to a handheld drill and the homogenised samples 
were centrifuged for 5 minutes at 80000xg at 4°C. The supernatant was collected and protein 
concentration was quantitated by the BioRad protein assay (BioRad, USA). 
 
2.10.2. Estimation of protein concentration by BioRad protein assay 
A standard was first constructed using IgG standards (range 0-8µg) which were prepared by 
dilution IgG (1mg/ml) with milli-Q water. From each sample, 2µl was drawn and diluted to 
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1:1000 in milliQ water and used for the assay to determine the protein concentration. Each well 
for sample (160µl) or standard (160µl) was mixed well with 40µl Bradford reagent in a flat 
bottom 96-well plate followed by 30 minutes of incubation away from light. The optical density 
(OD) of the wells were read at 595nm in the Omega plate reader. Excel data from the plate 
reader were transferred to GraphPad prism software to interpolate unknown concentrations of 
the diluted samples using the standard curve. The interpolated values were multiplied by the 
dilution factor (x1000) for the protein concentrations of the extracted proteins for each sample. 
 
2.10.3. Mouse suprarenal aortic SOST protein assay  
The measurement SOST protein was performed using the Quantikine® ELISA kit as described 
in manufacturer’s instruction (R&D Systems; cat#:MSST00). A 7 points standards was serially 
prepared with an 8th blank and loaded. Samples and standards were loaded in duplicates 
followed by incubation for three hours at room temperature. The plate was then washed four 
times with 400μl of the wash buffer and 100μl of mouse SOST conjugate was added to each 
well and incubated for 1 hour at room temperature. The plate was then washed five times before 
addition of the substrate solution. This was followed by a 30 minutes incubation at room 
temperature and the reaction was stopped by addition of the stop solution. The plate optical 
density was read at 540 nm and 450 nm (Omega, BMG Labtech). Plate’s optical wavelength 
correction was achieved by subtracting the readings at 540 from 450nm). 
2.10.4. Mouse suprarenal aortic phospho-GSK-3α/β (S21/S9) protein assay  
Mouse phospho-GSK-3α/β (S21/S9) levels were determined using DuoSet® IC ELISA in 
accordance with manufacturer’s instructions (R&D systems®, Cat#: DYC2630-2). Briefly, the 
mouse phospho-GSK-3α/β (S21/S9) capture antibody was reconstituted and diluted to a 
working concentration of 4.0 µg/ml in PBS and then coated into a 96-well micro-plate (100 µl) 
per well. The plate was sealed and incubated overnight at room temperature. On the following 
day, the plated contents were aspirated and the plate was washed 4x with was buffer 
(0.05%Tween-20 in PBS). 300 µl of blocking buffer (1% BSA, 0.05%NAN3 in PBS) was 
added to the plate and incubated for 2 hours at room temperature (RT). During the incubation 
time, a 7 standards points was serially prepared with a two-fold dilution starting from a working 
concentration of 10000µg/ml while the 8th standard was a blank diluent. All samples were 
centrifuged at 3000g for 10 minutes before addition. The plate was then washed as above and 
100 µl of sample or standards were added. The plate was sealed and incubated for 2 hours. The 
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plate was washed again and mouse GSK-3β and GSK-α detection antibodies were added. The 
plate was sealed again and incubated for another 2 hours.  The plate was washed and incubated 
with 100µl/ well of diluted streptavidin-HRP for 20 minutes (in a dark place). The plated was 
again washed followed by addition of 100µl (1:1) of the substrate solution [Colour reagent A 
(H2O2) and colour reagent B (tetramethylbenzidine)] and incubated for 20 minutes. The 
reaction was stopped after two minutes by addition of 50µl of the stop solution (2NH2SO4) to 
each well. The plate was read at 540 nm and at 450 nm (Omega, BMG Labtech). The 
wavelength correction was achieved by subtracting the optical density readings at 540 from 
those at 450nm. 
 
2.11. Extraction and purification of mRNA 
In all related experiments, extraction and of RNA was based on five principles tissue 
homogenisation, phase separation, RNA precipitation, RNA purification. First, the SRA tissue 
was homogenised using mechanical blender. RNA extraction was performed using an 
established phenol-chloroform extraction techniques (Toni et al., 2018). TRIzol reagent, a 
mono-phasic solution of phenol, guanidine isothiocyanate (Qiagen) was used for tissue lysis. 
Tissues segments were removed from the RNAlater and placed into Trizol (250 μL) for 30 
minutes while kept on ice. The segment was mechanically homogenised using sterile rods prior 
to addition of another 250μL of Trizol. The samples were then left on ice for an extra 20 min 
for proper lysis. Phase separation was achieved by addition of 400 μL of chloroform then 
vortexed. This mixture was then incubated for 5 minutes at RT. The tubes were then centrifuged 
for 10 minutes at 12000 x g at 40C. The upper aqueous phase chloroform (Fisher) was carefully 
pipetted into a new tube. RNA precipitation was achieved by addition of 200μL of molecular 
grade isopropyl alcohol (2-propanol) (Fisher) followed by quick vortex. The samples were then 
left at 40C for overnight to allow for RNA precipitation. The samples were then vortexed and 
centrifuged for 10 minutes at 12,000xg at 4oC to recover the precipitated pellet and the 
supernatant were carefully discarded. The pellets were resuspended in 500 μL of 75% ethanol 
in RNase free water (Qiagen). RNA resuspension and purification was achieved by repeated 
pipetting followed by quick vortex (in most of the tubes, precipitated RNA strands could be 
seen floating).  
This was then transferred into column tubes (Qiagen). The column tubes were centrifuged at 
8000x g for 30 secs and flow-through were discarded. Pellets were then washed with the RWI 
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buffer (700μL) and centrifuged at 8000xg for 15 minutes. Further purification was achieved 
through DNA digestion by addition of DNase I (Qiagen) to the column. This was then 
incubated for 15 min at RT (DNase was kept on ice). RNA was then washed in with 500 μL of 
RPE buffer and spun at 8000xg for 15 secs followed by another with the same buffer but spun 
for 2 minutes. The spin column were then transferred to new collection tubes (RNase free 
collection tubes, Qiagen). Excess ethanol left to evaporate at RT for 5 minutes. RNA elution 
was then achieved by adding 25 μL of warm RNase free water (550C) and spun at 8000xg for 
30 secs. This was repeated twice, thus achieving a total collection of 50 µL per sample. RNA 
tubes were then kept on ice at all times. RNA quality and concentration was determined for 
each sample by placing 1μL of original stock on a Nano-spectrophotometer (Nanodrop), 
blanked against the RNA free water. The ratio (A260/A280) range of 1.8-2.0 was assumed to 
be of good RNA quality (Toni et al., 2018). Extracted RNA was stored at -200C into 20µL 
aliquots. 
2.12. Analysis of gene expression by quantitative real time polymerase chain reaction 
Quantitative real time polymerase chain reaction (qRT-PCR) was used to assess relative gene 
expression. Total mRNA was extracted from cells using the RNeasy Mini kit (Qiagen) 
following the manufacturer’s instructions as detailed above. Quantification of RNA per sample 
was performed using a nano-spectrophotometer machine (Nanodrop2000). The forward and 
reverse primers were designed using (Premier 6 software, Premier Biosoft) and purchased from 
Sigma (Australia). A table comprising an exhaustive list of primers and target genes is provided 
in each study. Relative gene expression was calculated by using an auto-generated and 
corrected concentration-Ct-standard curve and normalized to relative expression of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a housekeeping gene. GAPDH was 
chosen as housekeeping gene since its expression was similar across the samples analysed. All 
reactions were independently repeated in duplicate. 
2.13. Statistical analysis 
D’Agostino and Pearson test was used to test the normality of the data. Results were expressed 
as median and interquartile range (IQR) for non-normally distributed data; and as mean ± SEM 
for normally distributed data. For non-normally distributed data, comparisons were made using 
Mann-Whitney U-test or Kruskal-Wallis test followed by Dunn’s multiple comparisons test, 
where appropriate. Normally distributed data were compared using ANOVA followed by 
Bonferroni’s multiple comparisons test. Mortality rate was tested using a survival Kaplan 
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Meier curve. Differences were considered to be statistically significant at P < 0.05. Elastin 
grading was analysed using Fischer exact test. Repeated measures were analysed using 
repeated measures ANOVA. All analyses were performed using GraphPad Prism 8.4.2 
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CHAPTER 3: 
IN VITRO EFFECTS OF VITAMIN D 
ON SOST IN HUMAN AORTIC 
SMOOTH MUSCLE CELLS AND IN 
VIVO EFFECTS OF VITAMIN D IN 
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3.1. INTRODUCTION 
Vitamin D is an umbrella term non-specifically used to describe cholecalciferol (CCF) and 
ergocalciferol as well as their downstream metabolites (Demer, Hsu, & Tintut, 2018; Holick, 
2007). Sunlight-derived (exogenous) and nutritional (endogenous) vitamin D must first 
undergo a step of hydroxylation to 25(OH)D which occurs in the liver (Demer et al., 2018; 
Holick, 2002; Holick, 2007). During the activation stage, circulating 25(OH)D is hydroxylated 
to produce the bioactive metabolite of vitamin D known as 1α,25(OH)2D (Demer et al., 2018; 
Holick, 2002; Holick et al., 2011; Holick, 2007). While it was previously thought that renal 
tubules was the only site for 25(OH)D hydroxylation to the bioactive 1α,25(OH)2D, current 
evidence indicates that a number of other extrarenal tissue targets have the ability to locally 
mediate this process (Christakos et al., 2016; Holick, 2007). Although the bioactive form of 
vitamin D is 1α,25(OH)2D, levels of circulating 25(OH)D is the best indicator for individual’s 
vitamin D status (Holick et al., 2011). Therefore, measurement of circulating 1α,25(OH)2D is 
not clinically recommended except in extenuating circumstances where renal insufficiency or 
genetic defects associated with vitamin D metabolism are present (Holick et al., 2011).  
A well-recognised role of vitamin D is to regulate calcium and phosphorus metabolism (Holick, 
2005; van Driel & van Leeuwen, 2017). Therefore, studies on the role of 1α,25(OH)2D have 
traditionally focused on bone and mineral homeostasis (Acibucu et al., 2016; Christakos et al., 
2016; Holick, 2005; van Driel & van Leeuwen, 2017). Nonetheless, emerging findings are now 
suggesting that deficiency of vitamin D is implicated in the pathophysiology of several 
diseases, including cancers, infectious diseases and cardiovascular diseases (Christakos et al., 
2016; Holick, 2002; Holick & Chen, 2008). The realization that many cells of the 
cardiovascular system, including immune cells, endothelial cells and VSMCs possess the 
enzymatic machinery to convert circulating 25(OH)D to active 1α,25(OH)2D have provided 
new insights into how vitamin D may be implicated in cardiac and vascular functions 
(Christakos et al., 2016; Demer et al., 2018; Holick, 2002; Holick et al., 2011; Holick, 2007; 
Norman & Powell, 2014). 1α,25(OH)2D is the most potent metabolite of vitamin D and a ligand 
for VDR (Carlberg & Molnar, 2012; Christakos et al., 2016). Therefore, almost all vitamin D 
actions are mediated through the binding of 1α,25(OH)2D to its cognate VDR, a transcriptional 
receptor located within the cell nucleus (Christakos et al., 2016). VDR is a nuclear receptor 
that regulates transcription of target genes through recruitment of ligand-dependent co-
regulators (Rachez & Freedman, 2000). 
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SOST is Wnt/β-catenin negative regulator with a seminal role in bone mineralisation (Moester, 
Papapoulos, Lowik, & van Bezooijen, 2010; van Bezooijen et al., 2005). Previously, there was 
no known role in the function of arterial wall; however, a recent study from our laboratory 
showed for the first time that downregulation of SOST is associated with AAA presence in 
human AAA tissue (Krishna et al., 2017). For the first time, the report provided new insights 
into the role of SOST in the pathogenesis of AAA. For instance, it was demonstrated that SOST 
plays a protective role in maintaining the aortic wall homeostasis via several mechanisms such 
as anti-atherosclerotic, anti-inflammatory, and anti-ECM degrading functions. Reduced SOST 
was reported to activate Wnt/ β-catenin signalling, which regulates downstream genes that are 
important in maintaining the aortic wall integrity (Krishna et al., 2017). Furthermore, it was 
demonstrated that both transgenic SOST overexpression and administration of exogenous 
human recombinant SOST were associated with reduced inflammation and matrix remodelling 
(Krishna et al., 2017). Two studies recently reported in vitro effects of 1α,25(OH)2D3 on SOST 
expression in human osteoclast cells (Wijenayaka et al., 2016; Wijenayaka et al., 2015). In both 
studies, 1α,25(OH)2D was shown to increase SOST gene expression in a dose-dependent 
manner (Wijenayaka et al., 2016; Wijenayaka et al., 2015). Administration of ergocalciferol 
has previously been reported to increase circulating SOST concentrations in patients with 
osteoporosis (Sankaralingam, Roplekar, Turner, Dalton, & Hampson, 2014). Moreover, a 
positive correlation between circulating 25(OH)D and SOST levels has been previously 
reported in human (Acibucu et al., 2016; Ardawi, Al-Kadi, Rouzi, & Qari, 2011; Pirgon, 
Sandal, Cetin, & Dundar, 2016). However, it remains currently unclear whether 1α,25(OH)2D 
upregulates SOST expression in VSMCs. It is also unknown whether dietary deficiency of 
vitamin D plays a direct role in reducing SOST and thus compromising the aortic wall integrity. 
Given that the key characteristics of AAA development include arterial wall remodelling due 
to focal inflammation and marked depletion of medial VSMCs (Aggarwal et al., 2011), it is 
plausible that Wnt/β-catenin signalling plays an important role in AAA development. 
Additionally, focal loss of contractile phenotype markers within VSMCs is also understood to 
be among the main causes for aortic wall disintegration and continuous remodelling (Peng et 
al., 2018).  
In this chapter, it was hypothesized that 1α,25(OH)2D3 upregulates SOST expression in human 
aortic VSMCs and that dietary restriction of vitamin D reduces circulating SOST and aortic 
wall SOST expression in ApoE-/- mice. Therefore, this study aimed to examine if 
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1α,25(OH)2D3 upregulated SOST expression in human aortic VSMCs and investigate whether 
dietary restriction of vitamin D reduced SOST in ApoE-/- mice. 
 
The hypotheses for this study were that: 
 
1. 1α,25(OH)2D3 upregulates SOST expression in human aortic VSMCs. 
2. Dietary restriction of vitamin D reduced circulating SOST and aortic wall SOST expression 
in ApoE-/- mice. 
 
 
Specifically, the aims of this study were: 
 
1. To examine if 1α,25(OH)2D3 induced SOST expression in human aortic VSMCs. 
2. To assess whether dietary restriction of vitamin D reduced circulating SOST and aortic wall 
SOST expression in ApoE-/- mice. 
 
3.2. MATERIALS AND METHODS 
 
3.2.1. CELL CULTURE STUDY 
Commercially available human aortic VSMCs (were purchased (CC-2571, Lonza). Cells were 
originally isolated from healthy young donors without a history of AAA or athero-occlusive 
diseases. All cell culture procedures were performed in an isolated PC2 room, in a laminar flow 
hood, under sterile conditions. Experiments were performed on cells from passage 4 to passage 
9. Cells were initially seeded in T75 flask and maintained in Dulbecco`s Modified Eagle Media 
(DMEM) which was supplemented with 10% foetal calf serum. Cells were then incubated in a 
humid-controlled atmosphere at 37°C, 5% CO2.  
3.2.2 Cell counting, passaging and storage 
3.2.2.1. Cell counting 
A cell count was performed to determine the seeding density before they were passaged or 
stored. A cell count technique was first performed using a haemocytometer whereby the dye 
exclusion test also known as trypan blue exclusion test was used to determine the number of 
viable cells. Trypan blue cell exclusion test is based on the principle that healthy cells possess 
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an intact membrane; and therefore are not permeable by heavy dyes (e.g. trypan blue, eosin or 
propium) whereas this ability is compromised in dying cells (Strober, 2015). In this experiment, 
viable cells manifested a clear cytoplasm with a circular or spindle-like shape while non-viable 
cells had a blue-stained cytoplasm. 
In preparation for trypan blue cell exclusion test, cell suspensions were centrifuged for 
5minutes at 100g x g and supernatants were discarded. Cell pellets were resuspended in 1 ml 
PBS and then mixed with 0.4% trypan blue (1:1 v/v). The mixture was then incubated at RT 
for ~2-3 minutes to avoid cell deaths that may be due to longer incubation times (Strober, 
2015). A drop of the mixture (cell suspension in PBS and 0.4 % trypan blue dye) was applied 
to the haemocytometer and the number of stained (dead) and unstained (viable) cells were 
counted. The haemocytometer cell count technique suggests that the average number of cells 
per ml (viable or non-viable) per ml is obtained by multiplying the total number of cells by the 
dilution factor of the dye then converted to (10000 x104). In addition, a cell count was also 
performed electronically using Scepter™ 2.0 Cell Counter (Sigma) with a sensor size operating 
range for 40-µm; 50,000–1,500,000 cells/mL; and for 60-µm 10,000–500,000 cells/ml.  
 
3.2.2.2. Cell Passaging 
Cells were passaged when they reached 80% to 90% confluency. VSMCs are adherent cells, 
therefore detachment of cells was required prior to passaging. The cell culture medium was 
discarded; and cells were washed (X 3) using a saline solution, Hanks' Balanced Salt Solution 
(HBSS; Gibco) that keeps the osmotic pressure and pH in cells. Cell detachment was performed 
by addition of Trypsin-EDTA (0.25% trypsin, 1 nM EDTA-4NA, Gibco) to cover the 
monolayer surface of cells. The flask was then placed in an incubator at 37°C in an atmosphere 
of 5% CO2 for ~3 minutes. The cell detachment process, also known as trypsinisation, was 
confirmed by visualisation of floating cells using light microscope. In order to neutralise the 
trypsinisation enzymatic process, DMEM culture medium containing 10% FCS was added and 
cells were resuspended by gently pipetting up and down while avoiding foaming. Suspension 
of cells was then divided equally into the number of required flasks for platting (e.g. in a T75 
flask, a total volume of 25 ml was achieved). 
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3.2.2.3. Cells storage 
For cell storage, the suspension was transferred into a sterile centrifuge tube and spun at 200g 
for 10 minutes. Cells were stored when they were actively proliferating at early passages (i.e. 
passages 4 to 6). All procedures in preparation for cells storage were performed in a laminar 
floor hood under sterile conditions. Culture medium was washed off by HBSS buffer and the 
monolayer of cells was trypsinised (as above) to obtain single cell suspension. The suspension 
was then transferred into a sterile centrifuge tube and spun at 200g for 10 minutes. The 
supernatant were carefully discarded and cell pellets were resuspended into required volumes 
of DMEM medium. Resuspension DMEM medium was reconstituted with 20% FCS and 10% 
dimethyl sulfoxide (DMSO) which was to be aliquoted as 1 ml/cryovial. The cryovials which 
are made from cryogenic elements were designed to store cells to low temperature (-1960C) 
without brittle breakage. Cell counting was performed to determine a dilution factor required 
in order for each cryovial to receive a minimum of 1x106 viable cells per ml. Cryovials were 
placed into freezing chambers (Mr Frosty®) containing isopropanol; and placed in a freezer at 
-800C. After 12 hours, the cryovials were transferred into liquid nitrogen (≥ 1200C) for long-
term storage. 
    
3.2.3. In vitro incubation of VSMCs with 1α,25(OH)2D3  
At 80% to 90% confluency, cells in T75 flasks were washed, trypsinised and resuspended as 
above. Cells were then plated into 6 separate 6-well cultures plates at 1x105 cells/ml. Plating 
of cells was performed using the growth media and incubated at 37°C with 5% CO2 
atmosphere. Confluency at 70—80% was confirmed after 72 hours of cell platting. Cells were 
then synchronised to the G0 phase by draining out the initial media and supplementation of 
FCS poor media for 12 hours. The FCS-poor medium was then drained out and cells were 
incubated with 1α,25(OH)2D3 (Sigma).  
 
Briefly, a 10 µg, vial of 1α,25(OH)2D3 (≥99% HPLC grade, molecular weight 416.64, Sigma) 
was dissolved with 1 ml of DMSO to make a stock concentration of 10µg/ml or (24 µM). The 
required doses (molarity) of 1α,25(OH)2D3 for this experiment were 0nM, 0.1M, 1nM, 10nM 
and 100nM. The preparation of 1α,25(OH)2D3 is depicted below (Figure 3.1). The final 
volume for media culture was 2ml per well. 
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3.2.4. RNA extraction and assessment of gene expression 
At the end of 48 hours incubation, supernatants were drained out by pipetting out and mRNA 
was extracted using TRIzol reagents (Qiagen) as previously described in Chapter (Section 
2.11). Details on genes that were assessed in human aortic VSMCs are presented Table 3.1. 
Primers were designed against human SOST (5’-CTAACTTGCTGTGTAACC -3’ and 5’- 
TATGCCAATAGTCTCCTC-3’), TNFRSF11B (5’-AATGTGGAATAGATGTTACC-3’ and 
5’-TCTACCAAGACACTAAGC-3’), OPN (5’-AATGATGAGAGCAATGAG-3’ and 5’-
GTCTACAACCAGCATATC-3’) using the Premier 6 Software (Premier Biosoft). Other 
primers were purchased pre-designed (Qiagen). 
The molecular weight of 1α,25(OH)2D3 is 416.64 g/mol. Therefore, 1α,25(OH)2D3 was 
dissolved in DMSO then diluted to the required concentrations by addition of the DMEM 
media. Increasing concentrations of 1α,25(OH)2D3 were then added to 60% to 70% confluent 
human aortic VSMCs in six well plates (i.e. n= 6/dose of 1α,25(OH)2D3). Abbreviations: Vit 
D: vitamin D; 1α,25(OH)2D3: 1α-dihydroxyvitamin D3; DMSO: dimethyl sulfoxide; DMEM: 
Dulbecco’s modified eagle medium; VSMCs: vascular smooth muscle cells.  
 
3.2.5. Characterisation of VSMCs in vitro 
 
In order to characterise contractile phenotype markers within human aortic VSMCs in response 
to 1α,25(OH)2D3 incubation, immunofluorescence staining was performed for α-actin smooth 
muscle (α-SMA). Analyses for gene expression were performed on VSMCs contractile 
Stock 1,25(OH)2D or vit D (24µM)
211.7 µl of DMSO= 500µl of 10 µM vit D
288.3 µl
19.8 ml of medium= 100 nM vit D
200 µl
100 nM x 6wells
50 µl
250 µl of DMSO= 500µl of 10 µM vit D 19.8 ml of medium= 10 nM vit D
200 µl
10 nM x 6wells
250 µl of DMSO= 500µl of 1.0 µM vit D 19.8 ml of medium= 1.0 nM vit D
200 µl
1.0 nM x 6wells
250 µl of DMSO= 500µl of 0.1 µM vit D 19.8 ml of medium= 0.1 nM vit D
200 µl
0.1 nM x 6wells
250 µl of DMSO= 500µl of 0.01 µM vit D 19.8 ml of medium= 0 nM vit D
200 µl




Figure 3.1: Preparation of 1α,25(OH)2D3 doses and study design 
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phenotype markers. For immunostaining, cells were grown on sterile coverslips for 24 hours 
in 370C/5% CO2 incubator. Cells were rinsed with HBSS and fixed using 70% methanol (in 
HBSS) for 10 minutes. For staining the cells were rinsed 3X with HBSS and incubated for 20 
minutes at RT with 10% normal goat serum (Vector Laboratory, CA;  Cat# S-1000)  PBS to 
block non-specific binding of IgG. Cells were then rinsed twice with HBSS and incubated with 
1µg/ml of α-SMA in HBSS -BSA solution for 1 hour at RT. Following 3 times washes with 
HBSS, cells were incubated with 1:250 (or 4µ/ml) biotin-conjugated secondary antibody for 1 
hour. Cells were then washed three times with HBSS before the coverslips on which cells were 
attached was removed from the plate wells. The coverslips were mounted inverted (i.e. the cells 
layer facing the glass slide surface) using 10µl Vectashield mounting media (Vector 
Laboratory, CA; Cat# S-1000) or DAPI medium.  Excess media was removed using a fibre-
free paper. The edges were sealed using regular transparent nail polish and slides were allowed 
to air dry for 5 minutes for long-term preservation of slides. The cytoskeleton filaments were 
visible in all differentiated healthy VSMCs (Figure 3.2). 
 
Table 3.1: List of Human primers for quantitative real time polymerase chain reaction 
Gene Primers Encoded protein Source Catalog # 
H_SOST Sclerostin Sigma  Designed in 
house 
H_TNFRSF11B Osteoprotegerin Sigma Designed in 
house 
H_OPN Osteopontin Sigma Designed in 
house 
H_MMP2 Matrix metalloprotenase-2 Qiagen PPH00151B 
H_VDR Vitamin D receptor Qiagen  PPH02123F 
H_CYP27B1 25-Hydroxyvitamin D3 1-alpha-hydroxylase Qiagen  PPH01242A 
H_CYP24A1 1α,25-dihydroxyvitamin D3 24-hydroxylase Qiagen  PPH01279A 
H_DKK-1 Dickkopf Wnt signalling inhibitor 1 Qiagen  PPH01752C 
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H_OCN Osteocalcin or bone gamma-carboxyglutamic 
acid-containing protein (BGLAP). 
Qiagen  PPH01898A 
H_CTNNB1 β-catenin Qiagen PPH00643F 
H_AGTR1 Angiotensin-II receptor 1 Qiagen PPH02362F 
H_MCP-1 Monocyte chemoattractant protein-1 Qiagen PPH00192F 
H_MYH11 myosin heavy chain 11 Qiagen  PPH02469A 
H_CNN1 Calponin-1 Qiagen  PPH02065A 
H_SMTN Smoothelin Qiagen  PPH12727A 
H_CALD1 Caldesmon 1 Qiagen  PPH21139A 
H_TAGLN Transgelin Qiagen  PPH19531F 
H_ACTA2 α-smooth muscle actin-2 Qiagen PPH01300B 
H_GAPDH Glyceraldehyde 3-phosphate dehydrogenase   




Figure 3.2: Analysis of VSMCs actin filaments. 
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Microscopic photographs of cytoskeletons in human aortic VSMCs (passage 9). A.  An isotype 
of cell nuclei are counterstained blue. B. Green filaments showing immuno-fluorescent 
polymerized filaments of α-smooth muscle actin. Microscopic cell count showed that more 
than 95% of cells were positively stained by α-SMA. 
 
3.2.6. MOUSE STUDIES 
 
ApoE-/- mice on C57BL/6J background were used in this study. Mice were sourced from 
Animal Resource Centre (ARC, Western Australia) and housed in cages that were individually 
ventilated and temperature/humidity-controlled (Aero IVC Green Line; Tecniplast). Mice were 
maintained under a 12-hour light-dark cycle (relative humidity: 55-60%; temperature: 22±1ºC) 
and given portable water ad libitum. The animal’s welfare, including weight and general health 
were monitored in accordance with internal regulations. All procedures in this study were 
approved by the James Cook University Animal Ethics Committee, Australia; and adhered to 
the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, USA). 
Animals experiments described in this chapter were approved under (AEC#: 1970; Appendix 
1A). 
 
3.2.7. Design of mouse studies 
At 13 weeks of age, mice were randomly split into two groups (n=8 per group) using Microsoft 
excel random number generator function (Microsoft EXCEL; 2016). One group was allocated 
to a vitamin D sufficient (VDS) diet while the other group was allocated to a vitamin D 
deficient diet (VDD) diet. The VDS group was allocated to a vitamin D3 enriched diet (2,200 
IU/ kg of feed) while the VDD group was maintained on a CCF-depleted diet (Table 3.2). 
Blood was collected prior to starting the diets; and every month thereafter. Mice were 
maintained on their respective diets for 5 months and then sacrificed at the terminal endpoint. 
At the endpoint (5 months), mice were euthanized by CO2 asphyxiation, followed by dissection 
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Thirteen weeks old mice (n=8/groups) were assigned to the vitamin D deficient diet (VDD; 0 
IU/kg cholecalciferol) or vitamin D sufficient (VDS; 2200 IU/kg of cholecalciferol) for five 
months. Time points (1-5 months) indicates the interval at which blood collection were 
performed. 
 
3.2.8. Animals and Diet 
Dietary formulations were organised through Speciality Feeds (WA, Australia). Dietary 
formulations were balanced to ensure that nutritional intake in both diets, including minerals, 
fats, proteins and vitamins were similar. CCF levels were 2200 IU/kg of feed for the VDS and 
was non-traceable in the VDD diet (Table 3.2). Mice were initially maintained on the normal 
mice chow that contained CCF levels of 3000 IU/kg of feed. When mice were 13 weeks old, 
they were randomly split into two groups. One group was allocated to the CCF-enriched diet 
(2200IU/kg of feed) while the other group was maintained on a control cholecalciferol-depleted 



















Figure 3.3: Experimental design 
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Table 3.2: Nutritional parameters in the vitamin D deficient and vitamin D sufficient 
dietary formulations 
Nutritional Parameters SF05-034 (VDS) SF05-033 (VDD) 
Protein 19.40% 19.40% 
Total Fat 7.00% 7.00% 
Crude fibre 4.70% 4.70% 
Adequate dietary fibre 4.70% 4.70% 
Digestible Energy 15.00 MJ / Kg 15.80 MJ / Kg 
Total energy from lipids 19.00% 19.00% 
Total energy from protein 23.00% 23.00% 
Calcium* 1.00% 2.00% 
Phosphorus* 0.70% 1.20% 
Vitamin D3 
(Cholecalciferol) 
2200 IU/kg Not traceable 
*Calcium and phosphorus minerals were balanced between the diets. The vitamin D 
sufficient (VDS) diet is formulated as the control diet for the vitamin D deficient (VDD) 
diet according the manufacturer. IU: international units. 
 
3.2.9. Plasma analyses 
Blood collection was performed by tail bleeding during the experiments and at the dissection 
end-point by cardiac apex puncture. The blood was collected into heparin-coated tubes (BD 
Microtainer). Plasma was isolated by centrifugation at 6400x g for 10 minutes at 40C and stored 
at -800C until analysed.  Assays for 25(OH)D, epi-25(OH)D3, and 25(OH)D2 were performed 
as previously detailed in Chapter 2 (Section 2.7.1). Briefly, plasma was diluted in RPMI Media 
1640 (ThermoFisher Scientific) (1:3 v/v) and assayed in a vitamin D assay accredited 
laboratory at the Centre for Metabolomics (WA, Australia). The assay was performed using a 
two-dimensional (2D) ultra-performance liquid chromatography (UPLC) separation coupled 
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to tandem mass spectrometry (MS/MS). The detectable levels for serum 25(OH)D were ˃5.0 
nmol/L. 25(OH)D assay methodology has been previously demonstrated to accurately detect 
and quantitate 25(OH)D3, epi-25(OH)D3, and 25(OH)D2 (Albarhani et al., 2015; Clarke et al., 
2013). 
 
Plasma SOST assay was performed as previously detailed in Chapter 2 (Section 2.7.2). Briefly, 
the assay was performed according to the manufacturer’s instruction. Serum SOST was 
measured using a Quantikine® enzyme-linked immunosorbent assay (ELISA) kit (R&D 
Systems; Cat#: MSST00) according to the manufacturer’s instructions. Serum samples 
required a 2-fold dilution using the calibrator diluent (RD6-12) provided with the kit. All 
samples and standards and were performed in duplicates. Mean intra-assay and inter-assay 
coefficient of variation (CV) were 5.1% and 5.8%, respectively. This described in details 
Chapter 2 (Section 2.7.2). 
 
3.2.10. Suprarenal aortic protein assay by ELISA 
SRA segments were cleared of OCT and homogenized in the presence of the radio-
immunoprecipitation assay buffer (1 x RIPA buffer; 50 mM Tris-HCl pH 7.4, 150 mM NaCl; 
2 mM EDTA, 1% TritonX-100, 0.1% SDS, and 0.1% sodium deoxycholate) supplemented 
with protease inhibitors and phosphatase inhibitor (Roche). Mouse SRA tissue SOST protein 
were assayed using a Quantikine® ELISA (R&D systems) as described above. Phospho-GSK-
3α/β (S21/S9) protein levels within the SRA were determined using DuoSet® IC ELISA (R&D 
systems) following the manufacture’s instruction. Briefly, a 96 well ELISA plate was coated 
with immobilized capture antibodies specific to mouse phospho-GSK-3α/β (S21/S9) and 
incubated overnight. After washing, a biotinylated detection antibody specific only to mouse 
phospho-GSK-3α/β (S21/S9) was used to detect phosphorylated protein levels using a standard 
streptavidin-horse radish peroxidase (HRP). All samples and standards were assayed in 
duplicates with a mean intra-assay coefficient of variation (CV) of 4.7% and 4.9% for SOST 
and phospho-GSK-3α/β (S21/S9) assays, respectively. This is described in details in Chapter 2 
(Section 2.10.4). 
 
3.2.11. RNA extraction and assessment of gene expression  
The SRA tissue that was previously stored in RNAlater was homogenised and mRNA was 
extracted using TRIzol reagents (Qiagen) as previously described in Chapter 2 (Section 2.11). 
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Details on genes that were assessed in mice SRA tissue are presented Table 3.3. Primers for 
mouse Sost (5’-CTTAAAGGGAAGGGAGTG-3’ and 5’-TTACATTTGGGTGGAAGG-3’), 
mouse Tnfrsf11b (5’-AAGATGGCTTCTATTACC3’ and 5’-GCTGAAGATAGTCTGTAG-
3’) and mouse Opn (5’-ACTCTTCCAAGCAATTCC3’ and 5’-GTCTCCATCGTCATCATC-
3’) were designed using the Premier 6 Software (Premier Biosoft) and purchased from Sigma 
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Table 3.3: Mouse Primers 
Primers Encoded protein Source Catalog # 
mm-Sost Sclerostin Sigma Designed in 
house 
mm_Tnfrsf1 Osteoprotegerin Sigma Designed in 
house 
mm_Opn Osteopontin Sigma Designed  in 
house 
mm_Vdr Vitamin D receptor Qiagen  PPM05132C 
mm_Cyp27b1 25-Hydroxyvitamin D3 1-alpha-hydroxylase Qiagen  PPM03992A 
mm_Dkk-1 Dickkopf WNT signalling pathway inhibitor 1 Qiagen  PPM05476F 
mm_Ocn Bone gamma-carboxyglutamic acid-containing 
protein (BGLAP) or osteocalcin  
Qiagen  PPM04465F 
mm_Ctnnb1 β-catenin Qiagen  PPM03384A 
mm_ Agtr1 Angiotensin-II receptor type 1 Qiagen PPM05162A 
mm_ Mcp-1 Monocyte chemoattractant protein 1 Qiagen PPM03151G 
Gapdh Glyceraldehyde 3-phosphate dehydrogenase Qiagen QT01658692 
Primers used for real-time quantitative polymerase chain reaction mice experiments. Shown 
are the primers used to assess gene expression within the suprarenal aortas of mice.  
 
 
3.2.12. Statistical analysis 
The D’Agostino and Pearson test were used to test normality of the data. Non-normally 
distributed data were expressed as median and interquartile range (IQR) and normally 
distributed data were expressed as mean ± SEM. For non-normally distributed data, 
comparisons were made using Mann-Whitney U-test or Kruskal-Wallis test followed by 
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Dunn’s multiple comparisons test. Normally distributed data were compared using ANOVA 
followed by Bonferroni’s multiple comparisons test. Animal experiments described in this 
chapter were primarily conducted as a pilot study to investigate whether dietary restriction of 
cholecalciferol (CCF) affected circulating levels of 25(OH)D and circulating SOST and SRA 
SOST in ApoE-/- null mice. Therefore, sample size calculation was not determined for this 
study. Changes in 25(OH)D levels over time were analysed by repeated measures ANOVA. 
All data were analysed using GraphPad Prism 8.4.2 software (GraphPad Software, Inc., USA). 
Differences were considered statistically significant at P < 0.05. 
 
3.4. RESULTS 
3.4.1. 1α,25(OH)2D3 upregulated SOST and attenuated Wnt/β-catenin signalling in 
human aortic vascular smooth muscle cells. 
Incubation of 1α,25(OH)2D3 with human aortic VSMCs for 48 hours resulted in dose-
dependent upregulation of SOST (P<0.001, Figure 3.4A). In contrast, CTNNB1 was dose-
dependently downregulated in human aortic VSMCs following incubation of with 
1α,25(OH)2D3 (P=0.007, Figure 3.4B). 
3.4.2. 1α,25(OH)2D3 modulated expression of genes implicated in vitamin D metabolism 
in human aortic vascular smooth muscle cells. 
 
Incubation of human VSMSCs with 1α,25(OH)2D3 significantly upregulated expression of 
VDR in a dose-dependent manner (P<0.001, Figure 3.5A) in VSMCs. Expression of OCN was 
also significantly upregulated in dose-dependent manner (P=0.112, Figure 3.5B). Similarly, 
CYP24A1 was significantly upregulated (P<0.001, Figure 3.5C). In contrast, expression of 
CYP27B1 which encodes an enzyme that catalyses the conversation of 25(OH)D to 
1α,25(OH)2D3, was significantly downregulated (P<0.001, Figure 3.5D). 
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Figure 3.4: Expression of SOST and CTNNB1 in VSMCs following incubation with 
1α,25(OH)2D3. 
The graph shows gene expression of (A) SOST and (B) CTNNB1 expression (relative to 
GAPDH) in response to increasing concentration of 1α,25(OH)2D3. Data expressed as median 
and interquartile range with maximum and minimum data points (whiskers) and compared with 
Kruskal-Wallis test (A, P<0.001; B, P=0.007). Gene expression at individual 1α,25(OH)2D3 
concentrations were compared to 0.0 nM (negative control) using Dunn’s multiple comparison 
test;  *P<0.05 and **P<0.01. 
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The graph shows gene expression of (A) VDR and (B) OCN, (C) CYP24A1 and CYP27B1 
expression relative to GAPDH. Data expressed as median and interquartile range with 
maximum and minimum data points (whiskers). Data were compared with Kruskal-Wallis 
test. 0.1 nM to 100 nM concentrations were compared to 0.0 nM (negative control) using 
Dunn’s multiple comparison test. Statistical significance is shown as *P<0.05 and **P<0.01.  
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Figure 3.5: Effects of 1α,25(OH)2D3 on vitamin D metabolism in VSMCs. 
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Figure 3.6: Expression of genes implicated inflammatory and matrix degradation 
following incubation of 1α,25(OH)2D3 with VSMCs. 
Following incubation of 1α,25(OH)2D3 with human aortic VSMCs for 48 hours expression 
of (A) OPN, (B) MMP-2, (C) AGTR1 and (D) MCP-1 was dose-dependently downregulated. 
Data expressed as median and interquartile range with maximum and minimum data points 
(whiskers). Data were compared among concentrations with Kruskal-Wallis test. 0.1 nM to 
100 nM concentrations were compared to 0.0 nM (negative control) using Dunn’s multiple 
comparison test. Statistical significance is shown as *P<0.05 and **P<0.01. 
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Figure 3.7: Expression of VSMCs contractile phenotype markers after incubation with 
1α,25(OH)2D3. 
Following incubation of 1α,25(OH)2D3 with human aortic VSMCs for 48 hours, expression 
of (A) CNN1, (B) MYH11, (C) SMTLN, (D) ACTA-2, (E) CALD1 and (F) TGLN1 was dose-
dependently upregulated. Data expressed as median and interquartile range with maximum and 
minimum data points (whiskers). Data were compared among concentrations with Kruskal-
Wallis test. 0.1 nM to 100 nM concentrations were compared to 0.0 nM (negative control) 
using Dunn’s multiple comparison test. Statistical significance is shown as *P<0.05 and 
**P<0.01. 
 
3.4.3. 1α,25(OH)2D3 promoted expression of contractile vascular smooth muscle cells 
phenotype 
Molecular regulation of contractile phenotype markers in VSMCs is important in 
atherosclerosis and aortic aneurysms (Ailawadi et al., 2009; Airhart et al., 2014; Rzucidlo, 
Martin, & Powell, 2007). Effects of 1α,25(OH)2D3 on human aortic VSMCs contractile 
markers were investigated in vitro. Treatment with 1α,25(OH)2D3 resulted in a dose-
dependent upregulation of CNN1 (P=0.002);  MYH11 (P<0.001), SMTN (P=0.002), CALD1 
(P=0.001), TAGLN (P=0.001) and ACTA2 (P=0.007) (Figure 3.7A-F). 
3.4.4. 1α,25(OH)2D3 downregulated pro-inflammatory and matrix degrading genes 
 
Incubation of VSMCs with 1α,25(OH)2D3 resulted in dose-dependent downregulation of 
constitutive genes that are known to be implicated in inflammation and ECM degradation. 
Expression of OPN (P<0.001), MMP-2 (P=0.004) AGTR1 (P=0.002), MCP-1 (P<0.001) 
(Figure 3.6) and MAPK13 (P<0.001) (Figure 3.8) were all downregulated in a dose-dependent 




























Incubation of 1α,25(OH)2D3 with human aortic VSMCs for 48 hours resulted in in dose-
dependently downregulation of MAPK13. Data expressed as median and interquartile range 
with maximum and minimum data points (whiskers). Data were compared among 
concentrations with Kruskal-Wallis test. 0.1 nM to 100 nM concentrations were compared to 
0.0 nM (negative control) using Dunn’s multiple comparison test. Statistical significance is 
shown as *P<0.05 and **P<0.01. 
 
4.4.5. Dietary restriction of vitamin D reduced plasma 25(OH)D, circulating SOST and 
suprarenal aortic SOST expression, resulting in activation of Wnt/β-catenin signalling 
in apolipoprotein E-null mice 
 
In this experiment, effects of dietary restriction of vitamin D on circulating plasma 25(OH)D, 
plasma SOST, SRA SOST protein, SRA p-GSK-3α/β protein and SRA Sost gene expression 
were assessed. At baseline, plasma levels of 25(OH)D were similar between the VDS and the 
VDD groups. After one month, circulating levels of 25(OH)D were no longer detectable in all 
mice that were receiving the  VDD diet while no significant changes were observed in the VDS 































Figure 3.8: Expression of MAPK13 in VSMCs following incubation with 1α,25(OH)2D3. 
80 | P a g e  
 
group. Overall, 25(OH)D levels were significantly lower in mice that were maintained on the 
VDD diet  compared with those on VDS mice (P<0.001; Figure 3.9A). At baseline, plasma 
SOST levels were similar between both groups. However, after five months of dietary 
supplementation, the mice receiving the VDD diet had significantly reduced SOST levels 
compared with baseline (P=0.016) while the levels did not significantly change in mice 
receiving the VDS diet. At the five months endpoint, the mice that received the VDD diet had 
significantly lower SOST levels compared the group of mice that received the VDS (P= 0.028; 
Figure 3.9B). SOST protein levels measured from the homogenised SRA tissue were 
significantly lower in mice that received the VDD diet compared to mice maintained on the 
VDS diet (P=0.015; Figure 3.9C). Conversely, protein expression of phosho-GSK-3α/β were 
significantly higher in mice receiving the VDD diet compared with those fed the VDS diet 
(P=0.001; Figure 3.9C). 
 
SRA gene expression was examined using rt-qPCR and normalised to the housekeeping gene 
Gapdh (Table 3.4). SRA Sost gene expression was significantly downregulated in mice that 
were fed the VDD diet compared with mice that received the VDS diet (P<0.001). Conversely, 
expression of Ctnnb1 was significantly upregulated in mice receiving the VDD diet compared 
to mice maintained on the VDS diet (P=0.007). Expression of Dkk-1 was similar in both groups 
of mice (Table 3.4). 
 
4.4.6. Dietary restriction of vitamin D modulated suprarenal aortic expression of genes 
that are implicated in vitamin D metabolism and upregulated pro-inflammatory genes 
within the apolipoprotein E-null mice 
 
SRA gene expression of Cyp27b1 (P=0.001) and Ocn (P=0.028) were significantly upregulated 
in the mice fed the VDD diet compared to mice fed the VDS diet and, respectively.   However, 
expression of Vdr was not significantly different between both groups of mice. Expression of 
pro-inflammatory genes, including Opn (P<0.001), Agtr1 (P=0.038) and Mcp-1 (P<0.001) was 
significantly upregulated in mice that received the VDD diet compared the group of mice that 
was fed the VDS diet. However, expression of Opg was not significantly different between the 
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Figure 3.9: Effects of dietary restriction of vitamin D on plasma SOST and the Wnt/β-
catenin signalling in the aortic wall of ApoE-/- mice. 
The graph shows (A) monthly plasma levels of circulating 25(OH)D, (B) plasma levels of 
SOST at baseline and endpoint, (C) SRA protein expression and (D) SRA p-GSK-3α/β protein 
expression. A. Compared with mice that received the VDS diet, the VDD diet resulted in 
depletion of circulating levels of 25(OH)D (below detectable levels; repeated measures 
ANOVA were performed to compare differences). Plasma SOST levels were compared 
between baseline and 5-months endpoint using by Wilcoxon paired test. SRA tissue SOST 
protein expression and phosphorylated GSK-3α/β (p-GSK-3α/β) complex were compared 
between groups with Mann Whitney U test. Statistical significance is shown as actual P-values. 
Abbreviations: 25(OH)D: 25-hydroxyvitamin D; SRA: suprarenal aorta; p-GSK-3α/β: 
phosphorylated glycogen synthase kinase 3α/β. 
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Table 4: Effect of dietary vitamin D restriction on gene expression in the suprarenal 
aorta of apolipoprotein E-null mice 
Gene VDS (n=8) VDD (n=8) Expression P 
Sost 1.32 [1.06-2.02] 0.14 [0.07-0.30]  <0.001 
Opg 0.07 [0.07-0.08] 0.08 [0.06-0.08]  0.863 
Opn 1.25 [0.76-1.81] 4.67 [2.97-8.26]  <0.001 
Vdr 0.42 [0.26-0.89] 0.53 [0.18-0.91]  0.959 
Cyp27b1 0.35 [0.24-0.44] 0.55 [0.47-0.77]  0.001 
Dkk-1 0.47 [0.32-0.66] 0.24 [0.17-0.40]  0.065 
Ocn 0.71 [0.44-107] 1.10 [0.91-1.31]  0.028 
Ctnnb1 0.69 [0.33-0.99] 1.11 [1.02-1.26]  0.007 
Agtr1 0.59[0.37-0.80] 0.83[0.70-0.97]  0.038 
Mcp-1 0.16[0.13-0.26] 0.39[0.30-0.47]  0.001 
Shown are relative gene expression as median (inter-quartile range) relative to 
glyceraldehyde 3-phosphate dehydrogenase (Gapdh) expression. Inter-group comparison 
was analysed using Mann-Whitney U test (n=8/group). Abbreviations: Sost: gene 
encoding sclerostin; Opg: osteoprotegerin; Opn: osteopontin (also known as secreted 
phosphoprotein 1, Spp1); Vdr: vitamin D receptor; Cyp27b1: gene encoding for 25-
hydroxvitamin D3 hydrolase; Dkk: Wnt inhibitor Dickkopf-1; Ocn: osteocalcin (also 
known as bone-Gla matrix); Ctnnb1: gene encoding for β-catenin; Agtr1: angiotensin-II 
receptor 1; Mcp-1: monocyte chemoattractant protein-1. 
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3.4. DISCUSSION 
The main findings from this study were that 1α,25(OH)2D3 induced SOST expression in human 
aortic VSMCs; and that dietary restriction of vitamin D reduced SOST in ApoE-/- mice. 
Incubation of 1α,25(OH)2D3 with human aortic VSMCs for 48 hours resulted in upregulation 
of SOST and downregulation of CTNNB1 in a dose-dependent manner. This resulted in dose-
dependent downregulation of genes that are implicated in inflammation and upregulation of 
contractile phenotype marker genes. Conversely, dietary restriction of vitamin D resulted in 
increased circulating SOST and SRA wall SOST expression in ApoE-/- mice. Expression of pro-
inflammatory and matrix degrading genes were downregulated within the SRA wall of these 
mice. These findings suggest that vitamin D modulates both in vitro expression of SOST within 
VSMCs and in vivo SOST in ApoE-/- mice. Downstream effects of SOST were demonstrated 
by activation of Wnt/β-catenin signalling. Effects of reduced SOST on the aortic wall 
inflammation and matrix degrading markers are supported by a previous study, which showed 
that transgenic downregulation of SOST promoted aortic aneurysm in experimental mice 
(Krishna et al., 2017). 
 
Findings from this study suggested that VDD diet resulted in downregulation of SOST and 
activation of the Wnt/β-catenin signalling within the SRA wall of ApoE-/- mice. In vitro data 
showed that 1α,25(OH)2D3 upregulated contractile phenotype makers in VSMCs, which is an 
important manifestation AAA (Peng et al., 2018). Activated Wnt/β-catenin signalling promotes 
mammalian aging and aging-related phenotype changes. In a recent study, findings from our 
group reported that SOST is epigenetically silenced in patients who are susceptible to AAA 
development as well as in mice (Krishna et al., 2017). Of importance, the role of vitamin D in 
epigenetic silencing is currently of interest as emerging evidence suggests that has vitamin D 
has the ability to mediate DNA demethylation in cells (Fetahu, Höbaus, & Kállay, 2014). It has 
also been previously reported that during arterial aging, VSMCs switch from a proliferative 
response to non-proliferative response as a result of Wnt/β-catenin activation (Carlberg, 2019; 
X. Gao, Zhang, Schottker, & Brenner, 2018; Marchand et al., 2011). This suggests that lower 
circulating 25(OHD)D which is a common finding in elderly populations (Fahrleitner et al., 
2002; Grober et al., 2013; Holick, 2007) may be implicated. Additionally, it has been reported 
that VSMCs in the vessels of elderly subjects may not proliferate efficiently in response to β-
catenin activation (Ruiz-Torres et al., 1999), which also favours arterial matrix remodelling. 
Plausibly, lower circulating 25(OH)D coupled with advanced age and other risk factors such 
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as smoking may act in concord to cause epigenetic silencing of the SOST gene, thus leading to 
susceptibility to aortic disease development older patients (Golledge, Biros, Bingley, Iyer, & 
Krishna, 2016; Krishna, Dear, Craig, Norman, & Golledge, 2013; Krishna, Dear, Norman, & 
Golledge, 2010; Krishna SM, 2014).  
 
VSMCs are abundantly present within the aorta and play a crucial role in its function and 
integrity (Michel, Jondeau, & Milewicz, 2018). Decreased SOST protein and mRNA 
expression following dietary restriction of vitamin D underscore the importance of vitamin D 
in modulating SOST levels within the aorta. In agreement with these findings, previous reports 
have shown that vitamin D deficiency is associated with lower SOST in human (Jorde et al., 
2019; Pirgon et al., 2016). Circulating levels of SOST have been inversely associated with the 
severity of aortic calcification and cardiovascular outcomes in dialysis patients (Yang et al., 
2015) which suggests a role of Wnt/β-catenin signalling plays in vascular inflammation and 
remodelling. 
 
Cellular experiments demonstrated a dose-dependent upregulation of SOST which was coupled 
with downregulation of CTNNB1 following incubation with 1α,25(OH)2D3. Similarly, reduced 
SOST in response to the VDD diet resulted in upregulation of aortic Ctnnb1 within the SRA of 
mice, also confirmed by upregulated expression of GSK-3α/β within the aortic wall. A number 
of studies have demonstrated a significant role for the Wnt signalling pathway in vascular 
function (Naito, Shiojima, & Komuro, 2010; Reis & Liebner, 2013). Notably, the study from 
our group which demonstrated that SOST deficiency promotes expression of several genes that 
are implicated in the pathogenesis of aortic aneurysm and atherosclerosis (Krishna et al., 2017). 
Expression of VDR has been suggested to have the ability to directly repress β-catenin 
activation resulting in deactivation Wnt/β-catenin signalling (Shah et al., 2006). Alternatively, 
it is also possible that repressive effects of 1α,25(OH)2D3 could have been mediated on Wnt/β-
catenin signalling, thus reducing CTNNB1 expression without direct effects of SOST, at least 
in in vitro studies. 
Incubation of 1α,25(OH)2D3 with VSMCs resulted in downregulation of pro-inflammatory and 
matrix remodelling markers. High serum concentrations of OPN were previously reported to 
be associated with a number CVD, including AAA (Golledge et al., 2007). OPN promotes 
inflammation (Denhardt, Noda, O'Regan, Pavlin, & Berman, 2001), and is also involved in the 
activation of proteolytic pathways including an increase of pro-MMP-9 and MMP-2 activity 
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(Lai et al., 2006). OPN deficiency has been shown to limit AAA development in the AngII-
infused mouse model, a disease well-characterised by SRA wall inflammation and remodelling 
(Bruemmer et al., 2003). Findings from this study are therefore consistent with investigations 
from our laboratory and elsewhere which have previously showed that OPN is implicated in 
the development of AAA, and plays a significant role in aortic inflammation and matrix 
remodelling (Filis et al., 2014; Koole et al., 2012; Krishna et al., 2012; Moran et al., 2005). In 
addition, incubation of 1α,25(OH)2D3 with VSMCs resulted in lower expression of MAPK13 
which is consistent with previous investigations showing that MAPK13 signalling is associated 
with aneurysmal development through upregulation of MMPs and inflammation (Martorell et 
al., 2016; Ortega et al., 2019; Wang et al., 2018). Nonetheless, although OPG has been shown 
to be positively associated with AAA formation (Moran et al., 2010; Moran et al., 2005), 
findings from this study did not find a difference in OPG gene expression between the VDD 
and the VDS groups nor was OPG downregulated following incubation of 1α,25(OH)2D3 with 
human VSMCs. However, VSMCs used in this experiment were not exposed to AngII or any 
pro-inflammation stimulant. A previous report showed that OPG promoted an inflammation in 
human aortic VSMCs, including upregulation of cathepsin S, MMP-2 and MMP-9 following 
incubation with AngII (Moran, Jose, E. Biros, & Golledge, 2014). While expression of MMPs, 
including MMP-9 would require incubation with an inflammatory stimulant with cells, MMP-
2 is constitutively expressed in VSMCs; and thus its expression was investigated in this study 
(Crowther, Goodall, Jones, Bell, & Thompson, 2000). 
 
Previous in vitro experiments have tended to use supra-physiological concentrations of 
1α,25(OH)2D3 in the ranges of 1nM-100 nM (i.e. ~100-1000-folds higher than circulating 
levels of 1α,25(OH)2D) (Lips, 2007). Selected doses of 1α,25(OH)2D3 for cellular experiments 
were based on  previous investigations examining the effects of 1α,25(OH)2D3 on SOST 
expression in osteoblastic cells (Wijenayaka et al., 2016; Wijenayaka et al., 2015). While SOST 
was previously known to be exclusively expressed in bones (Jorde et al., 2019; Veverka et al., 
2009; Weivoda & Oursler, 2014), expression of SOST was recently reported within the aortic 
tissue, albeit with an unknown function (Balemans et al., 2001; Brunkow et al., 2001; Rush et 
al., 2009). In order to confirm whether cultured human aortic VSMCs responded to 
1α,25(OH)2D3 treatment doses in this experiment, a number of key genes that are implicated 
the regulation of vitamin D metabolism were assessed. Significant upregulation of VDR, OCN 
and CYP24A1; and downregulation of CYP27B1 confirmed that effects observed within human 
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aortic VSMCs in this study were in response to 1α,25(OH)2D3 effects (Christakos et al., 2016). 
Upregulated expression of CYP27B1 is indicative of the ability for the tissue to locally 
metabolise bioavailable 25(OH)D while VDR expression shows receptor activation in response 
to 1α,25(OH)2D (Christakos et al., 2016; Dusso et al., 2005).  
These findings should be interpreted in light of several strengths and limitations. A noteworthy 
strength of this study was the design of in vitro experiments and in vivo studies in mice to 
demonstrated the effects of vitamin D on SOST. VSMCs play a paramount role in the function 
and integrity of the aorta (Gomez & Owens, 2012; Lacolley, Regnault, Nicoletti, Li, & Michel, 
2012; Mao et al., 2015); therefore, in vitro effects of 1α,25(OH)2D on VSMCs strongly 
suggested an important role of vitamin D on VSMCs function. While it is possible that different 
cells may respond differently to 1α,25(OH)2D3 effects, in vitro experiments focused on 
VSMCs due to the paramount role played by these cells in arterial remodelling and AAA 
formation. Future experiments may be focused on investigating and replicating effects of 
1α,25(OH)2D in other cell types that are known to contribute to aortic wall remodelling and 
matrix degradation. The role of dietary restriction of vitamin D on circulating SOST and aortic 
SOST in otherwise unmanipulated ApoE-/- mice is a novel finding in this study with potential 
to be investigated in the presence of AAA disease. Therefore, it would be important to assess 
effects dietary restriction of vitamin D on AAA development in this mouse model.  
In conclusion, an important and novel finding from this study was that SOST expression was 
upregulated in VSMCs following incubation with increasing doses of 1α,25(OH)2D3 whereas 
the VDD diet reduced SOST in ApoE-/- mice. Data from this chapter demonstrated that 
1α,25(OH)2D3 promoted expression of SOST in VSMCs in a dose dependent manner. Within 
ApoE-/- mice, dietary restriction of vitamin D deficiency resulted in reduced circulating SOST 
and decreased SRA SOST expression at protein and mRNA levels. Collectively, these findings 
suggested that deficiency of vitamin D coupled with resultant decrease in SOST promotes 
expression of markers that are implicated in aortic wall inflammation and matrix remodelling. 
Effects of vitamin D deficiency appear to be mediated via changes in reduced SOST and 
increased OPN, which promotes ECM degradation. Given the importance of inflammation and 
arterial remodelling in the pathogenesis of AAA, it would be interesting to examine whether 
deficiency of vitamin D and consequent lower SOST promote formation of severe AAAs 
within an experimental mouse model of AAA. In light of these findings, the following chapter 
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will examine effects of dietary restriction of vitamin D on AAA formation using the AngII- 

























CHAPTER 3 HIGHLIGHTS 
What is Known? 
 1α,25(OH)2D3 (the active metabolite of vitamin D3) has been shown to induce SOST 
expression in osteoclasts. 
 SOST is a negative regulator of Wnt/β-catenin signalling. 
 Downregulation of SOST was recently shown to increase infiltration of macrophages, 
remodelling of elastin and collagen ECM within AngII infused ApoE-/- mice. 
 Circulating 25(OH)D concentration is the best indicator of vitamin D status. 
 
What New Information Does This Chapter Add? 
 1α,25(OH)2D increased SOST expression and downregulated activation of Wnt/β-
catenin signalling in human aortic VSMCs. 
 1α,25(OH)2D increased expression of contractile phenotype markers and reduced 
expression of pro-inflammatory genes related to AAA formation in human aortic VSMCs.  
 Dietary restriction of vitamin D resulted in depletion of 25(OH)D levels and reduced 
circulating SOST and SRA SOST protein as well as SRA Sost gene expression in the ApoE-
/- mice. 
 Dietary restriction of vitamin D resulted in upregulation of pro-inflammatory genes 
within the SRA of ApoE-/- mice. 
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CHAPTER 4: 
EFFECT OF VITAMIN D DEFICIENCY ON 
ANGIOTENSIN II-INDUCED ABDOMINAL 
AORTIC ANEURYSM IN THE 
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4.1. INTRODUCTION 
AAA is a focal enlargement of the aorta characterised by degradation and weakening of the 
aortic wall. AAA is thought to be a multifactorial disease; however, current knowledge of exact 
pathophysiological mechanisms remains incomplete. Presently, no drug therapies that have 
been demonstrated to prevent AAA development or limit AAA growth and rupture (Golledge 
et al., 2019; Golledge, Norman, Murphy, & Ronald L. Dalman, 2017; Lindeman & Matsumura, 
2019). There is therefore great interests in identifying drug therapies that can effectively limit 
AAA growth and rupture.  
 
Data from experimental and epidemiologic studies support an association between vitamin D 
deficiency and arterial diseases such as CAD, PAD and atherosclerosis (Nsengiyumva et al., 
2015; Pilz, Verheyen, Grubler, Tomaschitz, & Marz, 2016). The relevance of vitamin D in 
AAA however has only recently become of interest. Reduced circulating concentration of 
25(OH)D is associated with human aortic aneurysms in a number of cross-sectional studies 
(Demir et al., 2012; Van De Luijtgaarden et al., 2012; Wong et al., 2013). AAA patients with 
lowest plasma levels of 25(OH)D were greater than five times likely to have an AAA larger 
than >4cm compared with those with the highest range of 25(OH)D levels. Contrary to this 
evidence, it is reported that the prevalence of AAA is highest in Australasia where levels of 
ultraviolet exposure (and thus likely vitamin D) are very high (Li et al., 2013; Sampson et al., 
2014). Excess vitamin D is believed to have potential pathological effects such as inhibiting 
production of elastin (an important aortic matrix protein) by VSMCs (Hinek et al., 1991; 
Norman et al., 1995; Norman et al., 2002). Further experimental research is therefore needed 
to resolve the importance of vitamin D in AAA pathogenesis. 
 
Expression of VDR within cardiac and arterial cells suggests that vitamin D plays a role within 
the cardiovascular system (Al Mheid, Patel, Tangpricha, & Quyyumi, 2013; Christakos et al., 
2016; Norman & Powell, 2014; Nsengiyumva et al., 2015; Pilz et al., 2016; Scragg et al., 2017). 
A recent study showed that administration of the VDR agonist 1α,25(OH)2D3 inhibited aortic 
aneurysm in a mouse model of AAA (Martorell et al., 2016). In addition, administration of the 
vitamin D analogue, paricalcitol, was reported to attenuate inflammation, by reducing 
infiltration of T-cell (CD3+) and T-helper cell (CD4+) within the aortic wall of  AAA patients 
(Nieuwland et al., 2016). Vitamin D deficiency is clinically managed by cholecalciferol 
supplementation with an aim to raise 25(OH)D (Bischoff-Ferrari, Giovannucci, Willett, 
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Dietrich, & Dawson-Hughes, 2006; Holick et al., 2011; Kennel, Drake, & Hurley, 2010; 
Kleerekoper et al., 2011). Vitamin D plays an important role in the control of bone 
mineralisation (Goltzman, 2015). The findings from the preceding chapter (Chapter 3) 
demonstrated that 1α,25(OH)2D3 upregulated SOST expression in cultured human aortic 
VSMCs. It was further shown that within the SRA of ApoE-/- mice, dietary restriction of vitamin 
D resulted in reduced SOST and downstream activation of Wnt/β-catenin pathway. The 
expression of SOST is reportedly reduced in experimental mice and human aortic aneurysms 
(Krishna et al., 2017; Towler, 2017). Mice in which SOST was transgenically overexpressed 
were protected from AAA development following Ang-II infusion (Krishna et al., 2017). 
Mechanistically, it was proposed that these effects were due to the ability of SOST to block 
signalling via the canonical ‘wingless-type mouse mammary virus integration site’, or Wnt/β-
catenin pathway (Krishna et al., 2017). However, it remains unknown whether dietary 
deficiency of vitamin D promotes AAA in this experimental mouse model.  
 
The following work examined the hypothesis that vitamin D deficiency promotes AAA growth. 
The aim of the study was to determine if dietary-induced deficiency of vitamin D promoted 
AAA in the ApoE-/-, Ang-II mouse model AAA. 
 
Specific hypotheses of this study were: 
1. Dietary deficiency of vitamin D promotes AAA development in AngII infused ApoE-/- 
mice. 
 
These hypotheses were assessed with the following specific aims: 
1. To determine whether dietary deficiency of vitamin D augments AngII-induced dilatation 
of the SRA in AngII infused ApoE-/- mice. 
2. To determine whether dietary deficiency of vitamin D promotes atherosclerosis in AngII-
induced dilatation of the SRA in AngII infused ApoE-/- mice. 
3. To determine whether dietary deficiency of vitamin D increases SBP in Ang-II infused 
ApoE-/- mice. 
4. To examine if dietary deficiency of vitamin D promotes inflammation and aortic wall 
matrix remodelling in AngII-induced infused ApoE-/- mice. 
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4.2. METHODS AND MATERIALS 
4.2.1. Sample size determination 
The sample size calculation was performed using GPower 3.1.9.2 software version. The 
primary outcome for this study was the SRA diameter serially measured by ultrasound. The 
intervention in this study was dietary restriction of vitamin D which was postulated to result in 
lower circulating 25(OH)D; and hence larger AAAs.  Therefore, sample size computation was 
based on a recent study by (Smriti M Krishna et al., 2015) in which randomisation of ApoE-/- 
mice (n=29) to intervention or placebo after 28 days of AngII infusion resulted in in larger 
AAAs  for the intervention group [1.30±0.21 (mean±SD)] compared with the SRA diameter 
for controls mice [1.15±0.16 (mean±SD)] which was similarly measured by ultrasound. 
Assuming a similar trend (80% power; α: 0.05), an estimated total of 48 mice was required 
(n=24 mice/group). This sample accounted for possible drop-outs in anticipation of mortality 
(15-20 %) due to AAA rupture following AngII infusion. 
 
4.2.1. Experimental design 
The James Cook University/Animal Ethics Committee approved all animal studies described 
in this Chapter (JCU/AEC no: 1970; Appendix 1A). 
All mice were initially maintained on standard chow that contained 3000 IU/kg of 
cholecalciferol. At 13 weeks old, mice (n=24/ group) were randomly allocated to a VDD or 
VDS diets using Microsoft excel random number generator function (Microsoft EXCEL, 
2016). The two groups were maintained on their respective diets for two months (8 weeks) 
prior to induction of AAA by AngII infusion. Dietary formulations were provided by Speciality 
Feeds (WA, Australia). Nutrient content of the feed was balanced such that essential vitamins 
and minerals, fats, and proteins were comparable between the diets, with exception of 
cholecalciferol. Cholecalciferol concentration in the VDS diet was 2200 IU/kg of feed, while 
non-traceable in the VDD diet (Table 3.2). At the end of the two-month dietary 
supplementation, AAA was induced via AngII infusion for 28 days at a flow rate of 
1µg/kg/min. At the end of the study, mice were euthanized by CO2 asphyxiation, followed by 
dissection and tissue samples collection. A detailed experimental design flow-chart is 
illustrated in Figure 4.1. 
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Apolipoprotein E-null (ApoE-/-) mice (n=49) were randomly allocated to either a vitamin D 
deficient (VDD; 0 IU/kg of feed; n=25) or a vitamin D sufficient (VDS; 2200 IU/kg of feed) 
diet (n=24). Three of the 24 mice allocated to the VDS diet were euthanized within the first 
three days due to due to unrelated health problems; leaving 21 mice. After 8 weeks, aortic 
aneurysm was induced by infusion of angiotensin II (AngII), 1µg/kg/min lasting for 28 days 
while the groups were maintained on their respective diets. Supra-renal aortic diameter, 
peripheral blood collection and blood pressure were performed at baseline (before diet 
introduction), at day 0 (before AngII infusion) and at day 14 and 28 post AngII infusion. 
After 28 days of AngII infusion (total duration was 12 weeks for the experiment), terminal 
dissection (TD) was performed and samples were collected. 
 
4.2.2. Non-invasive tail-cuff blood pressure assessment 
SBP, DBP and heart rate were measured in mice at baseline, prior to starting AngII infusion, 
at day 14 days post-AngII infusion, and at day 28 post-AngII infusion. Measurements were 
performed using a computerized non-invasive tail-cuff system (CODA Monitor, Kent 




4.2.3. Ultrasound monitoring 
SRA diameter in vivo was measured by ultrasound as described in Chapter 2 (Section 2.5.1), 
first at baseline (day 0, before AngII) and then at 14-day intervals following commencement 
of AngII infusion.  
 
 
Figure 4.1: Study Design 
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4.2.4. Morphometric analysis  
Measurement of SRA diameter and characterisation of aneurysm in aortas harvested from 
surviving mice at the completion of the study period was performed as described in Chapter 2 
(Section 2.5.2.). Gross morphology of the SRA (aneurysm type) was classified and compared 
between the two groups according to Daugherty, et al. (2001) (Daugherty et al., 2001). The 
inter-assessor rate on classification of aneurysms was achieved by 100% concordance as 
described in Chapter 2 (Section 2.5.2.). 
 
4.2.5. Plasma analyses 
Blood collection was performed by tail bleeding at baseline (before diet) at day 0 (before AngII 
infusion) and at 14 day intervals after AngII infusion. At the end-point, during terminal 
dissection, blood was collected by cardiac puncture. The blood was collected into heparin-
coated tubes (BD Microtainer) and plasma samples prepared for 25(OH)D and SOST assay as 
described in Chapter 2 (Sections 2.7). 
 
4.2.6. Protein assay by ELISA in suprarenal aortic tissue 
SRA segments were cleared of OCT and homogenized in the presence of the radio-
immunoprecipitation assay buffer (1 x RIPA buffer; 50 mM Tris-HCl pH 7.4, 150 mM NaCl; 
2 mM EDTA, 1% TritonX-100, 0.1% SDS, and 0.1% sodium deoxycholate) supplemented 
with protease inhibitors and phosphatase inhibitor. Mouse SRA SOST protein expression was 
assayed using a Quantikine® ELISA (R&D systems®) as described in Chapter 2, (Sections 
2.10.3). Mouse SRA phospho-GSK-3α/β (S21/S9) levels were determined using DuoSet® IC 
ELISA in accordance (R&D systems®) as described in Chapter 2 (Sections 2.10.4) 
 
4.2.7. Quantification of atherosclerotic lesion area 
Aortic arch samples were prepared for en face Sudan IV staining as described in Chapter 2 
(Section 2.7). The presence and severity of intimal surface atherosclerotic plaque was 
compared between arch samples obtained from mice on VDD (n=13) and VDS (n=17) by 
digital image analysis as described in Chapter 3 (Section 2.8). 
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4.3. Statistical analysis 
D’Agostino and Pearson test was used to test the normality of the data. Results were expressed 
as median and IQR for non-normally distributed data; and as mean ± SEM for normally 
distributed data. For non-normally distributed data, comparisons were made using Mann-
Whitney U-test or Kruskal-Wallis test followed by Dunn’s multiple comparisons test. 
Normally distributed data were compared using ANOVA followed by Bonferroni’s multiple 
comparisons test. Mortality rate was tested using a survival Kaplan Meier curve. Differences 
were considered to be statistically significant at P < 0.05. Repeated measures ANOVA were 
analysed using GraphPad Prism software All data were performed using GraphPad Prism 
(Version 8.4.2) software (GraphPad Software, Inc., USA). 
 
4.3. RESULTS 
4.3.1. Dietary restriction of vitamin D promoted development of larger AAAs that were 
prone to rupture. 
Two days after dietary allocation, three mice from the VDS group were euthanized due to ill-
health unrelated to the experiment and thus excluded from the study. Mice administered VDD 
diet exhibited a greater rate of SRA expansion over the intervention period compared to control 
mice receiving VDS diet (P=0.034; Figure 4.2.A).  Aortic rupture occurred in 48% of mice 
administered VDD diet (12 out of 25; arch rupture in 4 mice and SRA rupture in 8 mice). In 
contrast, 19% of mice (4 out of 21) receiving VDS diet died of aortic rupture (arch rupture in 
2 mice and SRA rupture in 2 mice). The incidence of aortic rupture was greater in mice 
allocated VDD diet compared to VDS diet as determined by Kaplan Meier analysis and log 
rank test (P=0.029; Figure 4.2.B).  
 
Morphometric analysis of aortas harvested from surviving mice at the end of the study 
demonstrated a median maximum and interquartile range [IQR] for SRA diameter significantly 
larger  in VDD mice compared to VDS  control mice (2.36 [2.08-3.10] mm vs 1.83 [1.28-2.53] 
mm, respectively; P=0.039; Figure 4.4.A). Gross morphology of the SRA (aneurysm types) 
was classified and compared between the dietary groups (Figure 4.4.B.). Four types of 
aneurysms were identified in each of the dietary groups. Two type I aortas were identified in 
the VDD group compared to five in the VDS group. Type II aneurysms were identified in five 
versus two aortas from the VDS and VDD group, respectively. Four of the more severe type 
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III aneurysms were identified in the VDD group compared to only two in the VDS group. 
Finally, two aortas from the VDD group were classified as exhibiting the most severe type IV 




Both groups of mice received their respective diets for 8 weeks, followed by AAA induction 
by AngII-infusion (1µg/kg/min) for a period of 4 weeks during which time the diets were 
continued. A. SRA expansion indicating aneurysmal development was assessed by ultrasound 
in both groups. Mice on the VDD diet developed larger aneurysms compared to those on the 
VDS diet (compared with repeated measures ANOVA using GraphPad Prism software). B. In 
mice allocated VDD diet (n=25), a total of 12 mice (48%) mice had aortic rupture. In mice 
receiving VDS diet (n=21), four mice (19%) died of aortic rupture. By Kaplan Meier analysis 
and log rank test, the incidence of aortic rupture was greater in mice allocated VDD diet than 






























Figure 4.2 Effect of vitamin D dietary supplementation on AAA development and rupture 
in angiotensin-II infused apolipoprotein E-null mice 
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4.3.2. Dietary restriction of vitamin D resulted in depletion of 25(OH)D and reduced 
SOST in angiotensin-II infused Apolipoprotein E-null  mice 
 
This experiment aimed to confirm whether dietary restriction of vitamin D affected the 
pathways involved in vitamin D metabolism and Wnt/β-catenin signalling within the AngII 
infused ApoE-/- mice. After completion  the study, comprising 8 weeks of dietary intervention 
and 4 weeks of AngII infusion (i.e. total duration of 12 weeks), median [IQR] plasma 
concentrations of 25(OH)D in mice receiving VDS diet was 26.90 [24.41-31.1] nmol/L, 
compared to a non-detectable 25(OH)D concentration in VDD diet-fed mice (P<0.001; Figure 
4.5A). At the same time point, plasma SOST was significantly lower in mice fed the VDD diet 
compared to baseline (P=0.008) and to mice receiving VDS diet (P=0.003; Figure 4.5B). 
Importantly, an inverse correlation was demonstrated between plasma SOST levels and AAA 
diameter as measured by ultrasound (r=-0.789; P<0.001; Figure 4.5C). SOST protein levels 
within the SRA of VDD mice were significantly reduced compared with the VDS group 
(P=0.028 Figure 4.5D). Conversely, p-GSK-3α/β protein was higher within the SRA of VDD 
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AngII-infused ApoE-/- + VDS Diet (n=17) 
 
 













Shown are gross morphology of aortas harvested from ApoE-/- mice that were supplemented 
with vitamin D sufficient diet (VDS) and vitamin D deficient diet (VDD) for 8 weeks, 
followed by 28 days of AngII infusion. Only aortas eased from surviving mice during 
terminal dissection are shown. 
Figure 3: Effect of dietary restriction of vitamin D on aortic dilatation in angiotensin-II 
infused apolipoprotein E-null mice 
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Types of aneurysms were scored and classified according to Daugherty, et al. (2001) 
(Daugherty et al., 2001) classification. Accordingly, type 0 were defined as aortas with no 
dilation in any given segment. Type I aneurysms were defined as dilated lumen in the supra‐
renal region of the aorta with no apparent thrombus. Type II aneurysms were defined as 
remodelled tissue in the supra‐renal region that contained evident thrombus. Type III was 
defined as a pronounced bulbous form of type II that contains thrombus. Type IV aneurysm 
were classified as multiple aneurysms containing thrombus, some overlapping, in the 
suprarenal area of the aorta or other areas of the aortas. Whole aortas tissue were categorized 
independently by two blinded observers with a 100% concordance in the designation between 
the two observers. Only surviving mice aortas are shown: VDS (grey boxes); VDD (open 
boxes) 
 
Furthermore, relative gene expression analysis performed on SRA segments recovered from 
surviving mice showed that dietary restriction of vitamin D modulated expression of genes 
implicated in vitamin D metabolism and Wnt/β-catenin signalling. Mice receiving VDD diet 
had significantly higher expression of Cyp27b1 (P=0.009) and Ocn (P=0.029) compared with 
the VDS controls. However, there was no significant difference in the expression of Vdr and 
Opg (Table 4.1). Mice receiving the VDD diet had significantly lower expression of Sost 
(P=0.029) while expression of Ctnnb1 was significantly higher (P=0.040). However, there was 





























































Figure 4.4: Morphometric analysis of aortas harvested during terminal experiment and effect 
of Vitamin D diet supplementation on the incidence of specific forms of aneurysms  
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4.3.3. Dietary restriction of vitamin D promoted atherosclerosis formation within the 
aortic arch and high blood pressure 
 
Overall, the SBP and DBP were significantly higher in mice fed the VDD diet compared with 
those marinated on the VDS diet (P<0.001; Figure 4.6A). Similarly, DBP was higher in the 
VDD group compared with the VDS group at these time points (P<0.001; Figure 4.6B). In 
order to assess whether dietary deficiency of vitamin D had effects on aortic arch plaque 
formation, Sudan IV staining was performed. Overall, the median (inter-quartile range) Sudan 
IV stained area was significantly greater in the VDD group compared with the VDS group 
(P<0.001; Figure 4.6C&D). 
4.3.4. Dietary restriction of vitamin D promoted inflammation and aortic wall matrix 
remodelling. 
 
Inflammation and aortic matrix degradation, namely depletion of collagen and elastin fibres, 
are common features of aneurysmal tissue (Isenburg, Simionescu, Starcher, & Vyavahare, 
2007). Effects of dietary restriction of vitamin D on expression of pro-inflammatory genes were 
investigated within the SRA of mice. Mice fed the VDD diet showed significant upregulation 
of Opn (P =0.040), Mcp-1 (P=0.029) and Agtr1 (P=0.004) (Table 4.1). However, there was no 
difference in the expression of Opg between the two groups. Assessment of genes implicated 
in matrix remodelling showed that there was significant upregulation of MMP-2 (P=0.021) and 
MMP-9 (P<0.001) (Table 4.1). 
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Mice were fed either the VDS or VDD diet for 8 weeks, followed by AngII infusion for 4 
weeks during which time mice were maintained on their respective diets. A. Median [IQR] 
Figure 4.5: Effect of dietary restriction of vitamin D on circulating levels of 25(OH)D and 
SOST in angiotensin-II infused apolipoprotein E-null mice 
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plasma concentrations of 25(OH)D in mice receiving the VDD diet were significantly lower 
compared to mice that were fed the VDS diet. B. Plasma SOST concentrations were 
significantly lower in VDD mice (white) compared to VDS mice (grey) at  study end (P=0.003). 
C. Inverse correlation between plasma SOST and AAA diameter measured by ultrasound at 
the end of the experiment (r=-0.789; P<0.001). D. Reduced SOST protein levels in the VDD 
group compared with the VDS group (P=0.028). E. Higher p-GSK-3α/β protein within the 
SRA of mice receiving the VDD diet compared to the VDS diet (P<0.001). Data expressed as 
median and interquartile range with maximum and minimum data points (whiskers) for 
concentration (pg/ml). P-value calculated for difference between groups by Mann-Whitney U 
test and within groups by Wilcoxon paired test. Abbreviations: 25(OH)D: 25-hydroxyvitamin 
D; VDD: vitamin D deficient; VDS: vitamin D sufficient; SOST: sclerostin; wks: weeks; SRA: 
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A. Systolic blood pressure (SBP) was higher in the VDD group compared to the VDs group. 
B. Similarly, diastolic blood pressure (DBP) was higher within the VDD group compared with 
the VDS group (compared using repeated measures ANOVA). C. Atherosclerotic plaque 
formation deposits (Red deposits indicate Sudan IV positive staining) was higher in the VDD 





Figure 4.5: Dietary restriction of vitamin D promoted high blood pressure and aortic arch 
atherosclerosis 
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Table 5: Effects of dietary restriction of vitamin D on suprarenal aortic gene expression 
in angiotensin-II apolipoprotein E-null mice 
Gene VDS (n=8) VDD (n=7) Expression P 
Sost 2.25 [1.27-4.11] 1.22 [0.99-1.35]  0.029 
Opg 2.49 [0.82-3.73] 2.01 [0.74-4.44]  0.999 
Opn 8.35 [6.08-19-36] 29.51 [9.05-59.09]  0.040 
Mmp-9 1.45 [0.028-3.76] 13.95 [9.07-21.98]  0.001 
Mmp-2 0.62 [0.09-1.82] 6.54 [1.61-9.38]  0.021 
Vdr 0.71 [0.29-1.32] 0.30 [0.12-0.58]  0.152 
Cyp27b1 0.81 [0.46-1.87] 2.40 [1.72-3.51]  0.009 
Dkk-1 0.91 [0.44-2.07] 0.46 [0.36-0.97]  0.281 
Ocn 0.93 [0.53-1.84] 2.35 [1.39-3.43]  0.029 
Ctnnb1 1.60 [0.60-4.37] 4.35 [3.11-8.84]  0.040 
Agtr1 0.71[0.35-0.88] 1.13 [0.92-1.84]  0.004 
Mcp-1 0.30[0.23-0.45] 0.52 [0.43-0.75]  0.029 
Shown are relative gene expression as median (inter-quartile range) relative to 
glyceraldehyde 3-phosphate dehydrogenase (Gapdh) expression. Samples in this study were 
randomly selected using random generated numbers. Inter-group comparison was analysed 
using Mann-Whitney U test. Abbreviations: CCF: cholecalciferol; Sost: sclerostin; Opg: 
osteoprotegerin; Opn: osteopontin; Vdr: vitamin D receptor; Cyp27b1: gene encoding for 
25-hydroxvitamin D3 hydrolase; Dkk: Wnt inhibitor Dickkopf-1; Ocn: osteocalcin (bone-
Gla matrix); Ctnnb1: gene encoding for β-catenin; Mmp-2/9: matrix metalloproteinase 2/9; 
Agtr1: angiotensin-II receptor 1; Mcp-1: monocyte chemoattractant protein-1. 
 
 




The main findings from this study were that dietary restriction of vitamin D promoted 
development of larger AAAs which were prone to rupture. Within AngII-induced mice, dietary 
restriction of vitamin D resulted in reduced circulating SOST, reduced SRA wall SOST protein 
and SRA Sost gene expression. Mechanistically, effects of vitamin D on SOST and downstream 
effects on Wnt/β-catenin signalling appear to be the link between vitamin D and AAA. Findings 
from this study built on the data presented in Chapter 3 to demonstrate that low SOST resulting 
from deficiency of vitamin D, in turn, promoted AAA development. These findings are 
supportive of a recent study whereby it was demonstrated that upregulation of SOST through 
transgenic breeding or intraperitoneal injection of human recombinant SOST (hrSOST) was 
protective against development of aortic aneurysms and atherosclerosis (Krishna et al., 2017). 
The present study provides the first evidence that effects of vitamin D on bone mineralisation 
proteins, particularly SOST, play an important role in AAA development. Indeed, the role of 
vitamin D in skeletal health is well-documented and clinical evidence attests that vitamin D 
limits fracture risks in patients with osteoporosis (Holick et al., 2011). Cellular experimental 
studies have already shown that vitamin D upregulate SOST secretion and SOST gene 
expression in osteoblasts (Wijenayaka et al., 2016; Wijenayaka et al., 2015). Depletion of 
plasma 25(OH)D resulted in reduced circulating SOST and aortic SOST expression which is 
in agreement with the preceding chapter. Given the role of 1α,25(OH)2D3 in upregulation of 
SOST and maintenance of contractile phenotypes within VSMCs, findings from this study 
indicate that the VDD diet had adverse effects on the aortic wall homeostasis (Krishna et al., 
2017). Downstream effects of reduced aortic Sost were demonstrated by upregulation of 
CTNNB1 in mice SRA wall. However, the difference in aortic expression of another Wnt 
competitive inhibitor (Jho et al., 2002; Larriba et al., 2013; Nusse & Clevers, 2017; 
Sankaralingam et al., 2014), Dkk-1, was not significant. These findings therefore underscore 
the importance of SOST and its effects on the Wnt/βcatenin signalling during AAA 
development as previously reported (Krishna et al., 2017). 
Lower levels of 25(OH)D have been linked to the presence of CVD, including occlusive arterial 
disease such as PAD and CAD (Nsengiyumva et al., 2015; Pilz et al., 2016). However, the 
relevance of vitamin D in AAA development remains relatively new. Previous epidemiologic 
studies have reported that lower levels of 25(OH)D are associated with presence of aortic 
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aneurysms, independent of traditional cardiovascular risk factors (Demir et al., 2012; Van De 
Luijtgaarden et al., 2012; Wong et al., 2013). Wong et al (2013) showed that the increase in 
AAA diameter was inversely associated with 25(OH)D levels in a dose-dependent manner. 
Dietary restriction of vitamin D, in this study, resulted in markedly lower circulating 25(OH)D 
(non-traceable) VDD mice and promoted larger AAAs, following AngII infusion. The 
implication of these findings suggests that patients who are vitamin D deficient may be prone 
to developing larger, rupture-prone AAAs. Furthermore, these findings are consistent with 
previous reports demonstrating that AAAs that are expanding at a faster rate are more likely to 
rupture (Aggarwal et al., 2011). However, from the current data it is not immediately clear how 
expansion rate of AAA in mice was dose-dependently related to circulating levels of 25(OH)D 
at all-time points. Nonetheless, a clear inverse correlation between circulating levels of SOST 
and AAA diameter was demonstrated. Moreover, two recent studies (Martorell et al., 2016; 
Nieuwland et al., 2016) respectively reported that administration of calcitriol or paricalcitol, 
which are vitamin D analogues, had potential to attenuate a number of pathways that are 
implicated in AAA development. Administration of calcitriol was reported to lower incidences 
of aortic rupture within the AngII-infused mouse model by limiting macrophage infiltration 
and downregulation of Mmp-2 and Mmp-9 expression within the SRA wall. In a small cohort 
of patients comprising patients who were given paricalcitol (n=11) as intervention and 
untreated controls (n=11), it was concluded that daily administration of 1μg for 2-4 weeks 
reduced of inflammatory markers which was characterised by aortic biopsies (Nieuwland et 
al., 2016). However, it remains inconclusively understood whether long-term intervention 
could have attenuated of AAA growth in these patients. Nevertheless, vitamin D deficiency is 
clinically managed through cholecalciferol supplementation in order to increase circulating 
25(OH)D  (Kennel et al., 2010). Findings from this study therefore suggest that lower levels of 
25(OH)D could explain the development of larger AAA post-AngII infusion in mice 
maintained on the VDD diet. 
The role of vitamin D in skeletal health is well-documented. Vitamin D deficiency has been 
associated with osteoporosis and increased risk of fractures in older adults and one potential 
mechanism for this association could be the effect of vitamin D on the expression of bone 
proteins (Holick et al., 2011). Incubation of osteoblasts with 1α,25(OH)2D3 has been reported 
to induce SOST expression (Wijenayaka et al., 2016). Ergocalciferol administration has 
previously been reported to increase circulating SOST concentrations in patients with 
osteoporosis (Sankaralingam et al., 2014). In the current study, a VDD diet resulted in 
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reduction in plasma SOST concentration, aortic SOST protein levels and aortic Sost gene 
expression. Aortic concentrations of p-GSK-3α/β, which is indicative of Wnt/β-catenin 
signalling activity, were also upregulated mice receiving the VDD diet. Phosphorylation of the 
GSK-3α/β leads to stabilization of β-catenin complex and consequent translocation to the 
nucleus (Nusse & Clevers, 2017). The Wnt/β-catenin signalling has been implicated in 
stimulating the activation of an inflammatory cascade in a number of autoimmune diseases 
(Beurel, Grieco, & Jope, 2015). In line with these findings, a VDD diet led to increased aortic 
expression of the Wnt pathway-signalling gene Ctnnb1. These responses were plausibly 
attributable to downregulation of SOST expression within the aortic wall. Indeed, vitamin D 
associated effects on Wnt/β-catenin signalling, including downregulation of β-catenin have 
been previously described, most notably in cancer cells (Larriba et al., 2007; Palmer et al., 
2001; Shah et al., 2006). It was recently reported that SOST upregulation in a mouse model 
reduced phosphorylation of GSK-3β and consequent β-catenin accumulation in SRA tissue 
(Krishna et al., 2017). Implicitly, these findings suggest that supplementation of higher doses 
of vitamin D may be an interesting therapy for AAA patients. It is therefore conceivably 
possible that higher doses of vitamin D will contribute to upregulation of SOST and 
Wnt/βcatenin signalling; and thus, inhibition of AAA progression. 
 
Chronic inflammation is a driving factor for AAA development and progression (Golledge et 
al., 2007; Krishna et al., 2010; Krishna et al., 2016). In this study, pro-inflammatory genes, 
including OPN, AGTR1, MCP-1 were upregulated within the group of mice maintained of the 
VDD diet. Expression of these genes has been previously implicated in the pathogenesis of 
AAA (Bruemmer et al., 2003; Filis et al., 2014; Golledge et al., 2007; Li et al., 2016). In 
particular, plasma concentrations of OPN have been reported to be increased in patients with 
AAA (Golledge et al., 2007). It was also demonstrated that increase in circulating OPN was 
positively correlated with AAA growth (Golledge et al., 2007). Within the AngII-infused 
mouse model, deficiency of OPN was reported to protect against AAA formation (Bruemmer 
et al., 2003). In turn, the current study showed that VDD diet resulted in upregulation of SRA 
expression of Opn. The effect of vitamin D deficiency on the expression of these pro-
inflammatory genes may, at least in part, explain greater expansion of AAA in mice that were 
maintained on the VDD diet. 
Degradation of the ECM has been strongly implicated in AAA pathogenesis (Galis & Khatri, 
2002; Krishna et al., 2017; Krishna et al., 2015; Moran et al., 2014). In particular, 
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overexpression of MMP-2 and MMP-9 has been consistently associated with AAA formation 
and progression (Krishna et al., 2017; Krishna et al., 2015; Moran et al., 2005). In this study, 
dietary deficiency of vitamin D resulted in higher aortic expression of Mmp-2 and Mmp-9 
within the SRA compared to controls. These findings are consistent with those from a recent 
publication in which it was shown that parenteral administration of 1α,25(OH)2D3 (1 μg/kg) 
downregulated aortic Mmp-2 and Mmp-9 and upregulated endogenous tissue inhibitor of Mmp-
1 expression in AngII-infused ApoE-/- mice (Martorell et al., 2016). Furthermore, VDR 
expression has also been reported to downregulate MMP-2 and MMP-9 activity and expression 
in cultured human VSMCs (Aoshima et al., 2012; Britt et al., 2015), although no significant 
upregulation of VDR was observed in this study.  
Physiologically, extrarenal expression of Cyp27b1 is indicative of the ability for the tissue to 
locally metabolise bioavailable 25(OH)D (Christakos et al., 2016; Dusso et al., 2005). 
1α,25(OH)2D3 targets its nuclear receptor Vdr expression resulting in downregulation or 
upregulation of targeted genes (Christakos et al., 2016). Almost all genomic effects of 
1α,25(OH)2D are mediated through activation of VDR to elicit gene expression within the 
target cell (Christakos et al., 2016). This study showed that gene expression of Cyp27b1 was 
downregulated within the SRA tissue in response to the VDD diet. However, VDR expression 
was not significantly different between the groups. It is plausible that 25(OH)D levels in the 
VDS group were insufficient to elicit VDR activity within the SRA wall. Nonetheless, findings 
suggest that bioavailability and conversion of 25(OH)D to 1α,25(OH)2D was locally reduced 
in these mice. Urbonavicius et al (2010) previously reported that VDR protein expression was 
downregulated in tissue samples from AAA patients and was correlated with AAA size.  
Hypertension has been reported to be a risk factor for AAA diagnosis and rupture (Kent et al., 
2010; Tang et al., 2016). SBP has previously been reported to rise in mice receiving AngII-
infusion although it is not thought to be responsible for the induction of AAA in this model 
(Ayabe et al., 2006; Cassis et al., 2009; Kawada, Imai, Karber, Welch, & Wilcox, 2002; 
Krishna et al., 2015). Consistent with previous findings, a VDD diet promoted higher SBP in 
ApoE-/- mice. Vitamin D has been reported to suppress renin expression (Ajabshir, Asif, & 
Nayer, 2014) and administration of CCF (25000 IU/week) has been reported to attenuate 
hypertension in patients (Carrara et al., 2014). However, given that AngII is not thought to 
induce AAA via increases in SBP, it is unlikely that the link between vitamin D deficiency and 
SBP is responsible for the findings in this study. Similarly, dietary restriction of vitamin D 
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resulted increased atherosclerotic plaque build-up within the aortic arch of mice. These findings 
are consistent with a recently reported studies, which demonstrated that ApoE-/- mice with low 
SOST were prone to atherosclerosis development (Costa, Bilezikian, & Lewiecki, 2014; 
Krishna et al., 2017). Additionally, there is a great body of literature to support the role of low 
vitamin D deficiency in atherogenesis (Bennett & Lavie, 2017). 
 
Strengths of this study include the use the AngII-infused, ApoE-/-  mouse model, the use of 
dietary intervention and measurement of 25(OH)D. The AngII-infused, ApoE-/-  mouse model 
has been shown to have several similarities with human AAA pathology, including medial 
degeneration;, inflammation; thrombus and atherosclerosis (Daugherty & Cassis, 2004; 
Kawada et al., 2002; Trollope et al., 2011). While vitamin D toxicity is extremely rare (Holick, 
2007; Marcinowska-Suchowierska, Kupisz-Urbańska, Łukaszkiewicz, Płudowski, & Jones, 
2018), the use of dietary intervention with a well-balanced formulation was a very important 
step to gauge actual levels of 25(OH)D in these mice. Furthermore, circulating 25(OH)D were 
measured using a highly sensitive mass spectrometry assay in a validated laboratory (Clarke et 
al., 2013; Holick, 2009; Kleerekoper et al., 2011). One major limitation of this study, plausibly 
inherent to most animal studies, is the difficult to extrapolate these findings to human studies. 
While depletion of 25(OH)D within this mouse model was an important step to investigate a 
causal role of vitamin in AAA development, at least experimentally, total depletion of 
25(OH)D is a less likely presentation in clinical settings. The reason for total depletion of 
25(OH)D in these mice can be explained by the fact that the only source of vitamin D for these 
mice was from the diet chow since mice were otherwise totally restricted from sun exposure. 
Indeed, severe vitamin D deficiency is a common presentation in institutionalised elderly who 
have limited sun exposure (Fahrleitner-Pammer et al., 2005; Fahrleitner et al., 2002). However, 
epidemiologic data do not suggest that 25(OH)D levels in AAA patients can be categorised a 
deficient (Demir et al., 2012; Van De Luijtgaarden et al., 2012; Wong et al., 2013). The levels 
in AAA patients are at best deemed suboptimal or insufficient in accordance with current 
vitamin D status categorisation (Holick et al., 2011). Therefore, this raises a question as to 
whether increasing 25(OH)D to optimal levels (i.e. ≥ 75 nM) could attenuate AAA progression. 
In conclusion, the findings from this study demonstrated that dietary deficiency of vitamin D 
promoted formation of larger AAA that were prone to rupture. Mice receiving the VDD diet 
had depleted levels of 25(OH)D which was accompanied by significantly lower SOST and 
activated Wnt/β-catenin signalling within the SRA. These findings are in agreement with the 
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previous study demonstrating that SOST deficiency promoted formation of AAA and 
atherosclerosis in a similar experimental mouse model. Furthermore, this study showed that 
VDD diet resulted in increased inflammatory markers and atherosclerosis within the mice. It 
remains unknown however, whether increasing circulating 25(OH)D to optimal levels could 
limit progression of pre-established AAA. Thus, in light of these findings the following chapter 
will examine whether vitamin D supplementation in the form of CCF can limit progression of 





















CHAPTER 4 HIGHLIGHTS 
What is Known? 
 
 A number of osteogenic proteins have been previously implicated in AAA development. 
 Recently, it was demonstrated that reduced SOST was associated with AAA development 
within an experimental mouse model. 
 The preceding chapter showed that 1α,25(OH)2D3 induced SOST expression in human 
aortic VSMCs while dietary restriction of vitamin D reduced SOST in ApoE-/- mice. 
 Dietary restriction of vitamin D was associated with increased expression of pro-
inflammatory genes and matrix remodelling genes. 
 
What New Information Does This Chapter Add? 
 
 Dietary restriction of vitamin D resulted in formation of larger AAAs that were prone to 
rupture mouse model.   
 Dietary restriction of vitamin D resulted in high blood pressure and atherosclerosis 
development in a mouse model of AAA. 
 Changes in AAA severity appeared to be mediated via changes in genes involved in ECM 
remodelling, particularly SOST. 






CHAPTER 5:  
EFFECTS OF CHOLECALCIFEROL 
SUPPLEMENTATION ON PROGRESSION 
OF PRE-ESTABLISHED ABDOMINAL 
AORTIC ANEURYSM IN THE 
ANGIOTENSIN-II INFUSED 
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5.1. INTRODUCTION 
AAA is characterized by progressive degradation and weakening of the aortic wall integrity. 
The lack of pharmacological agents to limit or slow AAA progression remains a challenging 
factor for medical management of patients with AAA. Finding pharmacological agents with 
potential to halt or slow AAA expansion is therefore of urgent necessity. 
 
Preceding chapters (Chapter 3 & 4) demonstrated that incubation of 1α,25(OH)2D3 with 
VCMCs promoted SOST expression while restriction of CCF intake resulted in decreased 
circulating SOST and SRA Sost expression. Vitamin D deficiency is clinically managed by 
CCF supplementation with an aim to raise circulating 25(OH)D levels (Bischoff-Ferrari et al., 
2006; Holick et al., 2011; Kennel et al., 2010; Kleerekoper et al., 2011). While epidemiological 
studies have shown that patients with aortic aneurysm have lower circulating 25(OH)D; these 
studies did not conclusively indicate that AAA patients are within the category currently 
defined as vitamin D deficiency (Demir et al., 2012; Van De Luijtgaarden et al., 2012; Wong 
et al., 2013). In particular, Wong et al (2013) reported that patients within the lowest quartile 
of 25(OH)D levels were five times more likely to have AAAs >40 mm compared with those 
with the highest range of 25(OH)D levels. However, a question that remains unaddressed was 
whether increasing 25(OH)D levels could slow or limit expansion of AAA. 
 
Currently, no pre-clinical studies have investigated the effects of CCF supplementation in 
animal models of AAA. Low circulating concentrations of 25(OH)D have been associated with 
presence of human aortic aneurysm in a number of cross-sectional studies (Demir et al., 2012; 
Van De Luijtgaarden et al., 2012; Wong et al., 2013). Contrary to this evidence, it has been 
reported that the prevalence of AAA is highest in Australasia where levels of ultraviolet 
exposure (and thus likely vitamin D) are very high (Li et al., 2013; Sampson et al., 2014). 
Excess vitamin D has also been reported to have potential pathological effects such as 
inhibiting production of elastin (an important aortic matrix protein) by VSMCs (Hinek et al., 
1991; Norman et al., 1995; Norman et al., 2002). AAAs are detected when they are still small 
and medical management is needed to slow the growth of an established AAA rather than 
prevent its formation as investigated in the previous study. 
 
While AAA was more common in men with lower circulating 25(OH)D, these levels were not 
in the deficient range as currently defined (Holick et al., 2011). This study sorted to assess the 
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effect of up-titration of 25(OH)D levels in Ang-II infused ApoE-/- mice maintained on normal 
laboratory chow diet in order to simulate clinical presentations. The study hypothesized that 
increasing the concentration of circulating 25(OH)D levels to >75 nM by CCF supplementation 
would limit AAA growth. Therefore, this study aimed to investigate whether increasing 
circulating 25(OH)D levels using CCF could attenuate AAA growth in ApoE-/- AngII-infused 
mice with pre-established AAA. 
 
Specifically, the primary hypothesis of this study were that: 
1. Up-titration of 25(OH)D by CCF supplementation attenuates growth and rupture of pre-
established AAA in Ang-II infused ApoE-/- mice. 
 
Secondary hypotheses 
1. Using a previously defined equation for repletion of circulating 25(OH)D, a loading dose 
of CCF can be used to achieve high (above sufficient) levels of 25(OH)D (i.e. ≥ 75 nM). 
2. CCF supplementation and consequent up-titration of circulating plasma 25(OH)D increase 
SOST in Ang-II infused, ApoE-/- mice.  
 
This study had the following specific aims: 
1. To examine if CCF supplementation attenuates growth and rupture of pre-established AAA 
in Ang-II infused ApoE-/- mice. 
2. To assess whether a loading dose of CCF can be used to increase circulating 25(OH)D 
levels (i.e. ≥ 75 nM) in Ang-II infused ApoE-/- mice. 
3. To examine whether CCF supplementation and consequent up-titration of circulating 
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5.2. MATERIALS AND METHODS 
5.2.1. Sample size determination  
Sample size calculation was performed using GPower 3.1.9.2 software version for t-test in this 
study. Sample size computation was based on a recent study by Seto et al (Seto et al., 2014). 
In this study, ApoE-/- mice (n=18) were randomised to intervention (Aliskiren) or placebo after 
establishment of AAA for 28 days. Subsequent treatment with a higher dose of at Aliskiren (50 
mg/kg/day) resulted in significant decrease in aortic diameter, measured by repeated ultrasound 
for a further 28 days, from 1.07±0.12 mm to 1.06±0.9 mm (mean±SD). Assuming a similar 
trend (80% power; α: 0.05), an estimate sample size of 17 mice were required per group for 
this study. Therefore, a total 34 ApoE-/- mice was required. Sample size estimation accounted 
for a potential drop-outs due to AAA rupture following AngII infusion prior to randomisation. 
All animal experiments described in this chapter received approval (AEC#: A2354; Appendix 
1B) from the JCU/AEC. 
 
5.2.2. Cholecalciferol Loading Dose Estimation. 
The dose of CCF that can rapidly and safely correct 25(OH)D levels in mice remains undefined 
(van Groningen et al., 2010). Preceding chapters (Chapter 3 & 4) showed that ApoE-/- mice that 
were maintained on a normal laboratory chow diet (i.e. 3000 IU/kg of feed) had insufficient 
plasma levels of 25(OH)D. The present study attempted to achieve up-titration of plasma 
25(OH)D levels that are comparable to what is currently defined as optimal levels in human 
(i.e.25(OH)D levels ≥75nM). Therefore, a formula suggested by Groningen et al (van 
Groningen et al., 2010) for calculating a loading dose of CCF intended to achieve plasma 
25(OH)D levels ≥ 75 nM was used in this study. Briefly, the loading dose of CCF (IU) = 40 × 
(75−baseline 25(OH)D) × body weight). For practicality, baseline plasma 25(OH)D were 
assumed to be approximately the median plasma 25(OH)D levels observed in mice in the 
previous experiments (Chapter 4). It was proposed that the average AAA patient weighs 
approximately 80 kg. Therefore, the human equivalent loading dose (IU) was computed as 40 
x (75-35.0) x 80 which equals to 128,000 IU (i.e. 3,200 μg/kg) of CCF (van Groningen et al., 
2010). The mouse equivalent dose of human equivalent dose was calculated as follows 12.3 x 
3,200= 39,360 μg/kg (15,744,000 IU), as proposed by Rockville et al (2005). In order to rapidly 
and safely achieve optimal plasma 25(OH)D levels (i.e. 75nmol/L), the loading dose was given 
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over five weeks (i.e. 7,872 μg/kg/week). For instance, assuming that an experimental mouse 
weighed 30g, a CCF dose of 236.2 μg/week was estimated per mouse (i.e. 9446 IU/week). It 
was assumed that plasma 25(OH)D levels ≥75 nM would be achieved in the circulation within 
5 weeks of supplementation (van Groningen et al., 2010). The actual dose was determined 
according to individual mouse’s weight prior to oral gavage. 
 
5.2.3. Experimental Design 
A detailed flow diagram of the experimental design is shown in Figure 6.1. In this study, 12-
13 weeks old ApoE-/- mice (n=32) were maintained on the normal laboratory chow (3000 
IU/kg/feed). AAA was induced by Ang-II infusion (1μg/kg/min) in all mice. SRA diameter 
was assessed using ultrasound at baseline (i.e. day 14-post AngII infusion). On day 14, 
surviving mice were stratified into two groups (intervention and control) with equivalent SRA 
diameter size (Figure 5.3). The intervention group  was subjected to oral gavage administration 
of the loading dose of CCF (OsteVit-D®). The control group was supplemented with 0.1% 
carboxymethylcellulose (Sigma) as a vehicle by oral gavage. Oral gavage was performed 
weekly at the same time of the day and under same conditions (i.e. day 14, day 21, day 28, day 
35, day 42 and day 56). Mice were fasted for 12 hours by removing the food tray. Mice were 
then monitored for 2 hours after oral gavage for any abdominal distention and docility. It was 
postulated that plasma 25(OH)D levels would be increased to ≥75 nM in CCF supplemented 
mice while the levels in control mice would remain unchanged.  
In this experiment, AAA was induced by AngII-infusion for the first two weeks. After the two 
weeks, mice were administered with either a weekly dose of 7,872 μg/kg/week of CCF or 0.1% 
CMC. The duration of the osmotic pumps at the proposed delivery rate is usually 28 days 
(Krishna et al., 2017; Krishna et al., 2015). Therefore, after 28 days, a second pump with a 
lower flow rate of AngII (0.5μg/kg/min) was inserted to maintain AAA growth. Assessment of 
the SRA diameter was performed every 14 days before the oral gavage. 
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Infusion of full dose of AngII (1µg/kg/min) for 28 days. After 14 days of AngII infusion 
surviving mice were stratified by median SRA diameter, assessed by ultrasonography, into two 
groups with equivalent SRA diameter. The intervention group was supplemented with 9446 
IU/Kg of cholecalciferol (CCF) per week. The control group was given 0.1% of 
carboxymethylcellulose (CMC) as a vehicle. At the end of 28 days, an additional low dose of 
AngII (0.5 µg/kg/min) was given to mice by inserting a second osmotic mini-pump. AAA 
progression was then followed up with fortnightly ultrasound for 42 days (in total 56 days of 
intervention). All mice were maintained on the normal laboratory chow during the experiment. 




Terminal Dissection and sample 
collection
AAA induction
Osmotic mini-pump insertion to deliver AngII (1μg/kg/min) (n=32)
CCF group (n=12)
Cholecalciferol 9446 IU/Kg /week via 
oral gavage
Control (n=13)
0.01 carboxymethylcellulose in H2O via 
oral gavage (n=13) 
AAA progression 
Assessment of SRA by US every two weeks; body weight and BP 2nd osmotic pump of 
AngII (0.5μg/kg/min)
Control
0.01 carboxymethylcellulose in 
H2O/week via oral gavage 
CCF
Cholecalciferol; 9446 IU/Kg /wk via oral 
gavage 









Figure 5.6: Experimental Flow Diagram 
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ApoE-/- mice (n=32) were infused with AngII (1µg/kg/min) lasting for 28 days. After 14 days, 
mice were stratified into two groups with equivalent median SRA diameter. One group was 
subjected to weekly oral gavage of cholecalciferol (CCF; 9446 IU/Kg) while the other groups 
was subjected to 0.1% of carboxymethyl cellulose (CMC) at the same time points. After 28 
days, AngII infusion was continued for an additional 28 days at a lower rate of (0.5 
µg/kg/min). Total experimental duration of 56 days or 8 weeks (including 6 weeks of oral 
gavage). 
 
5.2.4. Ultrasound monitoring 
 
In this mouse model, SRA expansion and aortic ruptures are usually established within 14 days 
of AngII infusion (Manning et al., 2002; Rateri et al., 2011).  SRA diameter in vivo (primary 
outcome) was measured by ultrasound as described in Chapter 2 (Section 2.5.1), first at 
baseline (day 0, before AngII) and then at 14-days intervals following commencement of AngII 
infusion.  
 
5.2.5. Morphometric analysis  
 
Morphometric analysis of aortas harvested from surviving mice at the completion of the study 
period was performed as described in Chapter 2 (Section 2.5.2.). Characterisation of gross 
morphology of aneurysm types was performed as reported by Daugherty, et al. (2001) 
(Daugherty et al., 2001). A 100% concordance was achieved within the inter-assessor rating 
for classification of aneurysms as described in Chapter 2 (Section 2.5.2). 
 
 






Figure 5.2: Study Deign 
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5.2.6. Plasma analyses 
 
Blood collection was performed by tail bleeding in Chapter 2 (Section 2.4.1) at baseline, before 
oral gavage, at day 14, at day 42 and at day 56. At the end-point, during terminal dissection, 
blood was collected by cardiac puncture. The blood was collected into heparin-coated tubes 
(BD Microtainer) and plasma samples prepared for 25(OH)D and SOST assay as described in 
Chapter 2 (Sections 2.4.1 and 2.7). 
 
5.2.7. Suprarenal aortic tissue protein assay by ELISA 
 
SRA segments were cleared of OCT and homogenized in the presence of the radio-
immunoprecipitation assay buffer (1 x RIPA buffer; 50 mM Tris-HCl pH 7.4, 150 mM NaCl; 
2 mM EDTA, 1% TritonX-100, 0.1% SDS, and 0.1% sodium deoxycholate) supplemented 
with protease inhibitors and phosphatase inhibitor. Mouse SRA SOST protein expression was 
assayed using a Quantikine® ELISA (R&D systems®) as described in Chapter 3 (Sections 
2.10.1). Mouse SRA phospho-GSK-3α/β (S21/S9) levels were determined using DuoSet® IC 
ELISA in accordance (R&D systems®) as described in Chapter 3 (Sections 2.10.4). 
5.2.8. Quantification of atherosclerotic lesion area 
 
Aortic arch samples were prepared for en face Sudan IV staining as described in Chapter 2 
(Section 3.3). The presence and severity of intimal surface atherosclerotic plaque was 
compared between arch samples obtained from mice on CCF (n=11) and control (n=7) by 
digital image analysis as described in Chapter 2 (Section 2.8). 
 
5.2.9. Histology & Immunohistochemistry 
 
Hematoxylin and eosin (H&E), Elastin Van Giessen (EVG) and picrosirius red staining were 
performed as described in Chapter 2 (Sections 2.9.1; 2.9.2; 2.9.3). Staining was performed on 
5 μM serial cryostat sections cut from the SRA of the CCF group (n=11) and control mice 
(n=7). Semi-quantitative assessment of staining area was performed using digital image 
analysis as described in Chapter 2 (Sections 2.9.1; 2.9.2; 2.9.3). 
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5.3. Statistical analysis 
 
The D’Agostino and Pearson test was used to test the normality of the data. Results were 
expressed as median and interquartile range (IQR) for non-normally distributed data and as 
mean ± SEM for normally distributed data. For non-normally distributed data, comparisons 
were made using Mann-Whitney U-test. Normally distributed data were compared using 
ANOVA followed by Bonferroni’s multiple comparisons test. Repeated measures were 
analysed using repeated measures ANOVA. All data analyses were performed using GraphPad 
Prism 8.4.2 software (GraphPad Software, Inc., USA). Differences were considered 
statistically significant at P < 0.05. 
 
5.4. RESULTS 
5.4.1. Cholecalciferol supplementation increased circulating levels of 25(OH)D and 
SOST in angiotensin-II infused apolipoprotein E-null mice. 
 
The dose of CCF to be administered was estimated in order to achieve relatively high 
circulating 25(OH)D concentrations of >75 nmol/L (van Groningen et al., 2010). After the first 
2 weeks, mice were allocated to intervention (CCF administration; 9446 IU/kg/week oral 
gavage; n=12) and control (0.1% carboxymethyl cellulose oral gavage; n=13) groups (Figure 
5.3). Both groups were maintained on a similar diet. The experiment continued for a further 6 
weeks during which time AngII infusion was continued. Baseline median [IQR] plasma 
25(OH)D was similar in both groups (CCF: 17.26 [13.47-21.52 nmol/L] vs control: 19.61 
[16.57-23.15] nmol/L; P=0.242). Within 4 weeks of CCF supplementation, the CCF group had 
already achieved the median [IQR] plasma levels of 25(OH)D 75.77[59.79- 95.13] nmol/L. 
Overall, mice receiving CCF exhibited a time-dependent increase in plasma levels of 25(OH)D 
at concentrations significantly higher than controls (P<0.001; Figure 5.4A). 
Median [IQR] plasma SOST was similar in both groups at baseline (CCF: 182.80 [167.70-
216.30] nmol/L vs control: 182.40 [160.80-212.30] nmol/L; P=0.832]. At the end of the 8-
week experiment, median plasma SOST was significantly higher in mice administered CCF 
compared to baseline (P=0.001) and to control mice (P=0.001; Figure 5.4B). In attempt to 
establish the relationship between circulating SOST and AAA diameter at the end of the study, 
it was found that AAA size was negatively correlated with SOST levels. An inverse correlation 
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was demonstrated between circulating SOST concentrations and maximum SRA diameter 
measured by ultrasound after 56 days (r=-0.653, P=0.003; Figure 5.4C). In contrast, SRA 
concentration of p-GSK-3α/β was lower within the CCF group compared to the control group 
(P=0.003, Figure 5.4D). Finally, SRA protein concentration of SOST was also higher in mice 
receiving CCF compared to controls (P=0.012, Figure 5.4E).  
 
 
After 14 days (two weeks) of AngII infusion, 
SRA diameter was assessed using ultrasound 
and mice were stratified into two groups of 
equivalent SRA diameter (P=0.974). One group 
was then allocated intervention (cholecalciferol; 
CCF) while the other group was maintained of 
carboxymethyl cellulose (control) for the 
following 42 days (6 weeks).   
 
In this study, relative gene expression analysis was performed on SRA segments recovered 
from mice at the end of the experiment. Effects of CCF supplementation on expression of genes 
that are implicated in vitamin D metabolism and Wnt/β-catenin signalling was demonstrated. 
Mice receiving CCF had significantly higher expression of Vdr (P=0.027), Sost (P=0.035) and 
Dkk-1 (P=0.004) and compared with controls. Conversely, mice that were administered with 
CCF had significantly lower SRA expression of Cyp27b1 (P<0.001) and Ctnnb1 (P=0.015). 
However, there was no significant difference in the expression of Opg and Ocn between the 
two groups (Table 5.1). 
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Figure 5.3: Stratification of mice into 
intervention and control groups following 
suprarenal aortic diameter assessment 
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Figure 5.4: Effects of cholecalciferol supplementation on 25(OH)D and SOST in 
angiotensin-II infused apolipoprotein E-null mice. AAA was first induced in mice through 
AngII-infusion for the first 2 weeks before being stratified into groups with equivalent SRA 
diameter. Mice were then supplemented with either the cholecalciferol (9446 IU/kg/week) or 
0.1% carboxymethyl cellulose (Control) by oral gavage for the next 6 weeks. Both groups were 
maintained on a similar diets throughout the experiment. A. Overall, plasma concentrations of 
25(OH)D in mice receiving CCF were significantly higher compared to control mice. B. 
Plasma Epi-25(OH)D3 remained negligible (*) in control mice but the levels rose significant 
higher between week 4 and week 8 in mice supplemented with CCF. C. Plasma SOST 
concentrations were significantly higher in mice supplemented with CCF compared with 
control mice at the end of study. D. There was an inverse correlation between plasma SOST 
and AAA diameter measured by ultrasound at the end of the experiment (r=-0.789). E. Aortic 
SOST protein levels were significantly increased in the CCF mice compared to controls. E. 
Aortic protein levels of p-GSK-3α/β were higher within the SRA of mice receiving CCF 
compared with control. F. Data expressed as median and interquartile range with maximum 
and minimum data points (whiskers). Data were compared between groups with a Mann-
Whitney U test; and within the same group, data were compared with Wilcoxon paired test (B 
& C). Abbreviations: 25(OH)D: 25-hydroxyvitamin D; CCF: cholecalciferol; Epi-25(OH)D3: 
C-3 epimer of 25-hydroxyvitamin D(3); SOST: sclerostin; wks: weeks; SRA: suprarenal aorta;  
p-GSK-3α/β: phosphorylated-glycogen synthase kinase-3α/β. 
 
5.4.2. Cholecalciferol limited growth and rupture of pre-established AAAs in 
angiotensin-II infused in Apolipoprotein-null mice  
AAA was firstly induced in mice (n=32) through infusion of AngII.  After 14 days following 
initial AngII infusion, 7 mice died from aortic rupture, leaving a total of 25 mice. Mice were 
then stratified into two groups with equivalent SRA diameter (Figure 5.3). One group was 
allocated to intervention (CCF administration; 9446 IU/kg/week; n=12) and the control group 
which was allocated to 0.1% CMC (carboxymethyl cellulose; n=13). The SRA dilatation was 
monitored fortnightly by ultrasound and a time-dependent increase in maximum SRA diameter 
in response to AngII was demonstrated by Repeated measures ANOVA. Overall, mice 
supplemented with CCF exhibited significantly smaller increases in SRA diameter compared 
to controls (P<0.001; Figure 5.5A). Furthermore, supplementation with CCF significantly 
limited rupture of pre-established AAA in the AngII-infused ApoE-/- mice (P=0.031; Figure 
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5.5B). Specifically, it was found that 6 out of 13 control mice (46%) exhibited aortic rupture 
compared to only one mouse of 12 mice (8%) administered CCF (Figure 5.5B).  
Morphometric analysis of aortas at completion of the study (excluding ruptures) confirmed 
significantly smaller median [IQR] maximum SRA diameter in mice receiving CCF compared 
to controls (P=0.036; Figure 5.7A). Gross morphology of the SRA (aneurysm types) was 
classified and compared between the dietary groups (Figure 5.7B). 
 
 
One group was allocated to CCF as intervention (9446 IU/kg/week; n=12) and the control 
group which was allocated to 0.1% CMC (carboxymethyl cellulose; n=13). The SRA diameter 
was monitored fortnightly by ultrasound and a time-dependent in maximum SRA diameter in 
response to AngII was assessed by repeated measures ANOVA (the P-value relates to 
interaction between time and treatment). A. Mice supplemented with CCF exhibited 
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Figure 5.5: Effects of cholecalciferol supplementation on AAA progression and rupture. 
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AngII-infused ApoE-/- + cholecalciferol (9446 IU/kg/week) (n=11) 
 
Shown are gross morphology of aortas harvested from ApoE-/- mice subjected to 56 days (8 
weeks) of AngII infusion and supplemented with carboxymethyl cellulose (0.1%) or 
cholecalciferol (9446 IU/kg/week) by oral gavage for 42 days (6 weeks). Only aortas excised 






Figure 5.6: Effect of cholecalciferol supplementation on AAA progression in 
angiotensin-II infused apolipoprotein E-null mice 
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Morphometric analysis showed that all areas of the aorta were significantly smaller in diameter 
compared with controls. B. Types of aneurysms were scored and classified according to 
Daugherty, et al. (2001) (Daugherty et al., 2001) classification. Accordingly, type 0 were 
defined as aortas with no dilation in any given segment. Type I aneurysms were defined as 
dilated lumen in the supra‐renal region of the aorta with no apparent thrombus. Type II 
aneurysms were defined as remodelled tissue in the supra‐renal region that contained evident 
thrombus. Type III was defined as a pronounced bulbous form of type II that contains 
thrombus. Type IV aneurysm were classified as multiple aneurysms containing thrombus, 
some overlapping, in the suprarenal area of the aorta or other areas of the aorta. Whole aortas 
tissue were categorized independently by two observers, one of them was blinded to the 
labelling of groups. There was a 100% concordance in the classification of the aortas between 
the two observers. Only surviving mice aortas are shown: CCF (grey boxes); Control (open 
boxes). *Denotes no entry on figure 6.6B. Abbreviations: TA: thoracic aorta; SRA: suprarenal 
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Figure 5.7: Morphometric analysis of aortas harvested during terminal experiment and 
effect of cholecalciferol supplementation on the incidence of specific forms of aneurysms on 
aortas 
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5.4.3. Cholecalciferol supplementation reduced inflammation and degradation of elastin 
and collagen within the suprarenal aortic wall of angiotensin-II infused Apolipoprotein 
E-null mice 
 
Inflammation and aortic matrix degradation are common features of aneurysmal tissue 
(Isenburg et al., 2007). Common features of aneurysmal tissue include depletion of collagen 
and elastin fibres, presence of inflammatory cells infiltrates and reduced medial VSMCs 
(Isenburg et al., 2007). Effects of CCF supplementation on the degradation of collagen and 
elastin fibres were characterised in the SRA of mice in both groups. Mice supplemented with 
CCF had significantly higher SRA collagen content (P=0.015) and elastin fibres content 
(P=0.033) compared with control mice (Figure 5.8 A&B). 
Similarly, effects of on expression of pro-inflammatory genes was compared within the SRAs 
of mice maintained on CCF and controls. Mice supplemented with CCF showed significant 
downregulation of Opn (P =0.035), Mcp-1 (P=0.035) and Agtr1 (P=0.002). Assessment of 
genes implicated in matrix remodelling showed that there was significant downregulation of 
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Representative images presented denote Hematoxylin and eosin (H&E), picrosirius red and 
Elastin Verhoeff–Van Gieson (EVG) stained suprarenal aortic (SRA) sections for the CCF (* 
denotes lumen). Gross assessment of H&E images showed that CCF supplemented mice had a 
relatively intact aortic wall with less dissection (false lumen) and accumulation of 
inflammatory cells within the aortic wall ( ) compared with the contol group. Picrosirius red 
stained collagen images were photographed using polarization microscopy (yellow or green). 
CCF supplemented mice showed increased collagen birefringence under polarization. 
Comparison of medial elastin filament breaks (black structures) within Verhoeff–Van Gieson 
(EVG)–stained sections of suprarenal aortas. The CCF supplemented mice had higher collagen 
and elastin content within the SRA wall compared with control mice (A & B). A. 
Quantification of polarization images for collagen content expressed as a percentage (%) of the 
total suprarenal aorta section area (n= 11 for CCF and 7 for control). B. Quantification graph 
showing elastin filament degradation (n= 11 for CCF and 7 for control). Aortic wall elastin 
filament degradation was graded based on the degree of breaks in elastin filaments (graded on 

















Figure 5.8: Effect of cholecalciferol supplementation on the aortic wall gross morphology, 
collagen and elastin fibres within the suprarenal aortas harvested from angiotensin-II 
infused apolipoprotein E-null mice 
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Table 6: Effects of cholecalciferol supplementation on gene expression within the 
suprarenal aorta of apolipoprotein E-null mice infused with angiotensin-II 
Gene Control (n=7) CCF (n=11) Expression P 
Sost 1.05 [0.55-1.91] 2.71 [1.53-5.97]  0.035 
Opg 1.10 [0.97-1.49] 1.19 [0.95-1.46]  0.724 
Opn 57.96 [35.14-82.32] 24.07 [13.68-48.24]  0.035 
Mmp-9 12.49 [8.452-34.06] 7.36 [5.05-9.20]  0.020 
Mmp-2 5.47 [2.94-13.68] 2.27 [1.86-3.56]  0.035 
Vdr 0.72 [0.21-0.97] 1.30 [0.75-2.23]  0.027 
Cyp27b1 1.33 [1.27-2.41] 0.77 [0.43-1.04]  <0.001 
Dkk-1 0.76 [0.51-0.95] 1.81 [1.16-2.27]  <0.001 
Ocn 1.17 [0.97-1.88] 1.22 [0.97-2.57]  0.930 
Ctnnb1 4.59 [3.66-8.28] 2.12 [1.79-4.02]  0.015 
Agtr1 1.95[1.39-2.44] 0.76[0.28-1.09]  0.002 
Mcp-1 1.05[0.86-1.46] 0.85[0.51-0.99]  0.035 
Shown are relative gene expression as median (inter-quartile range) relative to 
glyceraldehyde 3-phosphate dehydrogenase (Gapdh) expression. Inter-group comparison 
was analysed using Mann-Whitney U test. Abbreviations: CCF: cholecalciferol; Sost: 
sclerostin; Opg: osteoprotegerin; Opn: osteopontin; Vdr: vitamin D receptor; Cyp27b1: gene 
encoding for 25-hydroxvitamin D3 hydrolase; Dkk: Wnt inhibitor Dickkopf-1; Ocn: 
osteocalcin (bone-Gla matrix); Ctnnb1: gene encoding for β-catenin; Mmp-2/9: matrix 
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5.5. DISUSSION 
The main findings from this study were that supplementation of CCF attenuated progression 
and rupture of pre-established AAA within the AngII-infused ApoE-/- mouse model. Circulating 
levels of 25(OH)D levels were raised to >75 nmol/L (considered optimal vitamin D status) 
following CCF administration while these levels remained low within control mice. The 
present study demonstrated that supplementation of CCF by oral gavage resulted in increased 
plasma levels of 25(OH)D which was accompanied with increased levels of circulating SOST 
and aortic SOST expression. Preceding findings (Chapter 3 & 4) showed that low levels of 
plasma 25(OH)D coupled with reduced SOST promoted development of AAAs which were 
more likely to rupture. In this study, however, up-titration of 25(OH)D to >75nM was 
associated with slow growth of AAA and reduced rupture rate in AngII-infused ApoE-/- mice 
with  pre-established AAA. Recently, it was reported that transgenic upregulation and 
parenteral administration of SOST protected against experimental AAA development (Krishna 
et al., 2017). The present study shows that CCF supplementation resulted in increased plasma 
25(OH)D levels and SOST, which in turn, attenuated the progression of pre-established AAA 
within the AngII-infused mouse model. 
 
Association between low circulating 25(OH)D and CVD pathologies such as PAD, CAD and 
atherosclerosis has been reported, although the findings have been conflicting (Nsengiyumva 
et al., 2015; Pilz et al., 2016). Vitamin D in the form of CCF or ergocalciferol is a nutraceutical 
that is widely available as an over the counter supplement, although higher doses require a 
physician’s prescription. In clinical settings, vitamin D deficiency is conservatively managed 
by CCF or ergocalciferol supplementation with an intention to raise circulating levels of 
25(OH)D (Bischoff-Ferrari et al., 2006; Holick et al., 2011; Kennel et al., 2010; Kleerekoper 
et al., 2011). Achieving >75 nM of serum 25(OH)D concentration has been postulated to be 
beneficial in multiple health outcomes (Bischoff-Ferrari et al., 2006; Holick et al., 2011; 
Kennel et al., 2010; Kleerekoper et al., 2011). It has been suggested that CCF is more 
efficacious at raising circulating levels of 25(OH)D levels compared with ergocalciferol 
(Tripkovic et al., 2012); and thus a preferred choice for 25(OH)D replenishment for this study. 
Guidelines from the American endocrinology society suggest that vitamin D supplementation 
should be best maintained at weekly doses interval (Rosen et al., 2012). Weekly doses appear 
to be more efficacious in correcting circulating levels of 25(OH)D compared with daily, 
monthly, yearly or single doses supplementation of CCF (Rosen et al., 2012). Given that 
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25(OH)D levels associated with AAA presence are not definitively within the deficiency range 
(i.e. <50 nmol/L), this study postulated that raising 25(OH)D levels to ≥75 nM could confer 
protective effects against AAA progression. Findings from this study demonstrated that 
increasing plasma 25(OH)D levels slowed AAA growth. In addition, this was accompanied by 
limited aortic rupture incidences suggesting that vitamin D supplementation played a role in 
attenuation of pre-established AAA within the mice that were supplemented with CCF. In 
previous studies, it was shown that administration of 1α,25(OH)2D3, a VDR agonist, has been 
reported to limit AAA development in a mouse model, and paricalcitol administration has been 
reported to limit inflammation in human AAA (Martorell et al., 2016; Nieuwland et al., 2016). 
 
Mechanistic studies have previously suggested that vitamin D is multilevel repressor of Wnt/β-
catenin signalling (Larriba et al., 2013). It was recently reported that transgenic SOST 
downregulation and recombinant SOST administration resulted in hyper-phosphorylation of 
GSK-3β and accumulation of the β-catenin complex, indicating involvement Wnt/β-catenin 
signalling in AAA formation (Krishna et al., 2017). Nonetheless, it has been suggested that 
exogenous administration of SOST or overexpression of SOST could promote osteoporosis 
(Costa et al., 2014). However, total inhibition of SOST was also shown to promote 
inflammation, aortic aneurysms and atherosclerosis (Krishna et al., 2017; Wehmeyer et al., 
2016). Interestingly, ergocalciferol administration has previously been reported to increase 
circulating SOST concentrations in patients with osteoporosis (Sankaralingam et al., 2014). 
Emerging evidence suggests that vitamin D limits fracture risks in osteoporotic patients (Holick 
et al., 2011) while recent findings showed that vitamin D upregulated in osteoblasts 
(Sutherland, Geoghegan, Yu, Winkler, & Latham, 2004; Tartaglione et al., 2017; Wijenayaka 
et al., 2015; Wijenayaka et al., 2015). Consistent with these findings, data in Chapter 3 
demonstrated that 1α,25(OH)2D3 upregulated expression of SOST in VSMCs. This suggests 
that consequent increase of bioavailable 1α,25(OH)2D3 due to CCF supplementation resulted 
in higher SOST expression within VSMCs, particularly within the SRA wall. Moreover, 
Chapter 3 of this thesis showed that 1α,25(OH)2D3 promotes SOST expression in human aortic 
VSMCs while dietary deficiency of vitamin D resulted in reduced circulating and SRA wall 
SOST. It is therefore plausible that increased of circulating 25(OH)D levels were locally 
metabolised by SRA VSMCs, resulting in upregulation of SRA Sost expression as 
demonstrated by SRA upregulation of CYP27B1 (Christakos et al., 2016; Mitsuhashi, Morris, 
& Ives, 1991). Moreover, findings from this study further showed that CYP27B1 was 
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downregulated in the SRA tissue in response to CCF supplementation. Collectively, these 
findings suggested that bioavailability and conversion of circulating 25(OH)D to 1α,25(OH)2D 
were locally increases in these mice. CCF supplementation resulted in upregulation of VDR 
suggesting genomic effects of 1α,25(OH)2D to elicit gene expression within the SRA wall cells 
(Christakos et al., 2016).  
VSMCs play an important role that involves matrix synthesis and structural integrity of the 
aortic wall. Collagen and elastin are structural proteins that control arterial distension and 
elasticity within the aortic wall (Isenburg et al., 2007). Key histological features of AAA-
diseases tissues include evident depletion of elastin and collagen matrix fires (Krishna et al., 
2017; Norman et al., 1995). Indeed, matrix degradation has been consistently characterized 
within the ApoE-/-, AngII-infused mouse model (Krishna et al., 2017; Krishna et al., 2015; 
Moran et al., 2014). The present study demonstrated that CCF supplementation protected 
against proteolytic destruction of the aortic wall as evidenced by SRA elastin and collagen 
fibers and Mmp-2 and Mmp-9 expression within the SRA of mice that were supplemented with 
CCF. Specifically, this study showed integrity of both elastin and collagen fibres was higher in 
mice that were supplemented with CCF compared with controls. Furthermore, lower 
expression of Mmp-2 and Mmp-9 was demonstrated in CCF supplemented mice. This is 
consistent with previous studies advocating that these genes are associated with AAA 
formation and progression in both in human AAA and animal models. These findings are also 
in agreement with a recently publication by Martorell et al (2016) which reported that 
administration of 1α,25(OH)2D3 (1 μg/kg) downregulated SRA MMP-2 and MMP-9 and 
upregulated endogenous tissue inhibitor of metalloproteinases-1 (TIMP-1) expression in ApoE-
/- AngII infused mice. Consistently, it has been shown that demonstrated that VDR activation 
downregulated MMP2 and MMP-9 in cultured human VSMCs (Aoshima et al., 2012; Britt et 
al., 2015). In addition, Chapter 3 of this thesis showed that in vitro incubation of 1α,25(OH)2D3 
with VSMCs resulted in upregulated expression of contractile phenotype markers suggesting a 
homeostatic maintenance of SRA VSMCs by locally bioavailable 1α,25(OH)2D3. 
Interestingly, AAA is prevalent in elderly persons aged ˃65 years which coincides with the 
half-life of elastin (at ~70 years) and decreased cutaneous absorption of sunlight vitamin D 
(Holick, 2007; Norman et al., 1995), suggesting that lower 25(OH)D levels could insidiously 
contribute to AAA expansion. 
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Interpretation of these findings is prone to a number of strengths and limitations. Experimental 
design of this study aimed to partially simulate clinical settings where patients present with 
small established AAAs. Most previous rodent AAA studies have focused on the ability of 
interventions to limit AAA development (Golledge, Norman, et al., 2017); however, in the 
current study the ability of CCF supplementation to limit growth of pre-established AAAs was 
investigated. The loading dose of CCF required to rapidly achieve >75 nmol/L (defined as 
optimal 25(OH)D (Bischoff-Ferrari et al., 2006; Holick et al., 2011) was estimated using a 
previously proposed formula (van Groningen et al., 2010). Furthermore, circulating 25(OH)D 
were measured using a highly sensitive mass spectrometry assay in a validated laboratory 
(Clarke et al., 2013; Holick, 2009; Kleerekoper et al., 2011). It is noteworthy to mention; given 
that baseline 25(OH)D were similar after 14-days of AAA induction, it is unlikely that AAA 
is causative of low 25(OH)D which has been a limitation of previous epidemiologic findings. 
Nonetheless, circulating PTH levels were not measured in this study. Vitamin D is an important 
regulator of PTH, and high PTH levels are deleterious to cardiovascular function (Bischoff-
Ferrari et al., 2006; Christakos et al., 2016; Norman & Powell, 2014). Indeed, optimal 25(OH)D 
levels have been previously defined on the basis of maximal suppression of PTH secretion 
(Bischoff-Ferrari et al., 2006). While renal CYP27B1 expression is tightly regulated PTH and 
FGF23, it is still unknown whether similar mechanisms are involved extra skeletal control of 
this enzyme (Christakos et al., 2016).  
 
In conclusion, this study examined the efficacy of CCF supplementation in limiting the growth 
of pre-established AAA in the presence of continuous AngII infusion. Findings from this study 
showed that CCF supplementation attenuated AAA progression and limited aortic rupture rate 
in this experimental mouse model. CCF supplementation resulted in achievement of higher 
circulating 25(OH)D levels (≥ 75 nmol/L) which are currently defined as optimal levels (Holick 
et al., 2011). CCF supplementation also resulted in increased circulating SOST, SRA SOST 
protein and SRA Sost gene expression. Mice supplemented with CCF manifested lower 
expression of pro-inflammatory markers and matrix remodelling markers. Taken together, 
these findings also confirm that effects of CCF supplementation on SOST and Wnt/β-catenin 
signalling may plausibly explain the mechanism by which vitamin D limits AAA progression. 
CCF supplementation may be an attractive therapy in clinical settings where patients present 
with already established AAA. Further research is therefore needed to examine the ability to 
translate these findings to AAA patients. 

































CHAPTER 5 HIGHLIGHTS 
What is Known? 
 Vitamin D deficiency is clinically managed through CCF supplementation in order to 
raise circulating levels of 25(OH)D. 
 Optimal vitamin D status has been suggested to be 25(OH)D levels ≥  75 nmol/L for 
multiple health outcomes.  
 Chapters 3 &4 showed dietary deficiency of vitamin D promoted expression of genes 
involved in AAA inflammation and aortic wall matrix remodelling. 
 Chapter 4 showed that dietary restriction of vitamin D promoted formation of larger 
AAAs which were more prone rupture in the ApoE-/-, Ang-II infused mouse model. 
 Chapters 3 & 4 demonstrated that these effects are mediated through changes in 
circulating SOST and aortic SOST expression.    
 
What New Information Does This Chapter Add? 
 
 Using a previously defined formula for 25(OH)D up-titration, a human equivalent dose 
was calculated and defined for the loading dose of CCF. 
 Dietary restriction of vitamin D resulted in higher elastin and collagen degradation. 
 CCF supplementation and resultant increase in plasma 25(OH)D levels were associated 
with slower growth of AAA and lower rupture rate of pre-established AAA in the ApoE-
/-, Ang-II infused mouse model. 
 Effects of CCF supplementation appeared to be mediated via changes in expression of 
genes involved in ECM remodelling, particularly the increase of SOST. 
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6.1. Discussion of Findings 
 
In the present thesis, the effects of vitamin D on AAA development, growth and rupture were 
investigated in vivo using the ApoE-/- mouse model in which AAA was induced by AngII 
infusion. The thesis also investigated the effect of vitamin D on human aortic VSMCs in vitro. 
This thesis had 4 aims: (1) to examine whether the active metabolite of vitamin D, 
1α,25(OH)2D3, increased in vitro SOST expression in VSMCs; (2) to investigate whether 
dietary-induced vitamin D deficiency reduced circulating levels of SOST in ApoE-/- mice; (3) 
to investigate if dietary-induced deficiency of vitamin D promoted AAA development and 
rupture; and (4) to examine if up-titration of circulating 25(OH)D levels through CCF 
supplementation limited progression of pre-established AAA. 
 
The main findings of this thesis were that within the AngII-induced mouse model, diet-induced 
vitamin D deficiency promoted development of large AAAs which were prone to rupture; and 
that CCF supplementation to achieve high circulating concentrations of 25(OH)D limited 
growth and rupture of pre-established AAAs. These effects appeared to be linked to changes 
in circulating and aortic expression of SOST, along with effects on the Wnt/β-catenin signalling 
pathway within the aorta. These findings support those from a previous study, which suggested 
that transgenic upregulation and parenteral administration of hrSOST protected against AAA 
development in the same mouse model through competitive inhibition of the Wnt/β-catenin 
signalling pathway (Krishna et al., 2017; Towler, 2017)  
 
Guidelines recommend achieving circulating 25(OH)D concentrations of >75 nmol/L as 
optimal levels (Al Mheid et al., 2013; Bischoff-Ferrari et al., 2006; Holick et al., 2011; Kennel 
et al., 2010; Kleerekoper et al., 2011; van Groningen et al., 2010). In a previous community 
screening study in older men it was reported that men with plasma concentrations of 25(OH)D 
in the lowest quartile were more than five times as likely to have an AAA measuring >40 mm 
compared with men with 25(OH)D concentrations in the upper quartile (Wong et al., 2013). In 
keeping with those clinical findings, in Chapter 4 of this thesis, ApoE-/- mice with no detectable 
plasma 25(OH)D were predisposed to development of larger AAA which were more likely to 
rupture during AngII-infusion. While AAA diagnosis has been associated with lower 
circulating concentrations of 25(OH)D, most patients that develop AAA do not have 25(OH)D 
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concentrations within the deficient range of <50 nmol/L (Van De Luijtgaarden et al., 2012; 
Wong et al., 2013). In Chapter 5 of this thesis, raising 25(OH)D concentrations to ≥75 nmol/L 
limited growth and rupture of pre-established AAA within the AngII-mouse model. 
Supplementation of mice with CCF was associated with upregulation of the aortic expression 
of the VDR and downregulation of CYP27B1. Findings were similar within an in vitro 
experiment involving VSMCs in which incubation of cells with 1α,25(OH)2D3 led to a dose-
dependent upregulation of VDR and CYP24A1 while CYP27B1 was dose-dependently 
downregulated. 
 
The role of vitamin D in skeletal health is well-documented. Vitamin D deficiency has been 
associated with osteoporosis and increased risk of fractures in older adults and one potential 
mechanism for this association could be the effect of vitamin D on the expression of bone 
proteins (Holick et al., 2011). Incubation of osteoblasts with 1α,25(OH)2D3 has been reported 
to induce SOST expression (Wijenayaka et al., 2015). Ergocalciferol administration has 
previously been reported to increase circulating SOST concentrations in patients with 
osteoporosis (Sankaralingam et al., 2014). Current findings demonstrated that incubation of 
VSMCs with 1α,25(OH)2D3 led to a dose-dependent increase in SOST expression. In mice 
experiments, a VDD diet led to a reduction in plasma SOST concentration, aortic SOST protein 
levels and aortic SOST gene expression while supplementation of CCF in mice with established 
AAAs increased plasma and aortic SOST. Aortic concentrations of p-GSK-3α/β, which is 
indicative of Wnt/β-catenin signalling activity, were also lower in mice receiving CCF. 
Phosphorylation of the GSK-3α/β leads to stabilization of β-catenin complex and consequent 
translocation to the nucleus. The Wnt/β-catenin signalling has been implicated in stimulating 
the activation of an inflammatory cascade in a number of autoimmune diseases (Beurel et al., 
2015). Additionally, findings from this thesis showed that CCF administration upregulated 
aortic expression of Dkk-1, another Wnt pathway inhibitor (Larriba et al., 2013; Nusse & 
Clevers, 2017; Sankaralingam et al., 2014). In line with these findings, a VDD diet led to 
increased aortic expression of the Wnt signalling gene Ctnnb1 whereas CCF supplementation 
led to decreased aortic expression of Ctnnb1. In vitro experiments showed that CTNNB1 was 
dose-dependently downregulated in response to 1α,25(OH)2D3 administration, suggesting 
inhibition of Wnt/β-catenin signalling. This was associated with downregulation of AGTR1 
and MCP-1 as well as upregulation of key contractile markers in VSMCs (Lino Cardenas et 
al., 2018). These responses were plausibly attributable to upregulation in SOST expression. 
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Indeed, vitamin D associated effects on Wnt/β-catenin signalling, including downregulation of 
β-catenin have been previously described, most notably in cancer cells (Larriba et al., 2007; 
Palmer et al., 2001; Shah et al., 2006). It was recently reported that SOST upregulation in a 
mouse model reduced phosphorylation of GSK-3β and consequent β-catenin accumulation in 
SRA tissue (Krishna et al., 2017). These findings suggest that CCF supplementation 
upregulates SOST and inhibits experimental AAA progression by inhibiting Wnt/βcatenin 
signalling. 
 
Degradation of the ECM has been strongly implicated in AAA pathogenesis (Galis & Khatri, 
2002; Krishna et al., 2017; Krishna et al., 2015; Moran et al., 2014). In particular, 
overexpression of MMP-2 and MMP-9 has been consistently associated with AAA formation 
and progression in this experimental mouse model (Krishna et al., 2017;  Krishna et al., 2015;  
Moran et al., 2005). In the current thesis, mice administered a VDD diet had greater aortic 
expression of Mmp-2 and Mmp-9 compared to controls. Similarly, supplementation with CCF 
in mice with established AAA led to downregulation of aortic Mmp-2 and Mmp-9 expression 
compared to controls. Taken together, these findings suggest that an increase in circulating 
25(OH)D concentrations via CCF supplementation limited proteolytic degradation within the 
aorta. These findings are consistent with data from a recent publication, in which it was 
reported that parenteral administration of 1α,25(OH)2D3 (1 μg/kg) downregulated aortic Mmp-
2 and Mmp-9 and upregulated endogenous tissue inhibitor of Mmp-1 expression in AngII-
infused ApoE-/- mice (Martorell et al., 2016). In addition, VDR activation has been reported to 
downregulate MMP-2 and MMP-9 activity and expression in cultured human VSMCs 
(Aoshima et al., 2012; Britt et al., 2015). OPN, while initially described as a bone protein, has 
been strongly implicated in AAA development (Bruemmer et al., 2003; Filis et al., 2014; 
Golledge et al., 2007; Li et al., 2016). It has previously been reported that plasma 
concentrations of OPN are increased in patients with AAA and positively correlated with AAA 
growth rates (Golledge et al., 2007). Within the AngII infused mouse model, it has been 
reported that OPN deficiency protects against AAA formation (Bruemmer et al., 2003). 
Findings from this thesis suggest that a VDD diet upregulated aortic expression of Opn, while 
supplementation with CCF downregulated Opn in comparison to controls. In vitro incubation 
of VSMCs with 1α,25(OH)2D3 dose-dependently downregulated OPN expression. The effect 
of CCF supplementation on MMP-2, MMP-9 and OPN may, at least in part, explain its ability 
to limit AAA progression. 
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Traditionally, osteogenic markers of bone mineralisation such as OCN, OPN and OPG have 
been exclusively known to play a role in bone health with no known function in arterial health 
(Huang, Yang, Shao, & Li, 2007). Emerging evidence however, suggests increased OPN and 
OPG are associated with AAA pathology in both human and animal models, particularly the 
AngII infused ApoE-/- mice (Golledge et al., 2007; Golledge, Tsao, Dalman, & Norman, 2008;  
Moran et al., 2014). Recently, it was reported that increased circulating levels of OCN were 
associated with severe abdominal aortic calcification and acute aortic dissection in patients 
(Vianello et al., 2017). In this thesis, up-titration of 25(OH)D levels by CCF supplementation 
resulted in downregulation of OPN without changes on OPG and OCN which could be used as 
markers for calcification (Jono, Nishizawa, Shioi, & Morii, 1998). Experimental studies have 
suggested that high circulating 1α,25(OH)2D3( ≥ 100 mol/L) could induce calcification and 
upregulation of osteogenic markers, including OPN in VSMCs (Jono, Nishizawa, Shioi, & 
Morii, 1998). However, similar expression of Opg and Ocn between CCF supplemented mice 
and controls provides confidence that no calcification due to high CFF. Conversion of 
25(OH)D to 1α,25(OH)2D3 is tightly regulated physiologically (Christakos et al., 2016); and 
thus CCF supplementation is deemed safe even at higher doses. 
 
Hypertension is understood to be a risk factor for AAA development and rupture (Kent et al., 
2010; Tang et al., 2016). In patients with AAA, it recommended that blood pressure be 
controlled along with other traditional CVD risk factors (Golledge & Powell, 2007; Lindeman 
& Matsumura, 2019). A recent meta-analysis reported that hypertension increased the risk of 
developing AAA by 66% (Kobeissi et al., 2019). However, another meta-analysis previously 
suggested that hypertension may not be associated with AAA expansion (Takagi & Umemoto, 
2017). SBP has previously been reported to rise in mice receiving AngII-infusion, although it 
is not thought to be responsible for the induction of AAA in this experimental model (Ayabe 
et al., 2006; Cassis et al., 2009; Kawada et al., 2002; Krishna et al., 2015). A VDD diet 
promoted higher SBP in ApoE-/- mice. Vitamin D has been reported to suppress renin 
expression (Ajabshir et al., 2014) and administration of CCF (25000 IU/week) has been 
reported to attenuate hypertension in patients (Carrara et al., 2014).  In addition, findings from 
previous studies have reported that circulating 25(OH)D is may be associated with lower blood 
pressure (Kunutsor et al., 2014; Vimaleswaran et al., 2014), although trials with vitamin D 
supplementation have yielded conflicting outcomes (Beveridge et al., 2015). However, given 
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that AngII is not thought to induce AAA via increases in SBP it is unlikely that the link between 
vitamin D and SBP is responsible for AAA formation and progression in accordance with 
findings from this thesis (Chapter 4 & 5). Indeed, non-AngII targeted agents do not promote 
aneurysms ApoE-/- mice; and it has previously been established that blood pressure elevation 
is not responsible for the ability of AngII to promote aneurysm development in this mice model 
(Cassis et al., 2009). It can therefore be deduced that the blood pressure changes are not 
responsible for the effects of lower 25(OH)D in these studies. Moreover, calcium channel 
blockers, such as amlodipine, diltiazem and nifedipine, have been previously shown to limit 
experimental AAA within the angiotensin II model independent of any effects on blood 
pressure (Chen et al., 2013; Miao et al., 2015; Mieth et al., 2013); and therefore, administration 
of these agents will not advance understanding of the effect of vitamin D deficiency. On this 
basis, it may not be possible to isolate the effects of blood pressure from vitamin D deficiency 
since agents such as calcium channel blocking drugs have been shown to limit AAA 
development in this model independent of effects on blood pressure. 
 
6.2. Strengths and Limitations  
 
A number of strengths and limitations of studies in this thesis should be acknowledged. 
Strengths of the current the studies include the use of multiple mouse experiments designed to 
examine the link between vitamin D and AAA, in addition to an in vitro study. Most previous 
rodent AAA studies have focused on the ability of interventions to limit AAA development; 
however, in Chapter 5 of this thesis the ability of CCF supplementation to limit growth of 
established AAAs was also investigated (Golledge, Norman, et al., 2017). The design of animal 
experiment in Chapter 5 aimed to partially simulate the clinical settings where patients present 
with small established AAAs. The loading dose of CCF required to rapidly achieve >75 nmol/L 
[(defined as optimal 25(OH)D (Bischoff-Ferrari et al., 2006; Holick et al., 2011)] was estimated 
using a formula proposed by van Groningen et al (2010). In patients presenting with vitamin 
D deficiency, a loading dose is required in order to raise circulating 25(OH)D levels as rapidly 
as possible (>75nM) (Kennel et al., 2010) before placing patients on a maintenance dose. 
Furthermore, circulating 25(OH)D were measured using a highly sensitive mass spectrometry 
assay in a validated laboratory (Clarke et al., 2013; Holick, 2009; Kleerekoper et al., 2011). 
Oral supplementation of CCF has been previously shown to increase production of vitamin D 
epimers in mice (Ghaly et al., 2019); therefore, the LC-MS/MS technique was an excellent 
modality to discriminate between actual circulating plasma 25(OH)D and the C3-epimers (Al-
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Zohily et al., 2020). Some of the limitations in findings presented in this thesis include the use 
of one mouse model since animal experiments were limited to the AngII-infused ApoE-/- mouse 
model. In addition, while it is possible that different cell types might respond to 1α,25(OH)2D3 
effects differently, experiments in Chapter 3 focused on VSMCs effects due to the paramount 
role of these cells in arterial remodelling and AAA formation. It also remains uncertain what 
the precise mechanism involved in the protective effect of CCF administration against AAA 
development and progression. Characterisation of inflammatory cells infiltrates is another 
hallmark feature of AAA-diseased tissue (Isenburg et al., 2007); however attempts to 
characterise infiltration of macrophages within the SRA tissue using macrophages/monocytes-
2 (MOMA-2) antibodies were not successful, and should be acknowledged as a limitation. 
Finally, although the AngII-infused ApoE-/- mouse model shares several common pathological 
features with human AAA, direct translatability of findings from mice studies to human studies 
remains challenging (Patelis et al., 2017; Rush et al., 2009; Senemaud et al., 2017; Trollope et 
al., 2011) .   
 
Furthermore, circulating levels of PTH were not measured in mice studies presented in this 
thesis. Physiologically, PTH is an important regulator of vitamin D since optimal circulating 
25(OH)D is reflective of suppression of PTH levels (Bischoff-Ferrari et al., 2006; Christakos 
et al., 2016; Jones, 2013; Norman & Powell, 2014). PTH is also recognized as a negative 
regulator for SOST expression (Keller & Kneissel, 2005; Wijenayaka et al., 2015). Also, as a 
regulator of bone remodelling and ion homeostasis, PTH has been shown to reduce SOST 
expression in bone osteocytes and vascular VSMCs (Gooi et al., 2010; Keller & Kneissel, 2005; 
Silvestrini et al., 2007; Song, Fiaschi-Taesch, & Bisello, 2009). Several studies have shown 
that chronic or intermittent administration of PTH may be associated with downregulation of 
SOST in osteocytes (Bellido et al., 2005; Jilka, O'Brien, Bartell, Weinstein, & Manolagas, 
2010; Lavi-Moshayoff, Wasserman, Meir, Silver, & Naveh-Many, 2010). Chronically 
excessive circulating PTH (hyperparathyroidism) has been associated with presence and 
worsening CVD events and CVD risk factors, including hypertension, vascular calcification 
and PAD (Garcia, Clemens, Fagin, Finkielman, & Pirola, 1998; Ishikawa et al., 2000; Song et 
al., 2009). Although no studies have investigated the effects of circulating PTH on aortic 
aneurysm, Demir et al (2012) previously reported an increase in PTH levels among TAD 
patients compared with controls. However, it can be inferred that the indicator for this was the 
lower circulating levels of circulating 25(OH)D in these patients. It was previously reported 
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that PTH inhibited SOST expression via a non-direct mechanism which suggested a 
transcriptional regulatory pathway such as that implicated in the Wnt/β-catenin signalling 
(Brandenburg et al., 2015; Keller & Kneissel, 2005). 
 
6.3. Conclusions and Future Directions 
 
In conclusion, findings from these studies suggested that within an experimental mouse model 
of AAA, dietary vitamin D deficiency promoted formation of larger AAAs that were more 
prone to rupture. CCF supplementation limited growth and rupture of established AAAs within 
the same model. Vitamin D appears to act via changes in SOST and OPN, which limit ECM 
degradation promoted by MMP-2 and MMP-9. Further research is needed to examine the 
ability to translate these findings to AAA patients. Therefore, important additions to the current 
literature include ability of vitamin D to induce SOST in VSMCs, ability of VDD to promote 
development and rupture of AAAs, and more importantly, the ability of CCF supplementation 
and consequent 25(OH)D up-titration to attenuate growth and rupture of pre-established AAAs 
in an experimental mousse model of AAA. 
Clearly, AAA is multifaceted diseases, which encompasses a broad spectrum of potential areas 
for research, including pre-clinical and clinical research. Given that most human AAAs are 
discovered when they are still small, it is hoped that suitable pharmacological candidates will 
be found to assist with medical management of AAA patients with the ultimate goal of delaying 
the need for AAA surgical repair and potential AAA rupture. Accordingly, a number of future 
directions are proposed in response to the limitations deduced from this thesis. It remains 
unknown whether SOST could be inducible by vitamin D in other cells that are well-known to 
be involved in AAA pathogenesis. It would therefore be interesting to investigate whether these 
findings are repeatable in other cell lines such as monocytes, endothelial cells, and mast cells, 
particularly for the ability to induce SOST expression from these cells.  
A previous study demonstrated that exogenous administration of SOST was able to limit AAA 
development (Krishna et al., 2017) while Chapter 5 of this thesis showed that CCF 
supplementation upregulated both Sost and Dkk-1 expression within the SRA of mice. The 
findings showing that CCF supplementation upregulated Dkk-1 are potentially hypothesis 
generating and deserve further investigations. For instance, it would be interesting, at least 
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experimentally, to investigate whether exogenous administration of recombinant human Dkk-
1 has any therapeutic potential in pre-clinical studies such as mice and cellular experiments. 
Additionally, it would be worthwhile to investigate whether direct abrogation or modulation of 
β-catenin could confer therapeutic benefits with regard to attenuation of experimental AAA. 
Encouragingly, recent advances in the development of small molecules designed to directly 
bind to β-catenin could make these experiments possible (Cui, Zhou, Zhang, Qu, & Ke, 2018; 
Hwang et al., 2016). So far, five small molecules and two short peptides have been reportedly 
assessed for their ability to directly target β-catenin and thereby inhibiting Wnt/β-catenin 
signalling which is understood to be of experimental interests (Cui et al., 2018). Renewed 
interests, particularly in cancer research are already exploring these investigations (Cui et al., 
2018; Hwang et al., 2016). Nonetheless, clinical translatability of pre-clinical investigations 
with these agents would remain to be seen in vascular clinical research, especially in AAA 
clinical trials.  
Finally, it would be worthwhile to confirm whether observed lower circulating 25(OH)D levels 
are also associated with lower circulating SOST in epidemiological studies of AAA patients. 
Such investigations can be achieved as well by using retrospective cohorts. Finally, the findings 
from this thesis pave a solid foundation for translation into clinical trials. In particular, the 
design of animal studies presented in Chapter 5 can be directly translated into human clinical 
trials for patients presenting with small AAAs. Follow-up parameters in these patients should 
include measurement of aortic diameter and assessment of vitamin D metabolites as well as 
assessment of molecular pathways involved in vitamin D metabolism. Vitamin D in the form 
of CCF is an inexpensive nutraceutical with negligible side effects. Therefore, it is a good 
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